<?xml version="1.0" encoding="utf-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:snbh="http://sentientbrands.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
<head>
<title></title>
<meta content="text/html" http-equiv="Content-Type"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_snbh_sentientbrands.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001358633 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey">0001358633</ix:nonnumeric>
<ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonnumeric>
<ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonnumeric>
<ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonnumeric>
<ix:nonfraction contextref="AsOf2021-12-31" id="xdx2ixbrl0052" name="us-gaap:Supplies" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="AsOf2021-12-31" id="xdx2ixbrl0082" name="us-gaap:ShortTermBorrowings" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="AsOf2021-12-31" id="xdx2ixbrl0085" name="us-gaap:DerivativeLiabilitiesCurrent" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2020-01-012020-12-31" id="xdx2ixbrl0182" name="us-gaap:AmortizationOfDebtDiscountPremium" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2020-01-012020-12-31" id="xdx2ixbrl0185" name="us-gaap:OtherNonoperatingIncomeExpense" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2021-01-01to2021-12-31" id="xdx2ixbrl0226" name="us-gaap:IncreaseDecreaseInFinanceReceivables" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2021-01-01to2021-12-31" id="xdx2ixbrl0241" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2021-01-01to2021-12-31" id="xdx2ixbrl0244" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2020-01-012020-12-31" id="xdx2ixbrl0278" name="us-gaap:InterestPaidNet" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2021-01-01to2021-12-31" id="xdx2ixbrl0280" name="us-gaap:IncomeTaxesPaidNet" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2021-01-01to2021-12-31" id="xdx2ixbrl0305" name="snbh:CommonStockCancellationValue" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2021-01-012021-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0310" name="us-gaap:ProfitLoss" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="AsOf2019-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0326" name="us-gaap:StockholdersEquity" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="AsOf2019-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0332" name="us-gaap:SharesOutstanding" unitref="Shares" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="From2020-01-012020-12-31" id="xdx2ixbrl0356" name="snbh:CommonStockCancelledValue" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="AsOf2021-12-31" id="xdx2ixbrl0427" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitref="USD" xs:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="AsOf2020-12-31" id="xdx2ixbrl0429" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitref="USD" xs:nil="true"></ix:nonfraction>
</ix:hidden>
<ix:references>
<link:schemaref xlink:href="snbh-20211231.xsd" xlink:type="simple"></link:schemaref>
</ix:references>
<ix:resources>
<xbrli:context id="From2021-01-01to2021-12-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-01-01</xbrli:startdate>
<xbrli:enddate>2021-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-06-30">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2022-04-14">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2022-04-14</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-12-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-012020-12-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2020-01-01</xbrli:startdate>
<xbrli:enddate>2020-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-01-01</xbrli:startdate>
<xbrli:enddate>2021-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-012021-12-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-01-01</xbrli:startdate>
<xbrli:enddate>2021-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-01-01</xbrli:startdate>
<xbrli:enddate>2021-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-01-01</xbrli:startdate>
<xbrli:enddate>2021-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2020-01-01</xbrli:startdate>
<xbrli:enddate>2020-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-012020-12-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2020-01-01</xbrli:startdate>
<xbrli:enddate>2020-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2020-01-01</xbrli:startdate>
<xbrli:enddate>2020-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2020-01-01</xbrli:startdate>
<xbrli:enddate>2020-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-12-012020-12-09">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2020-12-01</xbrli:startdate>
<xbrli:enddate>2020-12-09</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-09">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-12-09</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">snbh:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-04-01</xbrli:startdate>
<xbrli:enddate>2021-04-27</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">snbh:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-04-27</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-12-31_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">snbh:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-09-012021-09-23_custom_PromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:PromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-09-01</xbrli:startdate>
<xbrli:enddate>2021-09-23</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-09-23_custom_PromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:PromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-09-23</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-10-012021-12-31_custom_PromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:PromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-10-01</xbrli:startdate>
<xbrli:enddate>2021-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-12-31_custom_PromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:PromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-11-012021-11-18_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">snbh:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-11-01</xbrli:startdate>
<xbrli:enddate>2021-11-18</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-11-18_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">snbh:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-11-18</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-12-16_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">snbh:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:SeniorSecuredConvertiblePromissoryNoteMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-16</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-01-03_custom_UnsecuredDemandNoteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:UnsecuredDemandNoteMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-01-03</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-012021-01-03_custom_UnsecuredDemandNoteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:UnsecuredDemandNoteMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-01-01</xbrli:startdate>
<xbrli:enddate>2021-01-03</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-03-012021-03-16_custom_UnsecuredDemandNoteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:UnsecuredDemandNoteMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-03-01</xbrli:startdate>
<xbrli:enddate>2021-03-16</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-04-18_custom_PaycheckProtectionProgramPromissoryNoteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:PaycheckProtectionProgramPromissoryNoteMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-04-18</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-04-012020-04-18_custom_PaycheckProtectionProgramPromissoryNoteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">snbh:PaycheckProtectionProgramPromissoryNoteMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2020-04-01</xbrli:startdate>
<xbrli:enddate>2020-04-18</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2021-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-03-012021-03-03">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-03-01</xbrli:startdate>
<xbrli:enddate>2021-03-03</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-06-012021-06-29_custom_AccreditedInvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AccreditedInvestorMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-06-01</xbrli:startdate>
<xbrli:enddate>2021-06-29</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-012021-12-31_custom_FurlanAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">snbh:FurlanAgreementMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-01-01</xbrli:startdate>
<xbrli:enddate>2021-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-012021-12-31_custom_MansourAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">snbh:MansourAgreementMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2021-01-01</xbrli:startdate>
<xbrli:enddate>2021-12-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2022-01-012022-03-31_us-gaap_SubsequentEventMember_custom_AdriaticAdvisorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001358633</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
<xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snbh:AdriaticAdvisorsMember</xbrldi:explicitmember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startdate>2022-01-01</xbrli:startdate>
<xbrli:enddate>2022-03-31</xbrli:enddate>
</xbrli:period>
</xbrli:context>
<xbrli:unit id="USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USDPShares">
<xbrli:divide>
<xbrli:unitnumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitnumerator>
<xbrli:unitdenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitdenominator>
</xbrli:divide>
</xbrli:unit>
<xbrli:unit id="Pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
</ix:resources>
</ix:header>
</div>
<p style="margin: 0"></p>
<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt"> </div></div><!-- Field: /Rule-Page -->
<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>U.S.
SECURITIES AND EXCHANGE COMMISSION</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
DC 20549</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_c20210101__20211231_zXTgPnKwOWGg"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentType">10-K</ix:nonnumeric></span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><span id="xdx_906_edei--DocumentAnnualReport_c20210101__20211231_z1EhRzHAVBCa"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">☒</ix:nonnumeric></span> <b>ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the Fiscal Year Ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20210101__20211231_zGj2b8Vp246k"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_900_edei--CurrentFiscalYearEndDate_c20210101__20211231_z6SVN9VeRSI8"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonnumeric></span>, 2021</ix:nonnumeric></span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><span id="xdx_902_edei--DocumentTransitionReport_c20210101__20211231_zBZmqG22Vjue"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">☐</ix:nonnumeric></span> <b>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the transition period from__________________ to _______________________.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Commission
File Number <span id="xdx_902_edei--EntityFileNumber_c20210101__20211231_z5Y7tqhBH3t5"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityFileNumber">001-34861</ix:nonnumeric></span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20210101__20211231_zWfLxhdlqBU3"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName">SENTIENT BRANDS HOLDINGS INC.</ix:nonnumeric></span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid; padding: 0pt; width: 49%; text-align: center; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20210101__20211231_zflsWrxqUDSi"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonnumeric></span></span></td>
<td style="width: 3%; padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; width: 48%; padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20210101__20211231_z1PixJL6Mlr5"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber">86-3765910</ix:nonnumeric></span></span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of incorporation)</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_908_edei--EntityAddressAddressLine1_c20210101__20211231_zIf4C5eYX3D8" style="font-family: Times New Roman, Times, Serif"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1">555
Madison Avenue</ix:nonnumeric></span><span style="font-family: Times New Roman, Times, Serif">, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20210101__20211231_zsiUbzCV26wj"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine2">5<sup>th
</sup>Floor</ix:nonnumeric></span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityAddressCityOrTown_c20210101__20211231_zcwtwXjNSgN7"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown">New York</ix:nonnumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20210101__20211231_z1hhZnLdI4n1"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonnumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20210101__20211231_zMnLG01UWf28"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode">10022</ix:nonnumeric></span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Address
of principal executive offices)</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issuer’s
telephone number: <span id="xdx_90A_edei--CityAreaCode_c20210101__20211231_zRctC3pA10u1"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:CityAreaCode">646</ix:nonnumeric></span>-<span id="xdx_902_edei--LocalPhoneNumber_c20210101__20211231_zJousCkQNkVi"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber">202-2897</ix:nonnumeric></span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(b) of the Act: None</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(g) of the Act: Common Stock, $.001 Par Value Per Share</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act. Yes ☐ <span id="xdx_90B_edei--EntityWellKnownSeasonedIssuer_c20210101__20211231_z0YPmT5zGqJc"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonnumeric></span> ☒</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ <span id="xdx_90C_edei--EntityVoluntaryFilers_c20210101__20211231_zOMmuUcPzKQb"><span id="xdx_90F_edei--EntityVoluntaryFilers_c20210101__20211231_zlYBvVgRQxnk"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonnumeric></ix:nonnumeric></span></span> ☒</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_903_edei--EntityCurrentReportingStatus_c20210101__20211231_zSxETQcSK2h8"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonnumeric></span> ☒ No ☐</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). <span id="xdx_902_edei--EntityInteractiveDataCurrent_c20210101__20211231_zNQmSuhmygi7"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonnumeric></span> ☒ No ☐</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. ☐</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<!-- Field: Page; Sequence: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or emerging growth company. See the definition of “large accelerated filer,” “accelerated filer”, “smaller
reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="padding: 0pt; width: 45%; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer ☐</span></td>
<td style="width: 10%"> </td>
<td style="width: 45%; padding-right: 0.8pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated filer ☐</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityFilerCategory_c20210101__20211231_zB3VsSpNtkOa"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonnumeric></span> ☐</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Smaller Reporting Company <span id="xdx_902_edei--EntitySmallBusiness_c20210101__20211231_zRhp0XVbjdw2"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">☒</ix:nonnumeric></span></span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Emerging Growth Company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20210101__20211231_zG3fbS17YEid"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">☐</ix:nonnumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act) Yes ☐ <span id="xdx_906_edei--EntityShellCompany_c20210101__20211231_zlMRIJBLG9da"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonnumeric></span> ☒</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
<td style="border-bottom: black 1pt solid; padding: 0pt; width: 28%; text-align: center; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; width: 28%; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading Symbol(s)</b></span></td>
<td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; width: 40%; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding: 0pt; text-align: center; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">None</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">N/A</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">N/A</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of June 30, 2021, the last business day of the Registrant’s most recently completed second fiscal quarter, the market value of
our common stock held by non-affiliates was $<span id="xdx_90E_edei--EntityPublicFloat_iI_c20210630_zV2UzCkk1yyj"><ix:nonfraction contextref="AsOf2021-06-30" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" unitref="USD">4,823,514</ix:nonfraction></span></span><span style="font-family: Times New Roman, Times, Serif">.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of April 14, 2022, there were <span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_c20220414_z3LOdCoc4UF4"><ix:nonfraction contextref="AsOf2022-04-14" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" unitref="Shares">51,920,387</ix:nonfraction></span> shares of common stock, par value $0.001 per share, outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Documents
incorporated by reference: NONE</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 2 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SENTIENT BRANDS HOLDINGS INC.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM 10-K ANNUAL REPORT</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>TABLE OF CONTENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
<td style="vertical-align: top; width: 0.75in; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 0.5in; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
<tr>
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_001">PART I</a></b></span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 1.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002">Business</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 1A.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003">Risk Factors</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 1B.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_004">Unresolved Staff Comments</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 2.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_005">Properties</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 3.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_006">Legal Proceedings</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 4.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_007">Mine Safety Disclosure</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_008">PART II</a></b></span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 5.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_009">Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 6.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_010">Selected Financial Data</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 7.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_011">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 7A.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_012">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 8.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_013">Financial Statements</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 9.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_014">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 9A.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_015">Controls and Procedures</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 9B.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_016">Other Information</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#a_017">PART III</a></b></span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 10.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_018">Directors, Executive Officers and Corporate Governance</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 11.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_019">Executive Compensation</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 12.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_020">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 13.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_021">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 14.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_022">Principal Accountant Fees and Services</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Item 15.</span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_023">Exhibits</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; vertical-align: top; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_024">Signatures</a></span></td>
<td style="vertical-align: bottom; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>
<!-- Field: Page; Sequence: 4 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>  </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORWARD-LOOKING STATEMENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>CERTAIN STATEMENTS IN THIS ANNUAL REPORT MAY
CONSTITUTE “FORWARD LOOKING STATEMENTS”. WHEN THE WORDS “BELIEVES”, “ANTICIPATES”, “INTENDS”,
“EXPECTS”, “PLANS”, “SEEKS”, “PROJECTS”, “ESTIMATES” AND SIMILAR EXPRESSIONS
ARE USED, THEY IDENTIFY FORWARD-LOOKING STATEMENTS. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON MANAGEMENT’S CURRENT BELIEFS AND
ASSUMPTIONS AND INFORMATION CURRENTLY AVAILABLE TO MANAGEMENT AND INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH
MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE
OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. INFORMATION CONCERNING FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS
TO DIFFER MATERIALLY FROM THESE FORWARD-LOOKING STATEMENTS CAN BE FOUND IN OUR PERIODIC REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. WE UNDERTAKE NO OBLIGATION TO PUBLICLY RELEASE REVISIONS TO THESE FORWARD-LOOKING STATEMENTS TO REFLECT FUTURE EVENTS OR CIRCUMSTANCES
OR REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Unless otherwise indicated, references to “we”,
“us”, “our”, “Company”, “Sentient Brands”, and “SNBH” mean Sentient Brands
Holdings Inc. and its subsidiaries, and references to “fiscal” mean the Company’s fiscal year ended December 31. References
to the “parent company” mean Sentient Brands Holdings Inc.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_002"></span>ITEM 1. BUSINESS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>General</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless the context otherwise requires, in this report,
the terms “Sentient Brands”, “Company”, “SNBH”, “we”, or “our” refers to Sentient
Brands Holdings Inc., a Nevada corporation. The Company’s principal office is located at 555 Madison Avenue, 5th Floor, New York,
New York 10022. The Company’s telephone number is (646) 202-2897. The Company’s website is www.sentientbrands.com. The Company
reports its operations using a fiscal year ending December 31, and the operations reported on this Form 10-K are presented on a consolidated
basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company files Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, registration statements and other items with the Securities and Exchange Commission
(“SEC”). In this Annual Report on Form 10-K, the language “this fiscal year” or “current fiscal year”
refers to the 12-month period ended December 31, 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the public may read and copy any materials
the Company’s files with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549.
The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains
an internet site ( <span style="text-decoration: underline">www.sec.gov</span> ) that contains reports, proxy and information statements regarding issuers, like the Company, that
file electronically with the SEC.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sentient Brands is a next-level product development
and brand management company with a focus on building innovative brands in the Luxury and Premium Market space. The Company has a Direct-to
Consumer business model focusing on the integration of CBD, wellness and beauty for conscious consumers. The Company incorporates an omnichannel
approach in its marketing strategies to ensure that its products are accessible across both digital and retail channels. The Company develops
and nurtures Lifestyle Brands with carefully thought-out ingredients, packaging, fragrance and design. Sentient Brands’ leadership
team has extensive experience in building world-class brands such as Hugo Boss, Victoria’s Secret, Versace, and Bath &amp; Body
Works. The Company is focused on two key market segments targeting: wellness and responsible luxury, which the Company believes represent
unique opportunities for its Oeuvre product line. Sentient Brands intends to leverage its in-house innovation capabilities to launch new
products that “disrupt” adjacent product categories. We plan to grow by leveraging our deep connections within our existing
network and attract consumers through increased brand awareness and investing in unique social media marketing. The Company’s goal
is to create customer experiences that have sustainable resonance with consumers and consistently implement strategies that result in
long-term profit growth for our investors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Principal Products and Services</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our proprietary formulations contain clean,
vegan, ethically and environmentally responsible ingredients. The Company currently has one main product line, and another in development.
The Company’s current active product line is <i>Oeuvre.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Oeuvre</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Oeuvre </i>- “A Body of Art” – is
a next generation CBD luxury skin care line and lifestyle brand. The foundation of our system of products is our proprietary OE Complex:
Botanicals + Gemstones + Full flower Hemp infused formulation. Each product in the Oeuvre Artistry Collection optimizes three functions:
cellular energy, moisture balance, and nutrient utilization. Four products comprise the <i>Oeuvre</i> collection:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in"> </td>
<td style="width: 0.25in; padding-right: 0.8pt"><span style="font-size: 10pt">●</span></td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt"><b>Purifying Exfoliator</b></span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt">●</span></td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt"><b>Replenishing Facial Oil</b></span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt">●</span></td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt"><b>Ultra-Nourishing Face Cream</b></span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt">●</span></td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt"><b>Revitalizing Eye Cream</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Drawing inspiration from petals, leaves, roots, minerals
and gemstones, <i>Oeuvre</i> celebrates the artistry of well-being and beauty, inside and out. <i>Oeuvre</i> products
are non-toxic, ungendered products made with zero GMO, retinyl palmitate, petroleum, mineral oil, parabens, sulfates, and synthetic colors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Oeuvre </span></i><span style="text-decoration: underline">Target Market</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Oeuvre</i> is our luxury segment product line.
With <i>Oeuvre</i>, we are targeting a large and influential consumer class of individuals that are “HENRYs” –
High-Earners-Not-Rich-Yet. They have discretionary income and are highly likely to be wealthy in the future. HENRYs earn between $100,000
and $250,000 annually. They are digitally fluent, love online shopping online, and are big discretionary spenders. Therefore, ouvreskincare.com
offers inclusive, aspirationally affordable luxury products positioned for them.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe the benefit of onboarding this demographic
to <i>Oeuvre</i> are twofold: securing valuable present customers and building relationships and business with those most likely
to be amongst the most affluent consumers in the future. By the year 2025, Millennials and Generation Z will represent more than 40% of
the overall luxury goods market, according to a 2019 report published by Boston Consulting Group. We seek to target such group for the
sale of our Oeuvre products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On social media, we target the following audiences
for our Oeuvre brand:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Women aged 30+</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luxury Skincare Enthusiasts</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBD Enthusiasts</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Crystal Lovers</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wellness Audience</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Makeup Artists</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Art</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beauty</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Influencers</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bloggers</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td>
<td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stores</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 6; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Future Product Lines</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has additional <i>Oeuvre</i> product skews
planned for introduction by the end of <span style="letter-spacing: -0.1pt">2022:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">Oeuvre fragrance amulets</td></tr>
<tr style="vertical-align: top">
<td></td><td>●</td><td style="text-align: justify">CBD infused candles</td></tr>
<tr style="vertical-align: top">
<td></td><td>●</td><td style="text-align: justify">CBD infused women’s fragrance</td></tr>
<tr style="vertical-align: top">
<td></td><td>●</td><td style="text-align: justify">OE complex bath and body regime</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -13.5pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Introduction of Recreational THC Beverages</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company plans on introducing a luxury lifestyle
THC beverage brand in the future. Upon development, product formulation, brand concept, packaging, and marketing presentations will be
designed to appeal to an upscale, sophisticated target audience. The Company is currently working with a formulator in developing unique
formulation attributes to achieve specific desired effects. This product launch is anticipated in approximately the fourth quarter of
2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Integrating the Metaverse </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Metaverse is a 3D experiential internet space
focused on social connection in which users can interact with computer-generated virtual worlds across a range of technologies. The Company
intends to integrate the Metaverse, including AI, Web 3.0 and non-fungible tokens (NFT’s), within our social media platforms and
interactive product displays.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Suppliers</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has several third-party suppliers and
is not reliant on any particular supplier for its product offerings. Many of our products contain CBD derived from industrial hemp or
cannabis which we obtain from third parties. Hemp cultivation can be impacted by weather patterns and other natural events, but we have
not yet faced any supply issues to date with obtaining raw materials for our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Distribution</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have two primary methods through which we sell
our products:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in"> </td>
<td style="width: 0.25in; padding-right: 0.8pt"><span style="font-size: 10pt">1.</span></td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt">Direct to Consumer online e-commerce platform</span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt">2.</span></td>
<td style="padding-right: 0.8pt"><span style="font-size: 10pt">Wholesale partners</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Marketing Strategy</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We support our brand launches through social media
and marketing campaigns, including utilizing influencers. Marketing and public relations firms are engaged by the Company to spearhead
its launch of <i>Oeuvre,</i> and will likely be engaged for our future planned brand launches as well.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sentient Brands Growth Strategies:</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To grow our company, Sentient Brands intends to:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 0.25in; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Create a leading consumer packaged goods company;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Partner with established distributers and retailers;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Focus on operational excellence and product quality; and</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Establish ongoing communication with the capital markets</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our mission is to create the next generation of CBD/THC
consumer brands. The Company believes it has assembled a highly accomplished team of branding and marketing professionals who have a combined
experience and track record of successfully launching and operating major brands in the consumer market space, which the Company believes
will provide it with it a competitive edge in its industry.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 7; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Customers</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company launched its <i>Oeuvre</i> product line
in the fourth quarter of 2021. The Company’s sales channels are direct to consumer and wholesale.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intellectual Property</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s <i>Oeuvre</i> brand is trademarked
in the United States, with a European trademark application pending. The Company expects to rely on trade secrets and proprietary know-how protection
for our confidential and proprietary information, however we have not yet taken security measures to protect this information.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Competition</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have experienced, and expect to continue to experience,
intense competition from a number of companies.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The current market for hemp-derived CBD products is
highly competitive, consisting of publicly-trade and privately-owned companies, many of which are more adequately capitalized than the
Company. The Company’s current publicly listed competitors include market leader Charlotte’s Web, CV Sciences, Elixinol, Abacus,
and Green Growth Brands, and private companies such as BeBoe, St. Jane. Mary’s, Lord Jones, Bluebird Folium Biosciences, Global
Cannabinoids, and Pure Kana. In addition, public and private U.S. and Canadian companies have entered the hemp-derived CBD consumer market
or have announced plans to do so. This market is highly fragmented, and according to the Hemp Business Journal, the vast majority of industry
participants generate less than $2 million in annual revenue. We see this an opportunity to get a foothold in the CBD consumer marketplace
with the goal of building Sentient Brands as a major brand name in this space.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Industry Overview</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market for products based on extracts of hemp
and cannabis, is expected to grow substantially over the coming years. Arcview Market Research and BDS Analytics are forecasting the combined
market to reach nearly $45 billion within the U.S. in the year 2024. While much of this market is expected to be comprised of high potency
THC-based products that will be sold in licensed dispensaries, certain research firms are still predicting the market to grow to $5.3
billion, $12.6 billion, and $2.2 billion by 2024 in the product areas of low THC cannabinoids, THC-free Cannabinoids and pharmaceutical
cannabinoids, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 20, 2018, President Donald J. Trump signed
into law the Agriculture Improvement Act of 2018, otherwise known as the “Farm Bill.” Prior to its passage, hemp, a member
of the cannabis family, and hemp-derived CBD were classified as a Schedule I controlled substances, and illegal under the Controlled Substances
Act (“CSA”). Under Section 10113 of the Farm Bill, hemp cannot contain more than 0.3 percent THC. THC refers to the chemical
compound found in cannabis that produces the psychoactive “high” associated with cannabis. Any cannabis plant that contains
more than 0.3 percent THC would be considered non-hemp cannabis or marijuana under federal law and thus would face no legal protection
under this new legislation and would be an illegal Schedule 1 drug under the CSA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With the passage of the Farm Bill, hemp cultivation
is broadly permitted. The Farm Bill explicitly allows the transfer of hemp-derived products across state lines for commercial or other
purposes. It also puts no restrictions on the sale, transport, or possession of hemp-derived products, so long as those items are produced
in a manner consistent with the law.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 8; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Developments</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Covid-19</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A novel strain of coronavirus (“Covid-19”)
emerged globally in December 2019 and has been declared a pandemic. The extent to which Covid-19 will impact our customers, business,
results and financial condition will depend on current and future developments, which are highly uncertain and cannot be predicted at
this time. While the Company’s day-to-day operations beginning March 2020 through the 2021 fiscal year have been impacted, we have
suffered less immediate impact as most staff can work remotely and can continue to develop our product offerings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 18, 2020, the Company, through its subsidiary
Jaguaring Company, entered into a Paycheck Protection Program Promissory Note and Agreement with KeyBank National Association, pursuant
to which the Company received loan proceeds of $231,500 (the “PPP Loan”). The PPP Loan was made under, and is subject to the
terms and conditions of, the PPP which was established under the CARES Act and is administered by the U.S. Small Business Administration.
The term of the PPP Loan is two years with a maturity date of April 18, 2022 and contains a favorable fixed annual interest rate of 1.00%.
Payments of principal and interest on the PPP Loan will be deferred for the first six months of the term of the PPP Loan until November
18, 2020. Principal and interest are payable monthly and may be prepaid by the Company at any time prior to maturity with no prepayment
penalties. Under the terms of the CARES Act, recipients can apply for and receive forgiveness for all or a portion of loans granted under
the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for certain permissible purposes
as set forth in the PPP, including, but not limited to, payroll costs (as defined under the PPP) and mortgage interest, rent or utility
costs (collectively, “Qualifying Expenses”), and on the maintenance of employee and compensation levels during the eight-week
period following the funding of the PPP Loan. The Company has been using the proceeds of the PPP Loan, for Qualifying Expenses. On December
8, 2021 the Company received notification from Key Bank that our forgiveness application has been approved in full by the Small Business
Administration, or SBA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Forward Stock Split / Increase of Authorized /
Name Change / Migratory Merger</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 9, 2020, the Company filed a Certificate
of Amendment of Articles of Incorporation (the “Certificate”) with the State of California to (i) effect a forward stock split
of its outstanding shares of common stock at a ratio of 7 for 1 (the “Forward Stock Split”), (ii) increase the number of authorized
shares of common stock from 50,000,000 shares to 500,000,000 shares, and (iii) effectuate a name change (the “Name Change”).
Fractional shares that resulted from the Forward Stock Split were rounded up to the next highest number. As a result of the Name Change,
the Company’s name changed from “Intelligent Buying, Inc.” to “Sentient Brands Holdings Inc.”. The Certificate
was approved by the majority of the Company’s shareholders and by the Board of Directors of the Company. The effective date of the
Forward Stock Split and the Name Change was March 2, 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the above, the Company filed an
Issuer Company-Related Action Notification Form with the Financial Industry Regulatory Authority. The Forward Stock Split and the Name
Change was implemented by FINRA on March 2, 2021. Our symbol on OTC Markets was INTBD for 20 business days from March 2, 2021 (the “Notification
Period”). Our new CUSIP number is 81728V 102. As a result of the name change, our symbol was changed to “SNBH” following
the Notification Period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, on January 29, 2021, the Company, merged
with and into its wholly owned subsidiary, Sentient Brands Holdings Inc., a Nevada corporation, pursuant to an Agreement and Plan of Merger
between Sentient Brands Holdings Inc., a California corporation, and Sentient Brands Holdings Inc., a Nevada corporation. Sentient Brands
Holdings Inc., a Nevada corporation, continued as the surviving entity of the migratory merger. Pursuant to the migratory merger, the
Company changed its state of incorporation from California to Nevada and each share of its common stock converted into one share of common
stock of the surviving entity in the migratory merger. No dissenters’ rights were exercised by any of the Company’s stockholders
in connection with the migratory merger.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the consummation of the migratory merger,
the articles of incorporation and bylaws of the Nevada corporation that was newly created as a wholly owned subsidiary of the Company
became the articles of incorporation and bylaws for the surviving entity in the migratory merger.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The foregoing information
is a summary of each of the matters described above, is not complete, and is qualified in its entirety by reference to the full text of
the exhibits, each of which is attached an exhibit to this Form 10-K Annual Report. Readers should review those exhibits for a complete
understanding of the terms and conditions associated with this matter.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<!-- Field: Page; Sequence: 9; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Government Regulation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The United States Food &amp; Drug Administration (“FDA”)
is generally responsible for protecting the public health by ensuring the safety, efficacy, and security of (1) prescription and over
the counter drugs; (2) biologics including vaccines, blood and blood products, and cellular and gene therapies; (3) foodstuffs including
dietary supplements, bottled water, and baby formula; and (4) medical devices including heart pacemakers, surgical implants, prosthetics,
and dental devices.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regarding its regulation of drugs, the FDA process
requires a review that begins with the filing of an investigational new drug (IND) application, with follow on clinical studies and clinical
trials that the FDA uses to determine whether a drug is safe and effective, and therefore subject to approval for human use by the FDA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aside from the FDA’s mandate to regulate drugs,
the FDA also regulates dietary supplement products and dietary ingredients under the Dietary Supplement Health and Education Act of 1994.
This law prohibits manufacturers and distributors of dietary supplements and dietary ingredients from marketing products that are adulterated
or misbranded. This means that these firms are responsible for evaluating the safety and labeling of their products before marketing to
ensure that they meet all the requirements of the law and FDA regulations, including, but not limited to the following labeling requirements:
(1) identifying the supplement; (2) nutrition labeling; (3) ingredient labeling; (4) claims; and (5) daily use information.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA has not approved cannabis, marijuana, hemp
or derivatives as a safe and effective drug for any indication. As of the date of this filing, we have not, and do not intend to file
an Investigational New Drug Application (IND) with the FDA, concerning any of our products that contain CBD derived from industrial hemp
or cannabis. Further, our products containing CBD derived from industrial hemp are not marketed or sold using claims that their use is
safe and effective treatment for any medical condition subject to the FDA’s jurisdiction.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Government Approvals</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not currently require any government
approvals for its operations or product offerings. In August 2019, the DEA affirmed that CBD preparations at or below the 0.3 percent
delta-9 THC threshold, is not a controlled substance, and a DEA registration is not required. As a result of the 2018 Farm Bill, the FDA
has been tasked with developing CBD regulations. The FDA has not yet published regulations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are continuously in the process of identifying
and/or developing potential new products to offer to our customers. Our expenditures on research and development have historically been
small and immaterial compared to our other business expenditures. We are currently developing new formulations for additional product
lines.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Employees</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that our success depends upon our ability
to attract, develop and retain key personnel. As of April 15, 2022, we employed two full-time employees. The Company otherwise currently
relies on the services of independent contractors. None of our employees are covered by collective bargaining agreements, and management
considers relations with our employees to be in good standing. Although we continually seek to add additional talent to our work force,
management believes that it currently has sufficient human capital to operate its business successfully.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our compensation programs are designed to align the
compensation of our employees with our performance and to provide the proper incentives to attract, retain and motivate employees to achieve
superior results. The structure of our compensation programs balances incentive earnings for both short-term and long-term performance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The health and safety of our employees is our highest
priority, and this is consistent with our operating philosophy. Since the onset of the COVID-19 pandemic, employees, including our specialized
technical staff, are working from home or in a virtual environment unless they have a requirement to be in the office for short-term tasks
and projects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The primary mailing address for the Company is 555
Madison Avenue, 5th Floor, New York, New York 10022. The Company’s telephone number is (646) 202-2897. The Company’s website
is <span style="text-decoration: underline">www.sentientbrands.com.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 10; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reports to Security Holders</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to furnish our shareholders annual reports
containing financial statements audited by our independent registered public accounting firm and to make available quarterly reports containing
unaudited financial statements for each of the first three quarters of each year. We file Quarterly Reports on Form 10-Q, Annual Reports
on Form 10-K and Current Reports on Form 8-K with the SEC in order to meet our timely and continuous disclosure requirements. We may also
file additional documents with the SEC if they become necessary in the course of our company’s operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The public may read and copy any materials that we
file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. The public may obtain information
on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports,
proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that site
is www.sec.gov.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Company History</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was incorporated in the State of California
on March 22, 2004. The Company was initially engaged in the business of asset management and sales of high-end computerized networking
equipment to emerging high technology companies. Commencing in 2011, the Company began providing advertising services to promote products
and services of third parties (primarily a related company, Anchorfree Wireless, Inc.) to the Company’s customer base. Under this
business model, third parties paid the Company a fee to disseminate their advertising to the Company’s customer base. On February
9, 2015, the Company’s principal shareholders sold their shares of common stock to AMS Encino Investments, Inc., a California corporation
controlled by Hector Guerrero, which resulted in a change of control of the Company. Following this change of control, in October 2016,
management discontinued the Company’s operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 13, 2019, we entered into a Reorganization
Agreement by and among Jaguaring Company, d/b/a Cannavolve (“Cannavolve”), a Washington corporation, and the shareholders
of Cannavolve listed in the Reorganization Agreement, pursuant to which the Company agreed to acquire 100% of the issued and outstanding
common stock of Cannavolve from these Cannavolve shareholders in exchange for up to 861,738 shares of common stock of the Company. On
April 27, 2019, and again on January 2, 2020, the Reorganization Agreement was amended. The Reorganization Agreement and its subsequent
amendments are referred to herein collectively as the “Reorganization Agreement.” On February 12, 2020, the parties to the
Reorganization Agreement entered into a termination agreement (the “Termination Agreement”) pursuant to which the Reorganization
Agreement was terminated by mutual consent of the parties in accordance with the terms of the Reorganization Agreement. The parties decided
to terminate the Reorganization Agreement in order to restructure the planned acquisition by the Company of Cannavolve. The foregoing
description of the Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the Termination
Agreement, a copy of which is filed as Exhibit 2.5 to this Annual Report on Form 10-K (this “Report”) and which is incorporated
herein by reference.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 14, 2020 (the “Closing Date”),
we entered into and closed (the “Closing”) an Agreement and Plan of Reorganization (the “Agreement”) with Cannavolve
and each of the 37 shareholders of Cannavolve who executed a counterpart signature to the Agreement (the “Cannavolve Shareholders”).
Pursuant to the Agreement, the Company agreed to acquire an aggregate of 33,674,262 shares of common stock of Cannavolve constituting
81.5% of the issued and outstanding shares of common stock of Cannavolve from the Cannavolve Shareholders in exchange for 702,111 shares
of common stock of the Company, constituting 9.6% of the issued and outstanding shares of common stock, $0.001 par value per share (the
“Common Stock”), of the Company (the “Reorganization “). Pursuant to the Agreement, the Company agreed to file
a Certificate of Determination with the State of California, as soon as practicable after the Closing, to create a new class of preferred
stock of the Company, the Series B Preferred Stock (the “New Preferred”), and further agreed to issue, as a post-Closing covenant,
1,000,000 shares of the New Preferred to Principal Holdings, LLC (“Principal”), in consideration of Principal successfully
negotiating the Agreement and performing due-diligence in connection with the Agreement. Additionally, pursuant to the Agreement, the
parties agreed that the Company’s then principal shareholder, Bagel Hole Inc. (“Bagel Hole”), which is owned solely
by Philip Romanzi, the Company’s Chief Executive, Chief Financial Officer, Treasurer, Secretary and sole director, would return
to the Company for cancellation and retirement an aggregate of 4,114,352 shares of Common Stock owned by Bagel Hole. Additionally, pursuant
to the Agreement, the parties agreed that at Closing, (i) Mr. Romanzi would resign from all executive officer and director positions with
the Company, (ii) George Furlan would be appointed as the Company’s Interim Chief Executive Officer, Interim Chief Financial Officer,
Interim Treasurer, Interim Secretary and Chief Operating Officer, and (iii) Dante Jones would be appointed as the Company’s sole
director. Further, the parties agreed that two additional directors would be appointed to the Company’s board of directors after
Closing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 11; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At Closing pursuant to the Agreement: (i) we issued
an aggregate of 702,111 shares of Common Stock to the Cannavolve Shareholders in exchange for 33,674,262 shares of Cannavolve common stock,
constituting 81.5% of the issued and outstanding shares of Cannavolve, resulting in Cannavolve becoming our 81.5% owned subsidiary; (ii)
Bagel Hole returned to the Company for cancellation and retirement 4,114,352 shares of Common Stock owned by Bagel Hole; (iii) Mr. Romanzi
resigned from all officer and director positions with the Company; (iv) George Furlan was appointed as the Company’s Interim Chief
Executive Officer, Interim Chief Financial Officer, Interim Treasurer, Interim Secretary and Chief Operating Officer; and (v) Dante Jones
was appointed as the Company’s sole director.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Agreement contains customary representations,
warranties, covenants and conditions for a transaction of this type for the benefit of the parties. For federal income tax purposes, it
is intended that the Reorganization qualify as a reorganization under the provisions of Section 368(a) of the Internal Revenue Code of
1986, as amended (the “Code”). However, we did not obtain any tax opinion and there can be no assurance that our intent that
the Reorganization qualify as a reorganization under the provisions of Section 368(a) of the Code is correct.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing description of the Agreement does not
purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which was previously filed with the Securities
and Exchange Commission as an Exhibit to Form 8-K on February 14, 2020 and which is incorporated herein by reference. Immediately prior
to the Closing of the Reorganization described in detail above pursuant to which Cannavolve became a majority owned subsidiary of the
Company, the Company was a “shell company,” as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934,
as amended (the “Exchange Act”).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Reorganization was accounted for using the acquisition
method of accounting and is based on the historical consolidated financial statements of the Company and Cannavolve. The acquisition method
of accounting is set forth in Accounting Standards Codification (“ASC”) 805, Business Combinations, and uses the fair value
concepts defined in ASC 820, Fair Value Measurement. Under the acquisition method of accounting, the assets acquired, and liabilities
assumed are generally recorded as of the completion of the purchase at their respective fair values and added to those of the Company.
Financial statements and reported results of operations of the Company issued after completion of the purchase will reflect these fair
value adjustments, but the Company’s previously issued historical financial statements will not be retroactively restated.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, on May 28, 2020, the Company entered
into and closed a Share Exchange Agreement (the “Share Exchange Agreement”) with the remaining 55 shareholders of Cannavolve
(the “Remaining Cannavolve Shareholders”). Pursuant to the Share Exchange Agreement, the Company acquired an aggregate of
7,656,441 shares of common stock of Cannavolve constituting the remaining 18.5% of the issued and outstanding shares of common stock of
Cannavolve from the Remaining Cannavolve Shareholders in exchange for 159,627 shares of common stock of the Company, constituting 0.02%
of the issued and outstanding shares of Common Stock of the Company (the “Share Exchange”). As a result of the Share Exchange,
Cannavolve is a wholly owned operating subsidiary of the Company. Additionally, On May 28, 2020, Mr. Furlan was appointed as a Director
of the Company. We anticipate that, in the near future, the size of the Board will be increased to three directors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Share Exchange Agreement contains customary representations,
warranties, covenants and conditions for a transaction of this type for the benefit of the parties. For federal income tax purposes, it
is intended that the Share Exchange qualify as a reorganization under the provisions of Section 368(a) of the Code. However, we did not
obtain any tax opinion and there can be no assurance that our intent that the Share Exchange qualify as a reorganization under the provisions
of Section 368(a) of the Code is correct.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 12; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing description of the Share Exchange Agreement
does not purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which is filed as an Exhibit
to this Form 10-K Annual Report. Readers should review those exhibits for a complete understanding of the terms and conditions associated
with this matter.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The offers, sales, and issuances of the securities
described above were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act
of 1933, as amended and/or Rule 506 as promulgated under Regulation D as transactions by an issuer not involving a public offering. The
recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale
in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each
of the recipients of securities in these transactions was an accredited or sophisticated person and had adequate access, through employment,
business or other relationships, to information about us.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Share Exchange was accounted for using the acquisition
method of accounting and is based on the historical consolidated financial statements of the Company and Cannavolve. The acquisition method
of accounting is set forth in Accounting Standards Codification (“ASC”) 805, Business Combinations, and uses the fair value
concepts defined in ASC 820, Fair Value Measurement. Under the acquisition method of accounting, the assets acquired, and liabilities
assumed are generally recorded as of the completion of the purchase at their respective fair values and added to those of the Company.
Financial statements and reported results of operations of the Company issued after completion of the purchase will reflect these fair
value adjustments, but the Company’s previously issued historical financial statements will not be retroactively restated.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 13; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_003"></span>ITEM 1A. RISK FACTORS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>You should carefully consider the following
material risk factors as well as all other information set forth or referred to in this report before purchasing shares of our common
stock. Investing in our common stock involves a high degree of risk. The Company believes all material risk factors have been presented
below. If any of the following events or outcomes actually occurs, our business operating results and financial condition would likely
suffer. As a result, the trading price of our common stock could decline, and you may lose all or part of the money you paid to purchase
our common stock.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Business and Industry</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are an early-stage company with very limited
operating history. Such limited operating history may not provide an adequate basis to judge our future prospects and results of operations.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have a limited operating history. We have limited
experience and operating history in which to assess our future prospects as a company, and this limited experience is compounded by our
recent shift in business towards product development and sales. In addition, the market for our products is highly competitive. If we
fail to successfully develop and offer our products and services in an increasingly competitive market, we may not be able to capture
the growth opportunities associated with them or recover our development and marketing costs, and our future results of operations and
growth strategies could be adversely affected. Our limited history may not provide a meaningful basis for investors to evaluate our business,
financial performance, and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Business interruptions, including any interruptions
resulting from COVID-19, could significantly disrupt our operations and could have a material adverse impact on us if the situation continues</i></b><i>.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Business interruptions, including any interruptions
resulting from COVID-19, could significantly disrupt our operations and could have a material adverse impact on the Company if the situation
continues.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, all employees, including our specialized
technical staff, are working from home or in a virtual environment. The Company always maintains the ability for team members to work
virtual and we will continue to stay virtual, until the State and or the Federal government indicate the environment is safe to return
to work. The ongoing coronavirus outbreak which began in China at the beginning of 2020 has impacted various businesses throughout the
world, including travel restrictions and the extended shutdown of certain businesses in impacted geographic regions. If the coronavirus
outbreak situation should worsen, we may experience disruptions to our business including, but not limited to equipment, to our workforce,
or to our business relationships with other third parties. The extent to which the coronavirus impacts our operations or those of our
third-party partners will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including
the duration of the outbreak, new information that may emerge concerning the severity of the coronavirus and the actions to contain the
coronavirus or treat its impact, among others. Any such disruptions or losses we incur could have a material adverse effect on our financial
results and our ability to conduct business as expected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may fail to successfully execute our business
plan.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our shareholders may lose their entire investment
if we fail to execute our business plan. Our prospects must be considered in light of the following risks and uncertainties, including
but not limited to, competition, the erosion of ongoing revenue streams, the ability to retain experienced personnel and general economic
conditions. We cannot guarantee that we will be successful in executing our business plan. If we fail to successfully execute our business
plan, we may be forced to cease operations, in which case our shareholders may lose their entire investment.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have a history of losses and may have to
further reduce our costs by curtailing future operations to continue as a business.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically we have had operating losses and our
cash flow has been inadequate to support our ongoing operations. For the year ended December 31, 2021, we had a net loss of $367,022,
and as of December 31, 2021, we had an accumulated deficit of $2,320,909. Our ability to fund our capital requirements out of our available
cash and cash generated from our operations depends on a number of factors, including our ability to gain market acceptance of our products
and continue growing our existing operations. If we cannot generate positive cash flow from operations, we will have to reduce our costs
and try to raise working capital from other sources. These measures could materially and adversely affect our ability to execute our operations
and expand our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<!-- Field: Page; Sequence: 14; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Company may suffer from lack of availability
of additional funds.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect to have ongoing needs for working capital
in order to fund operations and to continue to expand our operations. To that end, we may be required to raise additional funds through
equity or debt financing. However, there can be no assurance that we will be successful in securing additional capital on favorable terms,
if at all. If we are successful, whether the terms are favorable or unfavorable, there is a potential that we will fail to comply with
the terms of such financing, which could result in severe liability for our Company. If we are unsuccessful, we may need to (a) initiate
cost reductions; (b) forego business development opportunities; (c) seek extensions of time to fund liabilities, or (d) seek protection
from creditors. In addition, any future sale of our equity securities would dilute the ownership and control of your shares and could
be at prices substantially below prices at which our shares currently trade. Our inability to raise capital could require us to significantly
curtail or terminate our operations. We may seek to increase our cash reserves through the sale of additional equity or debt securities.
The sale of convertible debt securities or additional equity securities could result in additional and potentially substantial dilution
to our shareholders. The incurrence of indebtedness would result in increased debt service obligations and could result in operating and
financing covenants that would restrict our operations and liquidity. In addition, our ability to obtain additional capital on acceptable
terms is subject to a variety of uncertainties.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if we are unable to generate adequate
cash from operations, and if we are unable to find sources of funding, it may be necessary for us to sell all or a portion of our assets,
enter into a business combination, or reduce or eliminate operations. These possibilities, to the extent available, may be on terms that
result in significant dilution to our shareholders or that result in our shareholders losing all of their investment in our Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The commercial success of our products is dependent,
in part, on factors outside our control</i></b><i>.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The commercial success of our products is dependent
upon unpredictable and volatile factors beyond our control, such as the success of our competitors’ products. Our failure to attract
market acceptance and a sustainable competitive advantage over our competitors would materially harm our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are attempting to launch brands in new markets
and with new products. Our inability to effectively execute our business plan in relation to these new brands could negatively impact
our business.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are attempting launch new CBD product brands into
the marketplace. The CBD products market is relatively new, and therefore potentially more risky than other, more established product
categories. Further, we are attempting to launch new product lines containing CBD products, rather than rely on brands that we have currently
launched. Launching new products into new markets is risky and requires extensive marketing and business expertise. There can
be no assurances we will have the capital, personnel resources, or expertise to be successful in launching these new business efforts.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Business Can be Affected by Unusual Weather
Patterns</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hemp cultivation can be impacted by weather patterns
and these unpredictable weather patterns may impact our client-customers’ ability to harvest hemp. In addition, severe weather,
including drought and hail, can destroy a hemp crop, which could result a shortage of raw materials. If our suppliers are unable to obtain
sufficient hemp from which to process CBD, our ability to meet customer demand, generate sales, and maintain operations will be impacted.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our business and financial performance may be
adversely affected by downturns in the target markets that we serve or reduced demand for the types of products we sell.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Demand for our products is often affected by general
economic conditions as well as product-use trends in our target markets. These changes may result in decreased demand for our products.
The occurrence of these conditions is beyond our ability to control and, when they occur, they may have a significant impact on our sales
and results of operations. The inability or unwillingness of our customers to pay a premium for our products due to general economic conditions
or a downturn in the economy may have a significant adverse impact on our sales and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 15; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes within the cannabis industry may adversely
affect our financial performance.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Changes in the identity, ownership structure and strategic
goals of our competitors and the emergence of new competitors in our target markets may harm our financial performance. New competitors
may include foreign-based companies and commodity-based domestic producers who could enter our specialty markets if they are unable to
compete in their traditional markets.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are subject to certain tax risks and treatments
that could negatively impact our results of operations.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 280E of the Internal Revenue Code, as amended,
prohibits businesses from deducting certain expenses associated with trafficking-controlled substances (within the meaning of Schedule
I and II of the Controlled Substances Act). The IRS has invoked Section 280E in tax audits against various cannabis businesses in the
U.S. that are permitted under applicable state laws. Although the IRS issued a clarification allowing the deduction of certain expenses,
the scope of such items is interpreted very narrowly, and the bulk of operating costs and general administrative costs are not permitted
to be deducted. While there are currently several pending cases before various administrative and federal courts challenging these restrictions,
there is no guarantee that these courts will issue an interpretation of Section 280E favorable to cannabis businesses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Company’s industry is highly competitive,
and we have less capital and resources than many of our competitors which may give them an advantage in developing and marketing products
similar to ours or make our products obsolete.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are involved in a highly competitive industry where
we may compete with numerous other companies who offer alternative methods or approaches, who may have far greater resources, more experience,
and personnel perhaps more qualified than we do. Such resources may give our competitors an advantage in developing and marketing products
similar to ours or products that make our products less desirable to consumers or obsolete. There can be no assurance that we will be
able to successfully compete against these other entities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be unable to respond to the rapid change
in the industry and such change may increase costs and competition that may adversely affect our business</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rapidly changing technologies, frequent new product
and service introductions and evolving industry standards characterize our market. The continued growth of the Internet and intense competition
in our industry exacerbates these market characteristics. Our future success will depend on our ability to adapt to rapidly changing trends
and capitalize on them. We may experience difficulties that could delay or prevent the successful development, introduction or marketing
of our products. In addition, any new enhancements must meet the requirements of our current and prospective customers and must achieve
significant market acceptance. We could also incur substantial costs if we need to modify our products and services or infrastructures
to adapt to these changes. We also expect that new competitors may introduce products or services that are directly or indirectly competitive
with us. These competitors may succeed in developing products and services that have greater functionality or are less costly than our
products and services and may be more successful in marketing such products and services. Technological changes have lowered the cost
of operating, communications and computer systems and purchasing software. These changes reduce our cost of selling products and providing
services, but also facilitate increased competition by reducing competitors’ costs in providing similar products and services. This
competition could increase price competition and reduce anticipated profit margins.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 16; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our acquisition strategy creates risks for our
business.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect that we will pursue acquisitions of other
businesses, assets or technologies to grow our business. We may fail to identify attractive acquisition candidates, or we may be unable
to reach acceptable terms for future acquisitions. We might not be able to raise enough cash to compete for attractive acquisition targets.
If we are unable to complete acquisitions in the future, our ability to grow our business at our anticipated rate will be impaired. We
may pay for acquisitions by issuing additional shares of our Common Stock, which would dilute our stockholders, or by issuing debt, which
could include terms that restrict our ability to operate our business or pursue other opportunities and subject us to meaningful debt
service obligations. We may also use significant amounts of cash to complete acquisitions. To the extent that we complete acquisitions
in the future, we likely will incur future depreciation and amortization expenses associated with the acquired assets. We may also record
significant amounts of intangible assets, including goodwill, which could become impaired in the future. Acquisitions involve numerous
other risks, including:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 0.25in; padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">difficulties integrating the operations, technologies, services and personnel of the acquired companies;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">challenges maintaining our internal standards, controls, procedures and policies;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">diversion of management’s attention from other business concerns;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">over-valuation by us of acquired companies;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">litigation resulting from activities of the acquired company, including claims from terminated employees, customers, former stockholders and other third parties;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">insufficient revenues to offset increased expenses associated with the acquisitions and unanticipated liabilities of the acquired companies;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">insufficient indemnification or security from the selling parties for legal liabilities that we may assume in connection with our acquisitions;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">entering markets in which we have no prior experience and may not succeed;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">risks associated with foreign acquisitions, such as communication and integration problems resulting from geographic dispersion and language and cultural differences, compliance with foreign laws and regulations and general economic or political conditions in other countries or regions;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">potential loss of key employees of the acquired companies; and</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">impairment of relationships with clients and employees of the acquired companies or our clients and employees as a result of the integration of acquired operations and new management personnel.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our management team’s attention may be
diverted by recent acquisitions and searches for new acquisition targets, and our business and operations may suffer adverse consequences
as a result.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mergers and acquisitions are time intensive, requiring
significant commitment of our management team’s focus and resources. If our management team spends too much time focused on recent
acquisitions or on potential acquisition targets, our management team may not have sufficient time to focus on our existing business and
operations. This diversion of attention could have material and adverse consequences on our operations and our ability to be profitable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be unable to scale our operations successfully.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our growth strategy will place significant demands
on our management and financial, administrative and other resources. Operating results will depend substantially on the ability of our
officers and key employees to manage changing business conditions and to implement and improve our financial, administrative and other
resources. If the Company is unable to respond to and manage changing business conditions, or the scale of its operations, then the quality
of its services, its ability to retain key personnel, and its business could be harmed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Company may suffer from a lack of liquidity.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">By incurring indebtedness, the Company subjects itself
to increased debt service obligations which could result in operating and financing covenants that would restrict our operations and liquidity.
This would impair our ability to hire the necessary senior and support personnel required for our business, as well carry out its acquisition
strategy and other business objectives.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Economic conditions or changing consumer preferences
could adversely impact our business.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A downturn in economic conditions in one or more of
the Company’s markets could have a material adverse effect on our results of operations, financial condition, business and prospects
– especially in light of the fact that we are selling products generally considered non-essential and/or discretionary. Although
we attempt to stay informed of economic and customer trends, any sustained failure to identify and respond to trends could have a material
adverse effect on our results of operations, financial condition, business and prospects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 17; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The requirements of remaining a public company
may strain our resources and distract our management, which could make it difficult to manage our business.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are required to comply with various regulatory
and reporting requirements, including those required by the SEC. Complying with these reporting and other regulatory requirements are
time-consuming and expensive and could have a negative effect on our business, results of operations and financial condition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we secure intellectual property rights in
the future, such intellectual property rights will be valuable, and if we are unable to protect them or are subject to intellectual property
rights claims, our business may be harmed.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we secure intellectual property rights, including
those rights related to trademarks, copyrights and trade secrets, they will be important assets for us. We do not hold any patents protecting
our intellectual property at this time. Various events outside of our control may pose a threat to any intellectual property rights that
we acquire as well as to our business. For example, we may be subject to third-party intellectual property rights claims, and our technologies
may not be able to withstand any such claims. Regardless of the merits of the claims, any intellectual property claims could be time-consuming
and expensive to litigate or settle. In addition, if any claims against us are successful, we may have to pay substantial monetary damages
or discontinue any of our practices that are found to be in violation of another party’s rights. We also may have to seek a license
to continue such practices, which may significantly increase our operating expenses or may not be available to us at all. Also, the efforts
we may take to protect our proprietary rights may not be sufficient or effective. Any significant impairment of our potential future intellectual
property rights could harm our business or our ability to compete.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to protect the confidentiality
of our trade secrets and know-how, our business and competitive position would be harmed.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has not currently filed for any protection
of its intellectual property. We expect to rely on trade secrets and proprietary know-how protection for our confidential and proprietary
information, and we have taken security measures to protect this information. These measures, however, may not provide adequate protection
for our trade secrets, know-how, or other confidential information. Among other things, we seek to protect our trade secrets, know-how,
and confidential information by entering into confidentiality agreements with parties who have access to them, such as our employees,
collaborators, contract manufacturers, consultants, advisors, and other third parties. We cannot guarantee that we have entered into such
agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Moreover, there
can be no assurance that any confidentiality agreements that we have with our employees, consultants, or other third parties will provide
meaningful protection for our trade secrets, know-how, and confidential information or will provide adequate remedies in the event of
unauthorized use or disclosure of such information. Despite these efforts, any of these parties may breach the agreements and disclose
our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring
unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies
will be effective. Accordingly, there also can be no assurance that our trade secrets or know-how will not otherwise become known or be
independently developed by competitors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 18; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Enforcing a claim that a party illegally disclosed
or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade
secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary
information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed
by a competitor, our competitive position would be materially and adversely harmed. Trade secrets and know-how can be difficult to protect
as trade secrets and know-how will over time be disseminated within the industry through independent development, the publication of journal
articles, and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. If any
of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right
to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Because
from time to time we expect to rely on third parties in the development, manufacture and distribution of our products and provision of
our services, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into
confidentiality agreements and, if applicable, material transfer agreements, license agreements, collaboration agreements, supply agreements,
consulting agreements or other similar agreements with our advisors, employees, collaborators, licensors, suppliers, third-party contractors,
and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the
third parties to use or disclose our confidential information, including our trade secrets and know-how. Despite the contractual provisions
employed when working with third parties, the need to share trade secrets, know-how, and other confidential information increases the
risk that such trade secrets and know-how become known by our competitors, are inadvertently incorporated into the technology of others,
or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and
trade secrets, a competitor’s discovery of our trade secrets or know-how, or other unauthorized use or disclosure would impair our
competitive position and may have an adverse effect on our business and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, these agreements typically restrict the
ability of our advisors, employees, collaborators, licensors, suppliers, third-party contractors, and consultants to publish data potentially
relating to our trade secrets or know-how, although our agreements may contain certain limited publication rights. Despite our efforts
to protect our trade secrets and know-how, our competitors may discover our trade secrets or know-how, either through breach of our agreements
with third parties, independent development, or publication of information by any of our third-party collaborators. A competitor’s
discovery of our trade secrets or know-how would impair our competitive position and have a material adverse impact on our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The auditor included a “going concern”
note in its audit report.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As noted in our audited financials for the years ended
December 31, 2021 and 2020, we’ve sustained recurring operating losses and our accumulated deficit raises substantial doubt about
our ability to continue as a going concern. We may not have enough funds to sustain the business until it becomes profitable. Even if
we obtain financing, we may not accurately anticipate how quickly we may use the funds and whether these funds are sufficient to bring
the business to profitability.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are required to comply with certain provisions
of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”) and if we fail to continue to comply,
our business could be harmed, and the price of our securities could decline.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rules adopted by the SEC pursuant to Section 404 of
the Sarbanes-Oxley Act require an annual assessment of internal control over financial reporting, and for certain issuers an attestation
of this assessment by the issuer’s independent registered public accounting firm. The standards that must be met for management
to assess the internal control over financial reporting as effective are evolving and complex, and require significant documentation,
testing, and possible remediation to meet the detailed standards. We expect to incur significant expenses and to devote resources to Section
404 compliance on an ongoing basis. It is difficult for us to predict how long it will take or costly it will be to complete the assessment
of the effectiveness of our internal control over financial reporting for each year and to remediate any deficiencies in our internal
control over financial reporting. As a result, we may not be able to complete the assessment and remediation process on a timely basis.
In the event that our Chief Executive Officer or Chief Financial Officer determines that our internal control over financial reporting
is not effective as defined under Section 404, we cannot predict how regulators will react or how the market prices of our securities
will be affected; however, we believe that there is a risk that investor confidence and the market value of our securities may be negatively
affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Due to the economic hardships presented by the
COVID-19 pandemic, we obtained a loan from the Paycheck Protection Program (“PPP Loan”) from the U.S. Small Business Administration
(“SBA”) pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). We may not be entitled
to forgiveness under the PPP Loan which would negatively impact our cash flow, and our application for the PPP Loan could damage
our reputation.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 19; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 18, 2020, the Company received the proceeds
of a loan from a banking institution, in the principal amount of $231,500 (the “Loan”), pursuant to the Paycheck Protection
Program (the “PPP”) under Division A, Title I of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES
Act”), which was enacted on March 27, 2020. The Loan, which was in the form of a Note dated April 18, 2020, matures on April 18,
2022 and bears interest at a fixed rate of 1.00% per annum, payable monthly to KeyBank National Association, as the lender, commencing
on November 18, 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the CARES Act, as amended by the
Paycheck Protection Program Flexibility Act of 2020, the Company is eligible to apply for and receive forgiveness for all or a portion
of their respective PPP Loan. Such forgiveness will be determined, subject to limitations, based on the use of the Loan proceeds for certain
permissible purposes as set forth in the PPP, including, but not limited to, payroll costs (as defined under the PPP) and mortgage interest,
rent or utility costs (collectively, “Qualifying Expenses”) incurred during the 24 weeks subsequent to funding, and on the
maintenance of employee and compensation levels, as defined, following the funding of the PPP Loan. The Company used the proceeds of the
PPP Loan for Qualifying Expenses. However, no assurance is provided that the Company will be able to obtain forgiveness of the PPP Loan
in whole or in part. Any amounts that are not forgiven incur interest at 1.0% per annum and monthly repayments of principal and interest
are deferred for six months after the date of disbursement. While the PPP Loan currently has a two-year maturity, the amended law permits
the borrower to request a five-year maturity from its lender. The Company has applied for forgiveness for the full amount and is waiting
for the approval from the bank and the SBA. On December 8, 2021, the Company received notification from Key Bank that our forgiveness
application has been approved in full by the Small Business Administration, or SBA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to apply for the PPP Loan, we were required
to certify, among other things, that the current economic uncertainty made the PPP Loan request necessary to support our ongoing operations.
We made this certification in good faith after analyzing, among other things, our financial situation and access to alternative forms
of capital, and believe that we satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan was consistent
with the broad objectives of the CARES Act. At the time that we had made such certification, we could not predict with any certainty whether
we would be able to obtain the necessary financing to support our operations. The certification described above that we were required
to provide in connection with our application for the PPP Loan did not contain any objective criteria and was subject to interpretation.
However, on April 23, 2020, the SBA issued guidance stating that it is unlikely that a public company with substantial market value and
access to capital markets will be able to make the required certification in good faith. The lack of clarity regarding loan eligibility
under the CARES Act has resulted in significant media coverage and controversy with respect to public companies applying for and receiving
loans. If, despite our good-faith belief that we satisfied all eligible requirements for the PPP Loan, we are later determined to have
violated any of the laws or governmental regulations that apply to us in connection with the PPP Loan, such as the False Claims Act, or
it is otherwise determined that we were ineligible to receive the PPP Loan, we may be subject to penalties, including significant civil,
criminal and administrative penalties, and could be required to repay the PPP Loan in its entirety. In addition, our receipt of the PPP
Loan may result in adverse publicity and damage to our reputation, and a review or audit by the SBA or other government entity or claims
under the False Claims Act could consume significant financial and management resources.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Risks Related to Government Regulation</span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Possible yet unanticipated changes in federal
and state law could cause any of our current products, containing hemp-derived CBD oil to be illegal, or could otherwise prohibit,
limit or restrict any of our products containing CBD.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We distribute certain products containing hemp-derived CBD,
and we currently intend to develop and launch additional products containing hemp-derived CBD in the future. Until 2014, when 7 U.S. Code
§5940 became federal law as part of the Agricultural Act of 2014 (the “<i>2014 Farm Ac</i>t”), products containing oils
derived from hemp, notwithstanding a minimal or non-existing THC content, were classified as Schedule I illegal drugs. The 2014 Farm Act
expired on September 30, 2018, and was thereafter replaced by the Agricultural Improvement Act of 2018 on December 20, 2018 (the “<i>2018
Farm Act</i>”), which amended various sections of the U.S. Code, thereby removing hemp, defined as cannabis with less than 0.3%
THC, from Schedule 1 status under the Controlled Substances Act, and legalizing the cultivation and sale of industrial-hemp at the federal
level, subject to compliance with certain federal requirements and state law, amongst other things. More specifically, industrial hemp
is defined as “the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 tetrahydrocannabinol
concentration of not more than 0.3 percent on a dry weight basis.” The hemp oil we use comports with this definition of less than
0.3% THC. THC is the psychoactive component of plants in the cannabis family generally identified as marihuana or marijuana. There is
no assurance that the 2018 Farm Act will not be repealed or amended such that our products containing hemp-derived CBD would once again
be deemed illegal under federal law.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 20; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2018 Farm Act delegates the authority to the states
to regulate and limit the production of hemp and hemp derived products within their territories. Although many states have adopted laws
and regulations that allow for the production and sale of hemp and hemp derived products under certain circumstances, currently Idaho,
Mississippi and South Dakota have not adopted laws and regulations permitted by the 2018 Farm Act. No assurance can be given that such
state laws may not be implemented, repealed or amended such that our products containing hemp-derived CBD would be deemed legal in those
states that have not adopted regulations pursuant to the 2018 Farm Act, or illegal under the laws of one or more states now permitting
such products, which in turn would render such intended products illegal in those states under federal law even if the federal law is
unchanged. In the event of either repeal of federal or of state laws and regulations, or of amendments thereto that are adverse to our
intended products, we may be restricted or limited with respect to those products that we may sell or distribute, which could adversely
impact our intended business plan with respect to such intended products. Additionally, the FDA has indicated its view that certain types
of products containing CBD may not be permissible under the FDCA. The FDA’s position is related to its approval of Epidiolex, a
marijuana-derived prescription medicine to be available in the United States. The active ingredient in Epidiolex is CBD. On December 20,
2018, after the passage of the 2018 Farm Bill, FDA Commissioner Scott Gottlieb issued a statement in which he reiterated the FDA’s
position that, among other things, the FDA requires a cannabis product (hemp-derived or otherwise) that is marketed with a claim
of therapeutic benefit, or with any other disease claim, to be approved by the FDA for its intended use before it may be introduced into
interstate commerce and that the FDCA prohibits introducing into interstate commerce food products containing added CBD, and marketing
products containing CBD as a dietary supplement, regardless of whether the substances are hemp-derived. We do not believe that any of
our products fall within the FDA’s regulatory authority reiterated by Commissioner Gottlieb in December 2018, as we have not, and
do not intend to market any of our products with a claim of therapeutic benefit or with any other disease claim. However, should any regulatory
action, including action taken by the FDA, and/or legal proceeding alleging violations of such laws could have a material adverse effect
on our business, financial condition and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our hemp oil products are found to violate
federal law or if there is negative press from being in a hemp or cannabis-related business, we could be criminally prosecuted or forced
to suspend or cease operations.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is a misconception that that hemp and marijuana
are the same thing. This perception drives much of the regulation of hemp products. Although hemp and marijuana are both part of the cannabis
family, they differ in cultivation, function, and application. Despite the use of marijuana becoming more widely legalized, it is viewed
by many regulators and many others as an illegal product. Hemp, on the other hand, is used in a variety of other ways that include clothing,
skin products, pet products, dietary supplements (the use of CBD oil), and thousands of other applications. Hemp may be legally sold,
however the inability of many to understand the difference between hemp and marijuana often causes burdensome regulation and confusion
among potential customers. Therefore, we may be affected by laws related to cannabis and marijuana, even though our products are not the
direct targets of these laws.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cannabis is currently a Schedule I controlled substance
under the Controlled Substance Act (“CSA”) and is, therefore, illegal under federal law. Even in those states in which the
use of cannabis has been legalized pursuant to state law, its use, possession and/or cultivation remains a violation of federal law. A
Schedule I controlled substance is defined as one that has no currently accepted medical use in the United States, a lack of safety for
use under medical supervision and a high potential for abuse. The U.S. Department of Justice (the “DOJ”) describes Schedule
I controlled substances as “the most dangerous drugs of all the drug schedules with potentially severe psychological or physical
dependence.” If the federal government decides to enforce the CSA in the states, persons that are charged with distributing, possessing
with intent to distribute or growing cannabis could be subject to fines and/or terms of imprisonment, the maximum being life imprisonment
and a $50 million fine.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding the CSA, 29 U.S. states, the District
of Columbia and the U.S. territories of Guam and Puerto Rico allow their residents to use medical cannabis. The states of Alaska, California,
Colorado, Maine, Massachusetts, Nevada, Oregon, Vermont (effective July 1, 2018) and Washington, and the District of Columbia, allow cannabis
for adult recreational use. Such state and territorial laws are in conflict with the federal CSA, which makes cannabis use and possession
illegal at the federal level.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 21; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, cannabis, as mentioned above, is a schedule-I
controlled substance and is illegal under federal law. Even in those states in which the use of cannabis has been legalized, its production
and use remains a violation of federal law. Since federal law criminalizing the use of cannabis preempts state laws that legalize its
use, strict enforcement of federal laws regarding marijuana that would apply to the sale and distribution of our hemp oil products could
result in criminal charges brought against us and would likely result in our inability to proceed with our business plan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, any negative press resulting from any
incorrect perception that we have entered into the marijuana space could result in a loss of current or future business. It could also
adversely affect the public’s perception of us and lead to reluctance by new parties to do business with us or to own our Common
Stock. We cannot assure you that additional business partners, including but not limited to financial institutions and customers, will
not attempt to end or curtail their relationships with us. Any such negative press or cessation of business could have a material adverse
effect on our business, financial condition, and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our product candidates are not approved by the
FDA or other regulatory authority, and we face risks of unforeseen medical problems, and up to a complete ban on the sale of our product
candidates.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The efficacy and safety of pharmaceutical products
is established through a process of clinical testing under FDA oversight. Our products have not gone through this process because we believe
that the topical products, we sell are not subject to this process. However, if an individual were to use one of our products in an improper
manner, we cannot predict the potential medical harm to that individual. If such an event were to occur, the FDA or similar regulatory
agency might impose a complete ban on the sale or use of our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sources of hemp-derived CBD depend upon
legality of cultivation, processing, marketing and sales of products derived from those plants under state law.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hemp-derived CBD can only be legally produced in states
that have laws and regulations that allow for such production and that comply with the 2018 Farm Act, apart from state laws legalizing
and regulating medical and recreational cannabis or marijuana, which remains illegal under federal law and regulations. We purchase all
of our hemp-derived CBD from licensed growers and processors in states where such production is legal. As described in the preceding risk
factor, in the event of repeal or amendment of laws and regulations which are now favorable to the cannabis/hemp industry in such states,
we would be required to locate new suppliers in states with laws and regulations that qualify under the 2018 Farm Act. If we were to be
unsuccessful in arranging new sources of supply of our raw ingredients, or if our raw ingredients were to become legally unavailable,
our intended business plan with respect to such products could be adversely impacted.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Because our distributors may only sell and ship
our products containing hemp-derived CBD in states that have adopted laws and regulations qualifying under the 2018 Farm Act,
a reduction in the number of states having such qualifying laws and regulations could limit, restrict or otherwise preclude the sale of
intended products containing hemp-derived CBD.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The interstate shipment of hemp-derived CBD from one
state to another is legal only where both states have laws and regulations that allow for the production and sale of such products
and that qualify under the 2018 Farm Act. Therefore, the marketing and sale of our intended products containing hemp-derived CBD is limited
by such factors and is restricted to such states. Although we believe we may lawfully sell any of our finished products, including those
containing CBD, in a majority of states, a repeal or adverse amendment of laws and regulations that are now favorable to the distribution,
marketing and sale of finished products we intend to sell could significantly limit, restrict or prevent us from generating revenue related
to our products that contain hemp-derived CBD. Any such repeal or adverse amendment of now favorable laws and regulations could have an
adverse impact on our business plan with respect to such products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 22; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Risks Associated With Bank And Insurance Laws
And Regulations</span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We and our customers may have difficulty accessing
the service of banks, which may make it difficult to sell our products and services and manage our cash flows.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the commerce in cannabis, as not strictly defined
in the 2018 Farm Bill, is illegal under federal law, federally most chartered banks will not accept deposit funds from businesses involved
with cannabis. Consequently, businesses involved in the cannabis industry often have trouble finding a bank willing to accept their business.
The inability to open bank accounts may make it difficult for our customers to operate. There does appear to be recent movement to allow
state-chartered banks and credit unions to provide banking to the industry, but as of the date of this report there are only nominal entities
that have been formed that offer these services. Further, in a February 6, 2018, Forbes article, United States Secretary of the Treasury,
Steven Mnuchin, is reported to have testified that his department is “reviewing the existing guidance.” But he clarified that
he doesn’t want to rescind it without having an alternate policy in place to address public safety concerns.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial transactions involving proceeds generated
by cannabis-related conduct can form the basis for prosecution under the federal money laundering statutes, unlicensed money transmitter
statute and the U.S. Bank Secrecy Act. Despite guidance from the U.S. Department of the Treasury suggesting it may be possible for financial
institutions to provide services to cannabis-related businesses consistent with their obligations under the Bank Secrecy Act, banks remain
hesitant to offer banking services to cannabis-related businesses. Consequently, those businesses involved in the cannabis industry continue
to encounter difficulty establishing banking relationships. Our inability to maintain our current bank accounts would make it difficult
for us to operate our business, increase our operating costs, and pose additional operational, logistical and security challenges and
could result in our inability to implement our business plan. Similarly, many of our customers are directly involved in cannabis sales
and further restrictions to their ability to access banking services may make it difficult for them to purchase our products, which could
have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are subject to certain federal regulations
relating to cash reporting.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Bank Secrecy Act, enforced by FinCEN, requires
us to report currency transactions in excess of $10,000, including identification of the customer by name and social security number,
to the IRS. This regulation also requires us to report certain suspicious activity, including any transaction that exceeds $5,000 that
we know, suspect or have reason to believe involves funds from illegal activity or is designed to evade federal regulations or reporting
requirements and to verify sources of funds. Substantial penalties can be imposed against us if we fail to comply with this regulation.
If we fail to comply with these laws and regulations, the imposition of a substantial penalty could have a material adverse effect on
our business, financial condition and results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Due to our involvement in the cannabis industry,
we may have a difficult time obtaining the various insurances that are desired to operate our business, which may expose us to additional
risk and financial liability</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Insurance that is otherwise readily available, such
as general liability, and directors and officer’s insurance, is more difficult for us to find, and more expensive, because we are
service providers to companies in the cannabis industry. There are no guarantees that we will be able to find such insurances in the future,
or that the cost will be affordable to us. If we are forced to go without such insurances, it may prevent us from entering into certain
business sectors, may inhibit our growth, and may expose us to additional risk and financial liabilities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Risks Related to Our Common Stock</span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Our stock price has experienced volatility and
may continue to experience volatility, and as a result, investors in its common stock could incur substantial losses.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company’s stock
price has fluctuated in the past, has recently been volatile, and may be volatile in the future. During 2021, the highest bid price for
our common stock was $3.15 per share, while the lowest bid price during that period was $0.04 per share. The Company may incur rapid
and substantial decreases in its stock price in the foreseeable future that are unrelated to its operating performance or prospects.
In addition, the recent COVID-19 pandemic has caused broad stock market and industry fluctuations. The stock market has experienced extreme
volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors
may experience losses on their investment in the Company’s common stock. The trading price of our common stock could continue to
fluctuate widely due to:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<!-- Field: Page; Sequence: 23; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top">
<td style="width: 0.25in"> </td>
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">investor reaction to the Company’s business strategy;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">the success of competitive products or technologies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to the Company’s products;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">limited current liquidity and the possible need to raise additional capital;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">the Company’s ability or inability to raise additional capital and the terms on which it raises it;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">the Company’s public disclosure of the terms of any financing which it consummates in the future;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">declines in the market prices of stocks generally;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">variations in the Company’s financial results or those of companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">the Company’s failure to become profitable;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">the Company’s failure to raise working capital;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">announcements of technological innovations by us or our potential competitors;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">changes in or our failure to meet the expectations of securities analysts;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">new products offered by us or our competitors;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">announcements of strategic relationships or strategic partnerships;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">any acquisitions we may consummate;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">announcements by the Company or its competitors of significant contracts, new services, acquisitions, commercial relationships, joint ventures or capital commitments;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">cancellation of key contracts;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">the Company’s failure to meet financial forecasts we publicly disclose;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">future sales of common stock, or securities convertible into or exercisable for common stock;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">adverse judgments or settlements obligating us to pay damages;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">future issuances of common stock in connection with acquisitions or other transactions;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">acts of war, terrorism, or natural disasters;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">trading volume in our stock;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">sales of the Company’s common stock by it or its stockholders;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">developments relating to patents or property rights;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">general economic, industry and market conditions; and</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">government regulatory changes; or</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td> </td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">other events or factors that may be beyond our control, including those resulting from such events, or the prospect of such events, including war, terrorism and other international conflicts, public health issues including health epidemics or pandemics, such as the recent outbreak of the COVID-19 pandemic, and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United States or elsewhere, could disrupt the Company’s operations, disrupt the operations of its suppliers or result in political or economic instability.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"> </p>
<!-- Field: Page; Sequence: 24; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These broad market and industry factors may seriously
harm the market price of the Company’s common stock, regardless of its operating performance. Since the stock price of its common
stock has fluctuated in the past, has been recently volatile and may be volatile in the future, investors in its common stock could incur
substantial losses. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted
against companies. Such litigation, if instituted against the Company, could result in substantial costs and diversion of management’s
attention and resources, which could materially and adversely affect its business, financial condition, results of operations and growth
prospects. There can be no guarantee that the Company’s stock price will remain at current prices or that future sales of its common
stock will not be at prices lower than those sold to investors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the securities markets in general have
experienced extreme price and trading volume volatility in the past. The trading prices of securities of many companies at our stage of
growth have fluctuated broadly, often for reasons unrelated to the operating performance of the specific companies. These general market
and industry factors may adversely affect the trading price of our common stock, regardless of our actual operating performance. If our
stock price is volatile, we could face securities class action litigation, which could result in substantial costs and a diversion of
management’s attention and resources and could cause our stock price to fall.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are be subject to the “penny stock”
rules which adversely affect the liquidity of our Common Stock.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SEC has adopted regulations which generally define
“penny stock” to be an equity security that has a market price of less than $5.00 per share, subject to specific exemptions.
The market price of our Common Stock is less than $5.00 per share and therefore we are considered a “penny stock” according
to SEC rules. This designation requires any broker-dealer selling these securities to disclose certain information concerning the transaction,
obtain a written agreement from the purchaser and determine that the purchaser is reasonably suitable to purchase the securities. These
rules limit the ability of broker-dealers to solicit purchases of our Common Stock and therefore reduce the liquidity of the public market
for our shares should one develop.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Securities which are traded on the OTCPink®,
may not provide as much liquidity for our investors as more recognized senior exchanges such as the Nasdaq stock market or other national
or regional exchanges.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2010, the Company’s Common Stock was approved
by FINRA to trade on the OTCBB under the symbol “INTB” on an unpriced basis. There has never been a two-sided quotation for
the stock, and it has yet to trade. On December 9, 2020, the Company filed a Certificate of Amendment of Articles of Incorporation (the
“Certificate”) with the State of California to (i) effect a forward stock split of its outstanding shares of common stock
at a ratio of 7 for 1 (the “Forward Stock Split”), (ii) increase the number of authorized shares of common stock from 50,000,000
shares to 500,000,000 shares, and (iii) effectuate a name change (the “Name Change”). As a result of the Name Change, the
Company’s name changed from “Intelligent Buying, Inc.” to “Sentient Brands Holdings Inc.”. The Certificate
was approved by the majority of the Company’s shareholders and by the Board of Directors of the Company. The effective date of the
Forward Stock Split and the Name Change was March 2, 2021. In connection with the above, the Company filed an Issuer Company-Related Action
Notification Form with the Financial Industry Regulatory Authority. The Forward Stock Split and the Name Change was implemented by FINRA
on March 2, 2021. As a result of the name change, our symbol was changed to “SNBH”.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s Common Stock is currently quoted
on the Pink tier of OTC Markets under the symbol of “SNBH”. OTC Markets is a computer network that provides information on
current “bids” and “asks”, as well as volume information. As of the date hereof, no active trading market has
developed for our Common Stock. Securities traded on OTC Markets are usually thinly traded, highly volatile, have fewer market makers
and are not followed by analysts. The SEC’s order handling rules, which apply to NASDAQ-listed securities, do not apply to securities
quoted on OTC Markets. Quotes for stocks included on OTC Markets are not listed in newspapers and are often unavailable at many of the
online websites which publish stock quotes. Therefore, prices for securities traded solely on OTC Markets may be difficult to obtain and
holders of our securities may be unable to resell their securities at or near their original acquisition price, or at any price.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 25; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Industry Regulatory Authority (“FINRA”)
sales practice requirements may also limit a stockholder’s ability to buy and sell our Common Stock, which could depress the price
of our Common Stock.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FINRA has adopted rules that require a broker-dealer
to have reasonable grounds for believing that the investment is suitable for that customer before recommending an investment to a customer.
Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts
to obtain information about the customer’s financial status, tax status, investment objectives, and other information. Under interpretations
of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least
some customers. Thus, the FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our Common
Stock, which may limit your ability to buy and sell our shares of Common Stock, have an adverse effect on the market for our shares of
Common Stock, and thereby depress our price per share of Common Stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The sale of the additional shares of Common
Stock could cause the value of our Common Stock to decline.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The sale of a substantial number of shares of our
Common Stock, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future
at a time and at a price that we might otherwise wish.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The Common Stock constitutes restricted securities
and is subject to limited transferability.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Common Stock should be considered a long-term,
illiquid investment. The Common Stock has not been registered under the Securities Act of 1933, as amended (the “Securities Act”),
and cannot be sold without registration under the Securities Act or any exemption from registration. In addition, the Common Stock is
not registered under any state securities laws that would permit their transfer. Because of these restrictions and the absence of an active
trading market for our securities, a stockholder will likely be unable to liquidate an investment even though other personal financial
circumstances would dictate such liquidation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Because we will likely issue additional shares
of our Common Stock, investment in the Company could be subject to substantial dilution.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investors’ interests in the Company will be
diluted and Investors may suffer dilution in their net book value per share when we issue additional shares. We are authorized to issue
500,000,000 shares of Common Stock, $0.001 par value per share, and 25,000,000 shares of preferred stock, $0.001 par value per share.
We anticipate that all or at least some of our future funding, if any, will be in the form of equity financing from the sale of our Common
Stock. If we do sell or issue more Common Stock, investors’ investment in the Company will be diluted. Dilution is the difference
between what you pay for your stock and the net tangible book value per share immediately after the additional shares are sold by us.
If dilution occurs, any investment in the Company’s Common Stock could seriously decline in value.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Common Stock is subject to risks arising
from restrictions on reliance on Rule 144 by shell companies or former shell companies.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under a regulation of the SEC known as “Rule
144,” a person who beneficially owns restricted securities of an issuer and who is not an affiliate of that issuer may sell them
without registration under the Securities Act provided that certain conditions have been met. One of these conditions is that such person
has held the restricted securities for a prescribed period, which would be six months for shares of a company which has never been a
shell company. However, Rule 144 is unavailable for the resale of securities issued by an issuer that is a shell company (other than
a business combination related shell company) or, unless certain conditions are met, that has been at any time previously a shell company.
Because we had been a shell company in the past, shareholders purchasing restricted securities will be unable to publicly resell their
shares until one year after this Form 8-K is filed at the earliest, if at all.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 26; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The SEC defines a shell company as a company that
has (a) no or nominal operations and (b) either (i) no or nominal assets, (ii) assets consisting solely of cash and cash equivalents;
or (iii) assets consisting of any amount of cash and cash equivalents and nominal other assets.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the Closing of the Reorganization as
described in Items 1.01 and 2.01, the Company ceased being a shell company as such term is defined in Rule 12b-2 under the Exchange Act.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we believe that as a result of the Closing of
the Reorganization, the Company ceased to be a shell company, the SEC and others whose approval is required in order for shares to be
sold under Rule 144 might take a different view.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rule 144 is available for the resale of securities
of former shell companies if and for as long as the following conditions are met:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">(i) the issuer of the securities
that was formerly a shell company has ceased to be a shell company,</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">(ii) the issuer of the securities
is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act,</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">(iii) the issuer of the securities
has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period
that the issuer was required to file such reports and materials), other than Current Reports on Form 8-K; and</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">(iv) at least one year has elapsed
from the time that the issuer filed current comprehensive disclosure with the SEC reflecting its status as an entity that is not a shell
company known as “Form 10 Information.”</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders who receive the Company’s restricted
securities will not be able to sell them pursuant to Rule 144 without registration until the Company has met the other conditions to this
exception and then for only as long as the Company continues to meet the condition described in subparagraph (iii), above, and is not
a shell company. No assurance can be given that the Company will meet these conditions or that, if it has met them, it will continue to
do so, or that it will not again be a shell company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fiduciaries investing the assets of a trust
or pension, or profit-sharing plan must carefully assess an investment in our Company to ensure compliance with ERISA.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In considering an investment in the Company of a portion
of the assets of a trust or a pension or profit-sharing plan qualified under Section 401(a) of the Code and exempt from tax under Section
501(a), a fiduciary should consider (i) whether the investment satisfies the diversification requirements of Section 404 of ERISA; (ii)
whether the investment is prudent, since the Company’s common stock shares are not freely transferable and there may not be a market
created in which the Common Stock may be sold or otherwise disposed; and (iii) whether interests in the Company or the underlying assets
owned by the Company constitute “Plan Assets” under ERISA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Common Stock price may decrease due to factors
beyond our control.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The stock market from time to time has experienced
extreme price and volume fluctuations, which have particularly affected the market prices for emerging growth companies, and which often
have been unrelated to the operating performance of the companies. These broad market fluctuations may adversely affect the market price
of our stock, if a trading market for our stock ever develops. If our shareholders sell substantial amounts of their stock in the public
market, the price of our stock could fall. These sales also might make it more difficult for us to sell equity, or equity-related securities,
in the future at a price we deem appropriate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 27; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price of our stock may also fluctuate significantly
in response to the following factors, most of which are beyond our control:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 0.25in; padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">variations in our quarterly operating results,</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">changes in general economic conditions,</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">changes in market valuations of similar companies,</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">announcements by us or our competitors of significant acquisitions, strategic partnerships or joint ventures, or capital commitments,</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">poor reviews;</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">loss of a major customer, partner or joint venture participant; and</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">the addition or loss of key managerial and collaborative personnel.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any such fluctuations may adversely affect the market
price or value of our Common Stock, regardless of our actual operating performance. As a result, stockholders may be unable to sell their
shares, or may be forced to sell them at a loss.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>FINRA sales practice requirements may also limit
a stockholder’s ability to buy and sell our stock.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the “penny stock” rules
described above, FINRA has adopted Rule 2111 that requires a broker-dealer to have reasonable grounds for believing that an investment
is suitable for a customer before recommending the investment. Prior to recommending speculative low-priced securities to their non-institutional
customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status,
investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that
speculative low-priced securities will not be suitable for at least some customers. The FINRA requirements make it more difficult for
broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have
an adverse effect on the market for our shares.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We do not intend to pay dividends for the foreseeable
future.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never declared or paid any cash dividends
on our stock and do not intend to pay any cash dividends in the foreseeable future. We anticipate that we will retain all of our future
earnings for use in the development of our business and for general corporate purposes. Any determination to pay dividends in the future
will be at the discretion of our Board.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to comply with the financial
reporting requirements mandated by the SEC’s regulations, investors may lose confidence in our financial reporting and the price
of our common stock, if a market ever does develop for it, could decline.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we fail to maintain effective internal controls
over financial reporting, our ability to produce timely, accurate and reliable periodic financial statements could be impaired. If we
do not maintain adequate internal control over financial reporting, investors could lose confidence in the accuracy of our periodic reports
filed under the Exchange Act. Additionally, our ability to obtain additional financing could be impaired or a lack of investor confidence
in the reliability and accuracy of our public reporting could cause our stock price to decline. In the past we have been delinquent in
our SEC reporting and have not maintained adequate internal control over financial reporting. We plan remain current with our filing obligations
with the SEC after the filing of this Form 8-K. However, there can be no assurance that we will be able to do so.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_004"></span>ITEM 1B. UNRESOLVED STAFF COMMENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_005"></span>ITEM 2. PROPERTIES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our principal offices are located at 555 Madison
Ave., 5<sup>th </sup>Floor, New York, New York 10022.  Our principal office location is a virtual office, which provides us with
the flexibility of using office space on an as-needed basis. Pursuant to our office lease, we pay $89.00 per month on a month-to-month
basis. All of our employees, including our specialized technical staff, are currently working from home or in a virtual environment.
The Company always maintains the ability for our team members to work virtually, and we will continue to work virtually as an organization
for the foreseeable future.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 28; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_006"></span>ITEM 3. LEGAL PROCEEDINGS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we may become involved in various
lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties,
and an adverse result in these or other matters may arise from time to time that may harm our business. The Company had no pending legal
proceedings or claims.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None of our directors, officers, or affiliates are
involved in a proceeding adverse to our business or have a material interest adverse to our business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_007"></span>ITEM 4. MINE SAFETY DISCLOSURE</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<!-- Field: Page; Sequence: 29; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_008"></span>PART II</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_009"></span>ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY,
RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Market Information</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s common stock is traded on OTC
Markets under the stock symbol “SNBH”.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Holders of our Common Stock</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of April 14, 2022, there
were approximately 130 stockholders of record of our common stock, and 51,920,387 shares of common stock outstanding. This number does
not include shares held by brokerage clearing houses, depositories or others in unregistered form. The stock transfer agent for our securities
is Empire Stock Transfer, Inc., 1859 Whitney Mesa Dr., Henderson, NV 89014.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Dividends</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has never declared or paid any cash or
stock dividends on its common stock. The Company currently intends to retain future earnings, if any, to finance the expansion of its
business. As a result, the Company does not anticipate paying any cash dividends in the foreseeable future.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company presently does not have an equity compensation plan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recent Sales of Unregistered Securities</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>April 2021 Financing</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 27, 2021 (the “Issuance Date”),
the Company entered into a Securities Purchase Agreement with an accredited investor (the “April 2021 Investor”) providing
for the sale by the Company to the April 2021 Investor of a 10% Senior Secured Convertible Promissory Note in the principal amount of
$315,789 (the “April 2021 Note”, and, the “Financing”). The principal amount of the April 2021 Note includes an
Original Issue Discount of $15,789, resulting in $300,000 in total proceeds received by the Company in the Financing. In addition to the
April 2021 Note, the April 2021 Investor also received 250,000 shares of common stock of the Company (the “Commitment Shares”),
and a common share purchase warrant (the “April 2021 Warrant”, and together with the April 2021 Note and the Commitment Shares,
the “Securities”) to acquire 500,000 shares of common stock of the Company. The April 2021 Warrant is exercisable for five
years at an exercise price of $0.60. The closing of the Financing in the amount of $300,000 occurred on April 27, 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The April 2021 Note matures 12 months from the Issuance
Date (the “Maturity Date”), and interest associated with the April 2021 Note is the higher of 10% per annum or WSJ Prime plus
7%, which is payable monthly by the Company. The April 2021 Note may be prepaid by the Company in whole or in part at any time, at 110%
of the outstanding principal and accrued interest. The April 2021 Note is convertible at the option of the April 2021 Investor into shares
of common stock of the Company at $0.40 per share (the “Fixed Conversion Price”); <i>provided, however</i>, that in the
event of default by the Company of the April 2021 Note, the Conversion Price will immediately be equal to the lesser of (i) the Fixed
Conversion Price; (ii) seventy five percent (75%) of the lowest intraday price of the Company’s common stock during the twenty one
(21) consecutive trading day period immediately preceding the trading day that the Company receives a notice of conversion from the April
2021 Investor or (iii) the discount to market based on a subsequent financing of the Company. The April 2021 Note and the April 2021 Warrant
carry standard anti-dilution provisions. At all times while the April 2021 Note is outstanding, we agreed to reserve from our authorized
but unissued shares of common stock seven (7) times the number of shares that is actually issuable upon full conversion of the April 2021
Note, and for the initial issuance of the April 2021 Note, 6,000,000 shares of common stock will be reserved. In addition, pursuant to
the April 2021 Note we agreed to file a Form 1-A Regulation A Offering Statement to register the Securities (provided that the Securities
may legally be registered on a Form 1-A Regulation A Offering Statement pursuant to applicable U.S. securities laws and regulations).
The April 2021 Note might be accelerated if an event of default occurs under the terms of the April 2021 Note, including, but not limited
to, the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its
SEC filings. The April 2021 Note may not be converted and/or exercised by the April 2021 Investor into more than 4.99% of the Company’s
outstanding common stock at any point in time; <i>provided, however</i>, that this limitation on conversion may be waived by the
April 2021 Investor up to a maximum of 9.99%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 30; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If prior to the Maturity Date the Company enters into
a subsequent financing on terms that are more favorable to the investor(s) in the subsequent financing than the terms of the Financing,
then terms of the Financing will be amended to include such better terms so long as the April 2021 Note is outstanding. In addition, the
April 2021 Investor has the right of first refusal on any financing so long as the April 2021 Note is outstanding. Additionally, the April
2021 Investor has the right to be repaid 100% of the remaining balance of principal and interest under the April 2021 Note upon the Company
closing on a financing or asset sale in the minimum amount of $2,000,000. Further, the April 2021 Investor has the right to participate
in any future offering by the Company for a period of 18 months from the Issuance Date for an amount up to the Financing amount in strict
accordance with the terms of such future offering.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The obligations of the Company under the April 2021
Note constitute a first priority security interest and rank senior with respect to any and all indebtedness of the Company existing prior
to or incurred as of or following the initial Issuance Date. The obligations of the Company under the April 2021 Note are secured pursuant
to the Security and Pledge Agreement entered into between the Company and the April 2021 Investor on the Issuance Date. So long as the
Company has any obligation under the April 2021 Note, the Company will not incur or suffer to exist or guarantee any indebtedness that
is senior to or pari passu with the Company’s obligations under the April 2021 Note. The April 2021 Note is secured by (i) the assets
of the Company and (ii) 2,752,040 issued and outstanding shares of common stock of Nukkleus Inc. common stock held by a certain shareholder
of the Company (the “Pledgor”) pursuant to a stock pledge agreement to be entered into between the April 2021 Investor and
the Pledgor within two weeks of the Issuance Date.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company claims an exemption from the registration
requirements of the Securities Act of 1933 (the “Securities Act”) for the private placement of these Securities pursuant to
Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act. The April 2021 Investor is
an accredited investor as defined in Rule 501 of Regulation D promulgated under the Securities Act. As of the date hereof, the Company
is obligated on $315,789 in face amount of the April 2021 Note issued to the April 2021 Investor. The April 2021 Note is a debt obligation
arising other than in the ordinary course of business which constitutes a direct financial obligation of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing information is a summary of each of
the agreements involved in the transactions described above, is not complete, and is qualified in its entirety by reference to the full
text of those agreements, each of which is attached an exhibit to this Annual Report on Form 10-K. Readers should review those agreements
for a complete understanding of the terms and conditions associated with this transaction.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white"><i>September
2021 Financing</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i> </i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
September 23, 2021 (the “Issuance Date”)</span>, the Company issued an 18% Promissory Note in the principal amount of $125,000
(the “September 2021 Note”) to an accredited investor (the “September 2021 Investor”). The September 2021 Note
matures six (6) months from the Issuance Date (the “Maturity Date”), and the September 2021 Investor, at its sole election
on the Maturity Date, may convert the interest accrued on the September 2021 Note into shares of common stock of the Company at $0.05
per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company claims an exemption
from the registration requirements of the Securities Act of 1933 (the “Securities Act”) for the private placement of the September
2021 Note pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act. The
September 2021 Investor is an accredited investor as defined in Rule 501 of Regulation D promulgated under the Securities Act. As of the
date hereof, the Company is obligated on $125,000 in face amount of the September 2021 Note issued to the September 2021 Investor. The
September 2021 Note is a debt obligation arising other than in the ordinary course of business which constitutes a direct financial obligation
of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The foregoing information
is a summary of each of the agreements involved in the transaction described above, is not complete, and is qualified in its entirety
by reference to the full text of those agreements, each of which is attached an exhibit to this Annual Report on Form 10-K. Readers should
review those agreements for a complete understanding of the terms and conditions associated with this transaction.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<!-- Field: Page; Sequence: 31; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>November 2021 Financing</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i> </i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On November 18, 2021 (the
“Issuance Date”), the Company entered into a Securities Purchase Agreement with an accredited investor (the “November
2021 Investor”) providing for the sale by the Company to the November 2021 Investor of a 10% Senior Secured Convertible Promissory
Note in the principal amount of $400,000 (the “November 2021 Note”, and, the “Financing”), to be paid by
the November 2021 Investor to the Company in two tranches (each, a “Tranche”). The first Tranche consists of a payment by
the November 2021 Investor to the Company on the Issue Date of $200,000, from which the November 2021 Investor retained $5,000 to cover
its legal fees. A second Tranche consisting of $200,000 will be paid by the November 2021 Investor to the Company not later than 30 days
after the Issuance Date, resulting in $395,000 in total proceeds to be received by the Company in the Financing. In addition to the November
2021 Note, the November 2021 Investor also received a common share purchase warrant (the “November 2021 Warrant”, and together
with the November 2021 Note, the “Securities”) to acquire 666,667 shares of common stock of the Company. The November 2021
Warrant is exercisable for five years at an exercise price of $0.45. The closing of the Financing in the amount of $400,000 occurred on
November 22, 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The maturity date (“Maturity
Date”) for each Tranche is at the end of the period that begins from the date each Tranche is paid and ends 12 months thereafter,
and interest associated with the November 2021 Note is 10% per annum. The November 2021 Note may be prepaid by the Company in whole or
in part at any time at 105% of the outstanding principal and accrued interest. The November 2021 Note is convertible at the option of
the November 2021 Investor into shares of common stock of the Company at $0.30 per share; provided, however, that in the event of
default by the Company of the November 2021 Note, the Conversion Price will immediately be equal to the lesser of 22% per annum or the
maximum legal amount permitted by law. The November 2021 Note and the November 2021 Warrant carry standard anti-dilution provisions. At
all times while the November 2021 Note is outstanding, the Company agreed to reserve from its authorized but unissued shares of common
stock seven (7) times the number of shares that is actually issuable upon full conversion of the November 2021 Note, resulting in 10,500,000
reserved shares of common stock. The November 2021 Note might be accelerated if an event of default occurs under the terms of the November
2021 Note, including, but not limited to, the Company’s failure to pay principal and interest when due, certain bankruptcy events,
or if the Company is delinquent in its required SEC filings for 30 consecutive days. The November 2021 Note may not be converted and/or
exercised by the November 2021 Investor into more than 4.99% of the Company’s outstanding common stock at any point in time; provided,
however, that this limitation on conversion may be waived by the November 2021 Investor up to a maximum of 9.99%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If, prior to the Maturity
Date, the Company enters into a subsequent financing on terms that are more favorable to the investor(s) in the subsequent financing than
the terms of the Financing, then terms of the Financing will be amended to include such better terms so long as the November 2021 Note
is outstanding. In addition, the November 2021 Investor has the right of first refusal on any financing so long as the November 2021 Note
is outstanding. Additionally, the November 2021 Investor has the right to be repaid 100% of the remaining balance of principal and interest
under the November 2021 Note from the net cash proceeds of any future financing closed on by the Company, provided, however, that the
repayment obligation will not be applicable to the first $2,000,000 of cash proceeds in the aggregate generated by the Company from any
future financing proceeds. Further, the November 2021 Investor has the right to participate in any future offering by the Company for
a period of 18 months from the Issuance Date for an amount up to the Financing amount in strict accordance with the terms of such future
offering.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The obligations of the Company
under the November 2021 Note constitute a first priority security interest and rank senior with respect to any and all indebtedness of
the Company existing prior to or incurred as of or following the initial Issuance Date. The obligations of the Company under the November
2021 Note are secured pursuant to the Security and Pledge Agreement entered into between the Company and the November 2021 Investor on
the Issuance Date. So long as the Company has any obligation under the November 2021 Note, the Company will not incur or suffer to exist
or guarantee any indebtedness that is senior to the Company’s obligations under the November 2021 Note. The November 2021 Note is
secured by the assets of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<!-- Field: Page; Sequence: 32; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company claims an exemption
from the registration requirements of the Securities Act of 1933 (the “Securities Act”) for the private placement of these
Securities pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act. The
November 2021 Investor is an accredited investor as defined in Rule 501 of Regulation D promulgated under the Securities Act. As of the
date hereof, the Company is obligated on $400,000 in face amount of the November 2021 Note issued to the November 2021 Investor. The November
2021 Note is a debt obligation arising other than in the ordinary course of business which constitutes a direct financial obligation of
the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The foregoing information
is a summary of each of the agreements involved in the transactions described above, is not complete, and is qualified in its entirety
by reference to the full text of those agreements, each of which is attached an exhibit to this Annual Report on Form 10-K. Readers should
review those agreements for a complete understanding of the terms and conditions associated with this transaction.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The offers, sales, and issuances of the securities
described above were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act
of 1933, as amended and/or Rule 506 as promulgated under Regulation D as transactions by an issuer not involving a public offering. The
recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale
in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each
of the recipients of securities in these transactions was an accredited or sophisticated person and had adequate access, through employment,
business or other relationships, to information about us.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing information is a summary of each of
the agreements involved in the transactions described above, is not complete, and is qualified in its entirety by reference to the full
text of those agreements, each of which is attached an exhibit to this Annual Report on Form 10-K. Readers should review those agreements
for a complete understanding of the terms and conditions associated with this transaction.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Issuer Purchases of Equity Securities</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company has not repurchased
its securities during the year ended December 31, 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_010"></span>ITEM 6. SELECTED FINANCIAL DATA</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As the Company is a Smaller Reporting Company (as defined by Rule 229.10(f)(1)),
the Company is not required to provide the information under this item.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_011"></span>ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following discussion and analysis of our financial
condition and results of operations should be read in conjunction with the consolidated financial statements and the notes thereto contained
elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements
that involve risks and uncertainties.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unless otherwise indicated, references to the “Company,”
“us” or “we” refer to Sentient Brands Holdings Inc. and its subsidiaries.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Special Note Regarding Forward-looking Statements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">All statements other than
statements of historical fact included in this Form 10-K including, without limitation, statements under “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” regarding our financial position, business strategy and the plans
and objectives of management for future operations, are forward-looking statements. When used in this Form 10-K, words such as “anticipate,”
“believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to us
or our management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well
as assumptions made by, and information currently available to, our management. Actual results could differ materially from those contemplated
by the forward-looking statements as a result of a number of factors, including those set forth under the risk factors and business sections
in this Form 10-K.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<!-- Field: Page; Sequence: 33; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sentient Brands is a next-level product development
and brand management company with a focus on building innovative brands in the Luxury and Premium Market space. The Company has a Direct-to
Consumer business model focusing on the integration of CBD, wellness and beauty for conscious consumers. The Company incorporates an omnichannel
approach in its marketing strategies to ensure that its products are accessible across both digital and retail channels. The Company develops
and nurtures Lifestyle Brands with carefully thought-out ingredients, packaging, fragrance and design. Sentient Brands’ leadership
team has extensive experience in building world-class brands such as Hugo Boss, Victoria’s Secret, Versace, and Bath &amp; Body
Works. The Company is focused on two key market segments targeting: wellness and responsible luxury, which the Company believes represent
unique opportunities for its Oeuvre product line. Sentient Brands intends to leverage its in-house innovation capabilities to launch new
products that “disrupt” adjacent product categories. We plan to grow by leveraging our deep connections within our existing
network and attract consumers through increased brand awareness and investing in unique social media marketing. The Company’s goal
is to create customer experiences that have sustainable resonance with consumers and consistently implement strategies that result in
long-term profit growth for our investors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Principal Products and Services</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our proprietary formulations contain clean,
vegan, ethically and environmentally responsible ingredients. The Company currently has one main product line, and another in development.
The Company’s current active product line is <i>Oeuvre.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Oeuvre</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Oeuvre </i>- “A Body of Art” – is
a next generation CBD luxury skin care line and lifestyle brand. The foundation of our system of products is our proprietary OE Complex:
Botanicals + Gemstones + Full flower Hemp infused formulation. Each product in the Oeuvre Artistry Collection optimizes three functions:
cellular energy, moisture balance, and nutrient utilization. Four products comprise the <i>Oeuvre</i> collection:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 0.25in; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Purifying Exfoliator</b></span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Replenishing Facial Oil</b></span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Ultra-Nourishing Face Cream</b></span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Revitalizing Eye Cream</b></span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Drawing inspiration from petals, leaves, roots, minerals
and gemstones, <i>Oeuvre</i> celebrates the artistry of well-being and beauty, inside and out. <i>Oeuvre</i> products
are non-toxic, ungendered products made with zero GMO, retinyl palmitate, petroleum, mineral oil, parabens, sulfates, and synthetic colors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Oeuvre </span></i><span style="text-decoration: underline">Target Market</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Oeuvre</i> is our luxury segment product line.
With <i>Oeuvre</i>, we are targeting a large and influential consumer class of individuals that are “HENRYs” –
High-Earners-Not-Rich-Yet. They have discretionary income and are highly likely to be wealthy in the future. HENRYs earn between $100,000
and $250,000 annually. They are digitally fluent, love online shopping online, and are big discretionary spenders. Therefore, ouvreskincare.com
offers inclusive, aspirationally affordable luxury products positioned for them.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe the benefit of onboarding this demographic
to <i>Oeuvre</i> are twofold: securing valuable present customers and building relationships and business with those most likely
to be amongst the most affluent consumers in the future. By the year 2025, Millennials and Generation Z will represent more than 40% of
the overall luxury goods market, according to a 2019 report published by Boston Consulting Group. We seek to target such group for the
sale of our Oeuvre products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 34; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On social media, we target the following audiences
for our Oeuvre brand:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 0.25in; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Women aged 30+</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Luxury Skincare Enthusiasts</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">CBD Enthusiasts</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Crystal Lovers</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Wellness Audience</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Makeup Artists</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Art</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Beauty</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Influencers</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Bloggers</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Stores</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Future Product Lines</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has additional <i>Oeuvre</i> product skews
planned for introduction by the end of <span style="letter-spacing: -0.1pt">2022:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 13.5pt"></td><td style="width: 13.5pt">●</td><td style="text-align: justify">Oeuvre fragrance amulets</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -13.5pt"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 13.5pt"></td><td style="width: 13.5pt">●</td><td style="text-align: justify">CBD infused candles</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -13.5pt"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 13.5pt"></td><td style="width: 13.5pt">●</td><td style="text-align: justify">CBD infused women’s fragrance</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -13.5pt"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 13.5pt"></td><td style="width: 13.5pt">●</td><td style="text-align: justify">OE complex bath and body regime</td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -13.5pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Introduction of Recreational THC Beverages</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company plans on introducing a luxury lifestyle
THC beverage brand in the future. Upon development, product formulation, brand concept, packaging, and marketing presentations will be
designed to appeal to an upscale, sophisticated target audience. The Company is currently working with a formulator in developing unique
formulation attributes to achieve specific desired effects. This product launch is anticipated in approximately the fourth quarter of
2022.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Integrating the Metaverse </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Metaverse is a 3D experiential internet space
focused on social connection in which users can interact with computer-generated virtual worlds across a range of technologies. The Company
intends to integrate the Metaverse, including AI, Web 3.0 and non-fungible tokens (NFT’s), within our social media platforms and
interactive product displays.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Suppliers</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has several third-party suppliers and
is not reliant on any particular supplier for its product offerings. Many of our products contain CBD derived from industrial hemp or
cannabis which we obtain from third parties. Hemp cultivation can be impacted by weather patterns and other natural events, but we have
not yet faced any supply issues to date with obtaining raw materials for our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Distribution</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have two primary methods through which we sell
our products:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 0.25in; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Direct to Consumer online e-commerce platform</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Wholesale partners</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 35; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Marketing Strategy</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We support our brand launches through social media
and marketing campaigns, including utilizing influencers. Marketing and public relations firms are engaged by the Company to spearhead
its launch of <i>Oeuvre,</i> and will likely be engaged for our future planned brand launches as well.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sentient Brands Growth Strategies:</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To grow our company, Sentient Brands intends to:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 0.25in; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Create a leading consumer packaged goods company;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Partner with established distributers and retailers;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Focus on operational excellence and product quality; and</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="padding: 0pt; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Establish ongoing communication with the capital markets</span> <span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our mission is to create the next generation of CBD/THC
consumer brands. The Company believes it has assembled a highly accomplished team of branding and marketing professionals who have a combined
experience and track record of successfully launching and operating major brands in the consumer market space, which the Company believes
will provide it with it a competitive edge in its industry.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Customers</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company launched its <i>Oeuvre</i> product line
in the fourth quarter of 2021. The Company’s sales channels are direct to consumer and wholesale.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intellectual Property</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s <i>Oeuvre</i> brand is trademarked
in the United States, with a European trademark application pending. The Company expects to rely on trade secrets and proprietary know-how protection
for our confidential and proprietary information, however we have not yet taken security measures to protect this information.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Competition</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have experienced, and expect to continue to experience,
intense competition from a number of companies.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The current market for hemp-derived CBD products is
highly competitive, consisting of publicly-trade and privately-owned companies, many of which are more adequately capitalized than the
Company. The Company’s current publicly listed competitors include market leader Charlotte’s Web, CV Sciences, Elixinol, Abacus,
and Green Growth Brands, and private companies such as BeBoe, St. Jane. Mary’s, Lord Jones, Bluebird Folium Biosciences, Global
Cannabinoids, and Pure Kana. In addition, public and private U.S. and Canadian companies have entered the hemp-derived CBD consumer market
or have announced plans to do so. This market is highly fragmented, and according to the Hemp Business Journal, the vast majority of industry
participants generate less than $2 million in annual revenue. We see this an opportunity to get a foothold in the CBD consumer marketplace
with the goal of building Sentient Brands as a major brand name in this space.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Industry Overview</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The market for products based on extracts of hemp
and cannabis, is expected to grow substantially over the coming years. Arcview Market Research and BDS Analytics are forecasting the combined
market to reach nearly $45 billion within the U.S. in the year 2024. While much of this market is expected to be comprised of high potency
THC-based products that will be sold in licensed dispensaries, certain research firms are still predicting the market to grow to $5.3
billion, $12.6 billion, and $2.2 billion by 2024 in the product areas of low THC cannabinoids, THC-free Cannabinoids and pharmaceutical
cannabinoids, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 36; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 20, 2018, President Donald J. Trump signed
into law the Agriculture Improvement Act of 2018, otherwise known as the “Farm Bill.” Prior to its passage, hemp, a member
of the cannabis family, and hemp-derived CBD were classified as a Schedule I controlled substances, and illegal under the Controlled Substances
Act (“CSA”). Under Section 10113 of the Farm Bill, hemp cannot contain more than 0.3 percent THC. THC refers to the chemical
compound found in cannabis that produces the psychoactive “high” associated with cannabis. Any cannabis plant that contains
more than 0.3 percent THC would be considered non-hemp cannabis or marijuana under federal law and thus would face no legal protection
under this new legislation and would be an illegal Schedule 1 drug under the CSA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With the passage of the Farm Bill, hemp cultivation
is broadly permitted. The Farm Bill explicitly allows the transfer of hemp-derived products across state lines for commercial or other
purposes. It also puts no restrictions on the sale, transport, or possession of hemp-derived products, so long as those items are produced
in a manner consistent with the law.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Developments</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Covid-19</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A novel strain of coronavirus (“Covid-19”)
emerged globally in December 2019 and has been declared a pandemic. The extent to which Covid-19 will impact our customers, business,
results and financial condition will depend on current and future developments, which are highly uncertain and cannot be predicted at
this time. While the Company’s day-to-day operations beginning March 2020 through the 2021 fiscal year end have been impacted, we
have suffered less immediate impact as most staff can work remotely and can continue to develop our product offerings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 18, 2020, the Company, through its subsidiary
Jaguaring Company, entered into a Paycheck Protection Program Promissory Note and Agreement with KeyBank National Association, pursuant
to which the Company received loan proceeds of $231,500 (the “PPP Loan”). The PPP Loan was made under, and is subject to the
terms and conditions of, the PPP which was established under the CARES Act and is administered by the U.S. Small Business Administration.
The term of the PPP Loan is two years with a maturity date of April 18, 2022 and contains a favorable fixed annual interest rate of 1.00%.
Payments of principal and interest on the PPP Loan will be deferred for the first six months of the term of the PPP Loan until November
18, 2020. Principal and interest are payable monthly and may be prepaid by the Company at any time prior to maturity with no prepayment
penalties. Under the terms of the CARES Act, recipients can apply for and receive forgiveness for all or a portion of loans granted under
the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for certain permissible purposes
as set forth in the PPP, including, but not limited to, payroll costs (as defined under the PPP) and mortgage interest, rent or utility
costs (collectively, “Qualifying Expenses”), and on the maintenance of employee and compensation levels during the eight-week
period following the funding of the PPP Loan. The Company has been using the proceeds of the PPP Loan, for Qualifying Expenses. On December
8, 2021 the Company received notification from Key Bank that our forgiveness application has been approved in full by the Small Business
Administration, or SBA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Forward Stock Split / Increase of Authorized /
Name Change / Migratory Merger</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 9, 2020, the Company filed a Certificate
of Amendment of Articles of Incorporation (the “Certificate”) with the State of California to (i) effect a forward stock split
of its outstanding shares of common stock at a ratio of 7 for 1 (the “Forward Stock Split”), (ii) increase the number of authorized
shares of common stock from 50,000,000 shares to 500,000,000 shares, and (iii) effectuate a name change (the “Name Change”).
Fractional shares that resulted from the Forward Stock Split were rounded up to the next highest number. As a result of the Name Change,
the Company’s name changed from “Intelligent Buying, Inc.” to “Sentient Brands Holdings Inc.”. The Certificate
was approved by the majority of the Company’s shareholders and by the Board of Directors of the Company. The effective date of the
Forward Stock Split and the Name Change was March 2, 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the above, the Company filed an
Issuer Company-Related Action Notification Form with the Financial Industry Regulatory Authority. The Forward Stock Split and the Name
Change was implemented by FINRA on March 2, 2021. Our symbol on OTC Markets was INTBD for 20 business days from March 2, 2021 (the “Notification
Period”). Our new CUSIP number is 81728V 102. As a result of the name change, our symbol was changed to “SNBH” following
the Notification Period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 37; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, on January 29, 2021, the Company, merged
with and into its wholly owned subsidiary, Sentient Brands Holdings Inc., a Nevada corporation, pursuant to an Agreement and Plan of Merger
between Sentient Brands Holdings Inc., a California corporation, and Sentient Brands Holdings Inc., a Nevada corporation. Sentient Brands
Holdings Inc., a Nevada corporation, continued as the surviving entity of the migratory merger. Pursuant to the migratory merger, the
Company changed its state of incorporation from California to Nevada and each share of its common stock converted into one share of common
stock of the surviving entity in the migratory merger. No dissenters’ rights were exercised by any of the Company’s stockholders
in connection with the migratory merger.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the consummation of the migratory merger,
the articles of incorporation and bylaws of the Nevada corporation that was newly created as a wholly owned subsidiary of the Company
became the articles of incorporation and bylaws for the surviving entity in the migratory merger.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The foregoing information
is a summary of each of the matters described above, is not complete, and is qualified in its entirety by reference to the full text of
the exhibits, each of which is attached an exhibit to this Form 10-K Annual Report. Readers should review those exhibits for a complete
understanding of the terms and conditions associated with this matter.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Government Regulation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The United States Food &amp; Drug Administration (“FDA”)
is generally responsible for protecting the public health by ensuring the safety, efficacy, and security of (1) prescription and over
the counter drugs; (2) biologics including vaccines, blood and blood products, and cellular and gene therapies; (3) foodstuffs including
dietary supplements, bottled water, and baby formula; and (4) medical devices including heart pacemakers, surgical implants, prosthetics,
and dental devices.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regarding its regulation of drugs, the FDA process
requires a review that begins with the filing of an investigational new drug (IND) application, with follow on clinical studies and clinical
trials that the FDA uses to determine whether a drug is safe and effective, and therefore subject to approval for human use by the FDA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aside from the FDA’s mandate to regulate drugs,
the FDA also regulates dietary supplement products and dietary ingredients under the Dietary Supplement Health and Education Act of 1994.
This law prohibits manufacturers and distributors of dietary supplements and dietary ingredients from marketing products that are adulterated
or misbranded. This means that these firms are responsible for evaluating the safety and labeling of their products before marketing to
ensure that they meet all the requirements of the law and FDA regulations, including, but not limited to the following labeling requirements:
(1) identifying the supplement; (2) nutrition labeling; (3) ingredient labeling; (4) claims; and (5) daily use information.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA has not approved cannabis, marijuana, hemp
or derivatives as a safe and effective drug for any indication. As of the date of this filing, we have not, and do not intend to file
an Investigational New Drug Application (IND) with the FDA, concerning any of our products that contain CBD derived from industrial hemp
or cannabis. Further, our products containing CBD derived from industrial hemp are not marketed or sold using claims that their use is
safe and effective treatment for any medical condition subject to the FDA’s jurisdiction.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Government Approvals</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not currently require any government
approvals for its operations or product offerings. In August 2019, the DEA affirmed that CBD preparations at or below the 0.3 percent
delta-9 THC threshold, is not a controlled substance, and a DEA registration is not required. As a result of the 2018 Farm Bill, the FDA
has been tasked with developing CBD regulations. The FDA has not yet published regulations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 38; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are continuously in the process of identifying
and/or developing potential new products to offer to our customers. Our expenditures on research and development have historically been
small and immaterial compared to our other business expenditures. We are currently developing new formulations for additional product
lines.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Employees</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that our success depends upon our ability
to attract, develop and retain key personnel. As of April 15, 2022, we employed two full-time employees. The Company otherwise currently
relies on the services of independent contractors. None of our employees are covered by collective bargaining agreements, and management
considers relations with our employees to be in good standing. Although we continually seek to add additional talent to our work force,
management believes that it currently has sufficient human capital to operate its business successfully.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our compensation programs are designed to align the
compensation of our employees with our performance and to provide the proper incentives to attract, retain and motivate employees to achieve
superior results. The structure of our compensation programs balances incentive earnings for both short-term and long-term performance.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The health and safety of our employees is our highest
priority, and this is consistent with our operating philosophy. Since the onset of the COVID-19 pandemic, employees, including our specialized
technical staff, are working from home or in a virtual environment unless they have a requirement to be in the office for short-term tasks
and projects.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The primary mailing address for the Company is 555 Madison Avenue, 5th
Floor, New York, New York 10022. The Company’s telephone number is (646) 202-2897. The Company’s website is <span style="text-decoration: underline">www.sentientbrands.com.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Going Concern</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have a limited operating
history, and our continued growth is dependent upon the continuation of selling our products to our customers; hence generating revenues
and obtaining additional financing to fund future obligations and pay liabilities arising from normal business operations. We had an accumulated
deficit of $2,320,909 at December 31, 2021. The report of our independent registered public accounting firm on our financial statements
for the year ended December 31, 2021 contained an explanatory paragraph regarding our ability to continue as a going concern based upon
cash used in operating activities and the current cash balance cannot be projected to cover the operating expenses for the next twelve
months from the release date of this report. These factors, among others, raised substantial doubt about our ability to continue as a
going concern. Our financial statements appearing elsewhere in this report do not include any adjustments that might result from the outcome
of this uncertainty. There are no assurances we will be successful in our efforts to generate significant revenues or report profitable
operations or to continue as a going concern, in which event investors would lose their entire investment in our company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our ability to continue as
a going concern is dependent upon our ability to carry out our business plan, achieve profitable operations, obtain additional working
capital funds from our significant shareholders, and or through debt and equity financings. However, there can be no assurance that any
additional financings will be available to us on satisfactory terms and conditions, if any.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The accompanying consolidated
financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts
and classification of liabilities that may result should the Company be unable to continue as a going concern.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Critical Accounting Policies
and Estimates</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our discussion and analysis
of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements
requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related
disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts, recovery
of long-lived assets, income taxes and the valuation of equity transactions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<!-- Field: Page; Sequence: 39; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We base our estimates on
historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets
and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical
accounting policies affect our more significant judgments and estimates used in the preparation of the consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Revenue Recognition</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We recognize revenue when
persuasive evidence of an arrangement exists, delivery has occurred or products have been sold, the purchase price is fixed or determinable
and collectability is reasonably assured.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We sell CBD-infused products
to our customers. Our customers place orders for our products pursuant to their purchase orders and we are paid by our customers pursuant
to our invoices. Each invoice calls for a fixed payment in a fixed period of time. We recognize revenue by selling our products under
our customers’ purchase orders and our related invoices to our customers. Revenue related to the sales of our products to our customers
is recognized as the products are sold and amounts are paid, using the straight-line method over the term of the sales transaction. Prepayments,
if any, received from customers prior to the products being delivered are recorded as advance from customers. In these cases, when the
products are sold, the amount recorded as advance from customers is recognized as revenue.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We are governed by the income
tax laws of the United States. Income taxes are accounted for pursuant to ASC 740 “Accounting for Income Taxes,” which is
an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences
of events that have been recognized in our financial statements or tax returns. The charge for taxes is based on the results for the period
as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively
enacted by the balance sheet date.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Deferred tax is accounted
for using the balance sheet liability method in respect of temporary differences arising from differences between the carrying amount
of assets and liabilities in the financial statements and the corresponding tax basis used in the computation of assessable tax profit.
In principle, deferred tax liabilities are recognized for all taxable temporary differences, and deferred tax assets are recognized to
the extent that it is probably that taxable profit will be available against which deductible temporary differences can be utilized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Deferred tax is calculated
using tax rates that are expected to apply to the period when the asset is realized, or the liability is settled. Deferred tax is charged
or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred
tax is changed to equity. Deferred tax assets and liabilities are offset when they related to income taxes levied by the same taxation
authority and we intend to settle its current tax assets and liabilities on a net basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-based Compensation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock based compensation is accounted for based on
the requirements of the Share-Based Payment topic of Accounting Standards Codification (“ASC”) 718 which requires recognition
in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over
the period the employee or director is required to perform the services in exchange for the award. The Accounting Standards Codification
also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair
value of the award.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 505-50, for share-based payments
to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized
over the period of services or the vesting period, whichever is applicable. Until the measurement date is reached, the total amount of
compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The
awards to consultants and other third parties are then revalued, or the total compensation is recalculated based on the then current fair
value, at each subsequent reporting date.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 40; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In August 2016, the Financial
Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15, Statement of Cash Flows
(Topic 230): Classification of Certain Cash Receipts and Cash Payments. This ASU addresses the classification of certain specific cash
flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments
made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method
investees. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with
early adoption permitted. An entity that elects early adoption must adopt all of the amendments in the same period. We are currently evaluating
the impact it may have on our consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Other accounting standards
that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact
on our consolidated financial statements upon adoption. We do not discuss recent pronouncements that are not anticipated to have an impact
on or are unrelated to our consolidated financial condition, results of operations, cash flows or disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>RESULTS OF OPERATIONS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Comparison of Results of Operations for the Year
Ended December 31, 2021 and the Year Ended December 31, 2020.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Revenue</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We did not generate significant
revenue for the years ended December 31, 2021 and 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Operating Expenses</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the years ended December
31, 2021 and 2020:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt"> </td>
<td> </td>
<td colspan="7" style="text-align: center"><span style="font-size: 10pt">For the year ended December 31,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt"> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2020</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt"> </td>
<td> </td>
<td colspan="3" style="text-align: center"> </td>
<td> </td>
<td colspan="3" style="text-align: center"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 42%; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Advertising and Marketing</span></td>
<td style="width: 7%"> </td>
<td style="width: 1%"><span style="font-size: 10pt">$</span></td>
<td style="width: 20%; text-align: right"><span style="font-size: 10pt">4,874</span></td>
<td style="width: 1%"> </td>
<td style="width: 7%"> </td>
<td style="width: 1%"> </td>
<td style="width: 20%; text-align: right"><span style="font-size: 10pt">54,182</span></td>
<td style="width: 1%"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">General and Administrative</span></td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">57,632</span></td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">135,654</span></td>
<td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Legal and Professional</span></td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">293,070</span></td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">342,016</span></td>
<td> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Office rent</span></td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">1,190</span></td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">16,351</span></td>
<td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Management Fees</span></td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">159,000</span></td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">210,636</span></td>
<td> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Product development cost</span></td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">6,343</span></td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">28,750</span></td>
<td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 20pt; text-indent: -10pt"><span style="font-size: 10pt">TOTAL OPERATING EXPENSES</span></td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
<td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">522,109</span></td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
<td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">787,589</span></td>
<td style="padding-bottom: 2.5pt"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; margin-right: 0pt">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"> </td>
<td style="width: 0.25in; text-align: left">●</td>
<td style="text-align: justify">Our selling and advertising expense mainly includes our costs of branding, design and materials. The decrease of $49,308 or 91% was primarily due to the selling expenses in previous year include staff salaries and other expenses in promoting our product lines which we did not incur this year.</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td> </td>
<td style="text-align: left"> </td>
<td style="text-align: justify"> </td></tr>
<tr style="vertical-align: top; text-align: justify">
<td> </td>
<td style="text-align: left">●</td>
<td style="text-align: justify">Professional fees primarily consisted of the following:</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt; background-color: white"> </p>
<!-- Field: Page; Sequence: 41; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt; background-color: white">  </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt"> </td>
<td> </td>
<td colspan="7" style="text-align: center"><span style="font-size: 10pt">For the year ended December 31,</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt"> </td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2021</span></td>
<td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">2020</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 42%; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Accounting and Auditing</span></td>
<td style="width: 7%"> </td>
<td style="width: 1%"><span style="font-size: 10pt">$</span></td>
<td style="width: 20%; text-align: right"><span style="font-size: 10pt">33,700</span></td>
<td style="width: 1%"> </td>
<td style="width: 7%"> </td>
<td style="width: 1%"><span style="font-size: 10pt">$</span></td>
<td style="width: 20%; text-align: right"><span style="font-size: 10pt">43,628</span></td>
<td style="width: 1%"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Other advisory Services</span></td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">141,638</span></td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">105,919</span></td>
<td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Legal Fees in relation to SEC fillings</span></td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">109,732</span></td>
<td> </td>
<td> </td>
<td> </td>
<td style="text-align: right"><span style="font-size: 10pt">174,569</span></td>
<td> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">Social Media Consulting</span></td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid"> </td>
<td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">8,000</span></td>
<td style="padding-bottom: 1pt"> </td>
<td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: black 1pt solid"> </td>
<td style="border-bottom: black 1pt solid; text-align: right"><span style="font-size: 10pt">17,900</span></td>
<td style="padding-bottom: 1pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 10pt; text-indent: -10pt"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
<td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">293,070</span></td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: black 2.25pt double"><span style="font-size: 10pt">$</span></td>
<td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-size: 10pt">342,016</span></td>
<td style="padding-bottom: 2.5pt"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt; background-color: white">  </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; margin-right: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"> </td>
<td style="width: 0.25in"><span style="font-size: 10pt">●</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Professional fees decreased by $48,946 or 12% primarily due to adecrease in legal fees.</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"> </td>
<td> </td>
<td style="text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"> </td>
<td><span style="font-size: 10pt">●</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Management fees primarily consisted of compensation of our Chief Operating officer and Chief Marketing Officer, and the President of our wholly owned subsidiary, Cannavolve. Compared to the previous year Management fees decreased by $51,636 primarily due to the departure of one of our management staff members.</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"> </td>
<td> </td>
<td style="text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"> </td>
<td><span style="font-size: 10pt">●</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Our general and administrative costs have also decreased by $78,022 or 58% compared to the previous year primarily due to the $67,500 bad debts written off. No such bad debts for this year ended December 31, 2021.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt; background-color: white">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Income (Loss) from
Operations</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the foregoing, for the year ended December
31, 2021, loss from operations amounted to $660,775, as compared to loss from operations of $785,296 for the year ended December 31, 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Income (Expense)</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other income (expense) was $154,429 for the year ended December 31, 2021,
compared to $(30,965) for the year ended December 31, 2020. The variance was due to income from the forgiveness of the PPP loan of $231,500
during 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Income Taxes</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We did not have any income
taxes expense for the years ended December 31, 2021 and December 31, 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Net Income (Loss)</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Net loss for the years ended
December 31, 2021, and 2020 were $367,022 and $816,261, respectively. The decrease in Net Loss was primarily due to the recognition of
$231,500 other income due the forgiveness of PPP loan obtain in previous year.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Liquidity and Capital
Resources</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> The consolidated financial
statements have been prepared using generally accepted accounting principles in the United States of America (“GAAP”) applicable
for a going concern, which assumes that the Company will realize its assets and discharge its liabilities in the ordinary course of business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">To the extent we are successful
in growing our business both organically and through acquisition, we continue to plan our working capital and the proceeds of any financing
to finance such acquisition costs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Liquidity is the ability
of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate on an ongoing
basis. At December 31, 2021 and 2020, we had cash balance of approximately $96,198 and $68,047, respectively. These funds are kept in
financial institutions located in United States.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<!-- Field: Page; Sequence: 42; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Covid 19</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A novel strain of coronavirus (“Covid-19”)
emerged globally in December 2019 and has been declared a pandemic. The extent to which Covid-19 will impact our customers, business,
results and financial condition will depend on current and future developments, which are highly uncertain and cannot be predicted at
this time. While the Company’s day-to-day operations beginning March 2020 have been impacted, we have suffered less immediate impact
as most staff can work remotely and can continue to develop our product offerings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">That said we have seen our business opportunities
develop more slowly as business partners and potential customers are dealing with Covid-19 issues, working remotely and these issues are
causing delays in decision making and finalization of negotiations and agreements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash flows from Operating Activities</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating activities used $751,272 in cash the year
ended December 31, 2021, as compared with $709,761 for the year ended December 31, 2020. Our net loss was $367,022 the main component
of our negative operating cash flow in 2021 further increase by the non-cash income of $231,500 loan forgiveness., added by increase in
accounts inventory $258,781, offset mainly by decrease in advances to supplier $154,893. In 2020 net loss of $816,261 was the main component
of our negative operating cash flow offset by a decrease in accounts payable and accrued expenses of $64,658.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash flows from Investing Activities</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no Investing activities in for the year
ended December 31, 202. In 2020 our investing activities used $39,277 for purchase of various machinery and equipment .</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash flows from Financing Activities</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Cash flows provided by financing activities during
the year ended December 31, 2021 amounted to $779,423 as compared with $808,061 for the year ended December 31, 2020. Our positive cash
flow in 2021 consisted of net proceeds from convertible notes $695,078 and short term loans net proceeds of $83,245. Our positive cash
flow in 2020 consisted mostly of proceeds from the sale of issuance of common stocks $471,560 and proceeds from SBA loans payable of $256,500
and proceeds from notes payable $80,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify; background-color: white">Our capital requirements
for the next twelve months primarily relate to $950,000. In addition, we expect to use cash to pay salaries, consulting fees and fees
related to third parties’ professional services. All funds received have been expended in the furtherance of growing the business.
The following trends are reasonably likely to result in a material decrease in our liquidity over the near to long term:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify; background-color: white"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"> </td>
<td style="width: 24px"><span style="font-size: 10pt">●</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">An increase in working capital requirements to finance our current business;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"> </td>
<td style="width: 24px"><span style="font-size: 10pt">●</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Addition of administrative and sales personnel as the business grows; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"> </td>
<td style="width: 24px"><span style="font-size: 10pt">●</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">The cost of being a public company.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify; background-color: white">We will need to raise additional
funds, particularly if we are unable to generate positive cash flow as a result of our operations. We estimate that based on current plans
and assumptions, that our available cash will be insufficient to satisfy our cash requirements under our present operating expectations.
Other than working capital and advance received from related parties and funds received pursuant to securities purchase agreements, we
presently have no other significant alternative source of working capital. We have used these funds to fund our operating expenses, pay
our obligations and grow our company. We will need to raise significant additional capital to fund our operations and to provide working
capital for our ongoing operations and obligations. Therefore, our future operation is dependent on our ability to secure additional financing.
Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms.
However, the trading price of our common stock and a downturn in the U.S. equity and debt markets could make it more difficult to obtain
financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could
incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore,
if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have
rights, preferences or privileges senior to those of existing holders of our common stock. The inability to obtain additional capital
may restrict our ability to grow and may reduce our ability to continue to conduct business operations. If we are unable to obtain additional
financing, we will be required to cease our operations. To date, we have not considered this alternative, nor do we view it as a likely
occurrence.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Going Concern</i></b>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company’s financial
statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and
commitments in the normal course of business. During the year ended December 31, 2021, the Company incurred a net loss of $439,143 The
Company had an accumulated deficit of $2,393,0331 as of December 31, 2021. These factors, among others, raise substantial doubt about
the Company’s ability to continue as a going concern.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<!-- Field: Page; Sequence: 43; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Off-balance Sheet Arrangements</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <b><span id="a_012"></span>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a smaller reporting company, as defined in Rule
12b-2 of the Exchange Act, we are not required to provide the information required by this Item.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_013"></span>ITEM 8. FINANCIAL STATEMENTS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements begin on Page F-1.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_014"></span>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_015"></span>ITEM 9A. CONTROLS AND PROCEDURES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Evaluation of Disclosure Controls and Procedures</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain disclosure controls and procedures that
are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange
Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s
rules and forms and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer
and Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure. We carried out an evaluation, under
the supervision and with the participation of our management, including the principal executive officer and the principal financial officer
(principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined
in Rule 13(a)-15(e) under the 1934 Act, as of the end of the period covered by this report. Based on this evaluation, because of
the Company’s limited resources and limited number of employees, management concluded that our disclosure controls and procedures
were ineffective as of December 31, 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Management’s Report on Internal Control
over Financial Reporting</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management is responsible for establishing and
maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is designed
to provide reasonable assurances regarding the reliability of financial reporting and the preparation of the financial statements of the
Company in accordance with U.S. generally accepted accounting principles, or GAAP. Because of its inherent limitations, internal control
over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the
policies or procedures may deteriorate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 44; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With the participation of our Chief Executive Officer
and Chief Financial Officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal
control over financial reporting as of December 31, 2021 based on the framework in Internal Control—Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on our evaluation and the material
weaknesses described below, management concluded that the Company did not maintain effective internal control over financial reporting
as of December 31, 2021 based on the COSO framework criteria. Management has identified control deficiencies as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; margin-right: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"> </td>
<td style="width: 0.25in; padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">●</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">The Company has not established adequate financial reporting monitoring activities to mitigate the risk of management override, specifically because there are few employees and only two officers with management functions and therefore there is lack of segregation of duties.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; margin-right: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"> </td>
<td style="width: 0.25in; padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">●</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">There is a strong reliance on outside consultants to review and adjust the annual and quarterly financial statements, to monitor new accounting principles, and to ensure compliance with GAAP and SEC disclosure requirements.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; margin-right: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"> </td>
<td style="width: 0.25in; padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">●</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">There is a strong reliance on the external attorneys to review and edit the annual and quarterly filings and to ensure compliance with SEC disclosure requirements.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; margin-right: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"> </td>
<td style="width: 0.25in; padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">●</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">A formal audit committee has not been formed.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management of the Company believes that these material
weaknesses are due to the small size of the Company’s accounting staff and reliance on outside consultants for external reporting.
The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due
to the cost/benefit of such remediation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To mitigate the current limited resources and limited
employees, we rely heavily on direct management oversight of transactions, along with the use of legal and outside accounting consultants.
As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the
internal control framework.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These control deficiencies could result in a misstatement
of account balances that would result in a reasonable possibility that a material misstatement to our consolidated financial statements
may not be prevented or detected on a timely basis. Accordingly, we have determined that these control deficiencies as described above
together constitute a material weakness.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In light of this material weakness, we performed additional
analyses and procedures in order to conclude that our consolidated financial statements for the year ended December 31, 2021 included
in this Annual Report on Form 10-K were fairly stated in accordance with US GAAP. Accordingly, management believes that despite our material
weaknesses, our consolidated financial statements for the year ended December 31, 2021 are fairly stated, in all material respects, in
accordance with US GAAP.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This annual report does not include an attestation
report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report
was not subject to attestation by our independent registered public accounting firm pursuant to rules of the Securities and Exchange Commission
that permit us to provide only management’s report in this Annual Report on Form 10-K.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 45; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Limitations on Effectiveness of Controls and Procedures</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management, including our Chief Executive Officer and Chief Financial
Officer (principal financial officer), does not expect that our disclosure controls and procedures or our internal controls will prevent
all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company
have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be
faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual
acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls
also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes
in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective
control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in Internal Controls</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2021, there have
been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially
affect our internal controls over financial reporting.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_016"></span>ITEM 9B. OTHER INFORMATION</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 9, 2020, the Company filed a Certificate
of Amendment of Articles of Incorporation (the “Certificate”) with the State of California to (i) effect a forward stock split
of its outstanding shares of common stock at a ratio of 7 for 1 (the “Forward Stock Split”), (ii) increase the number of authorized
shares of common stock from 50,000,000 shares to 500,000,000 shares, and (iii) effectuate a name change (the “Name Change”).
Fractional shares that resulted from the Forward Stock Split will be rounded up to the next highest number. As a result of the Name Change,
the Company’s name changed from “Intelligent Buying, Inc.” to “Sentient Brands Holdings Inc.”. The Certificate
was approved by the majority of the Company’s shareholders and by the Board of Directors of the Company. The effective date of the
Forward Stock Split and the Name Change was March 2, 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the above, the Company filed an
Issuer Company-Related Action Notification Form with the Financial Industry Regulatory Authority. The Forward Stock Split and the Name
Change was implemented by FINRA on March 2, 2021. Our symbol on OTC Markets was INTBD for 20 business days from March 2, 2021 (the “Notification
Period”). Our new CUSIP number is 81728V 102. As a result of the name change, our symbol was changed to “SNBH” following
the Notification Period.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, on January 29, 2021, the Company, merged
with and into its wholly owned subsidiary, Sentient Brands Holdings Inc., a Nevada corporation, pursuant to an Agreement and Plan of Merger
between Sentient Brands Holdings Inc., a California corporation, and Sentient Brands Holdings Inc., a Nevada corporation. Sentient Brands
Holdings Inc., a Nevada corporation, continued as the surviving entity of the migratory merger. Pursuant to the migratory merger, the
Company changed its state of incorporation from California to Nevada and each share of its common stock converted into one share of common
stock of the surviving entity in the migratory merger. No dissenters’ rights were exercised by any of the Company’s stockholders
in connection with the migratory merger.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the consummation of the migratory merger,
the articles of incorporation and bylaws of the Nevada corporation that was newly-created as a wholly owned subsidiary of the Company
became the articles of incorporation and bylaws for the surviving entity in the migratory merger.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The foregoing information
is a summary of each of the matters described above, is not complete, and is qualified in its entirety by reference to the full text of
the exhibits, each of which is attached an exhibit to this Form 10-K Annual Report. Readers should review those exhibits for a complete
understanding of the terms and conditions associated with this matter.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
<!-- Field: Page; Sequence: 46; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_017"></span>PART III</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_018"></span>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the names and positions
of our current executive officers and directors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid; width: 21%; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name</b></span></td>
<td style="width: 1%; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; width: 10%; padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Age</b></span></td>
<td style="width: 1%; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; width: 67%; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Position</b></span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">George Furlan</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">66</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Interim Chief Executive Officer, Interim President, Interim Chief Financial Officer, Interim Treasurer, Interim Secretary, Chief Operating Officer, and Director</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">James Mansour</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">61</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Chief Marketing Officer</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Dante Jones</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Background of Executive Officers and Directors</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>George Furlan, <i>Interim Chief Executive Officer,
Interim President Interim Chief Financial Officer, Interim Treasurer, Interim Secretary, Chief Operations Officer, and Director</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">George Furlan was appointed as the Company’s
Chief Operating Officer on December 26, 2019, and, on February 14, 2020, Mr. Furlan was appointed as the Company’s Interim Chief
Executive Officer, Interim President, and Interim Chief Financial Officer, Interim Treasurer, and Interim Secretary. Additionally, On
May 28, 2020, Mr. Furlan was appointed as a Director of the Company. Mr. Furlan brings more than 20 years of experience in building and
expanding early stage, mid-tier and global brands. In his role as COO of the Company, Mr. Furlan is responsible for managing the day-to-day
operations of the Company. Mr. Furlan has held senior positions with Hugo Boss and Versace. From 2014 to 2019, Mr. Furlan served as a
Principal of GF Partners, Inc., a consulting service to fashion businesses. Prior to joining GF Partners, Inc. in 2014, Mr. Furlan served
as president of NAHM Apparel, LLC, a women’s young designer fashion company, which was backed by Mr. Tommy Hilfiger. He built the
organization’s infrastructure, guided the successful global launch and lead sales and marketing efforts for U.S. and Canadian and
global markets.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>James Mansour, <i>Chief Marketing Officer</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">James Mansour was appointed as the Chief Marketing
Officer of the Company on February 14, 2020. Mr. Mansour is an award-winning branding authority who was instrumental in the development
of many retail brands that became icons in the marketplace, including Bath and Body Works, Abercrombie &amp; Fitch and Victoria’s
Secret. Mr. Mansour has created award-winning work for 3M, Dupont Corian and others. From February 2015 to February 2020 Mr. Mansour served
the President and Branding Consultant of Mansour Design Inc. Consulting where he ran the day to day operations of the business.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Dante Jones, <i>Director</i></b>  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dante Jones was appointed as a Director of the Company
on February 14, 2020. Mr. Jones co-founded Cannavolve in 2012 with the mission to incubate businesses and accelerate fellow cannabis industry
entrepreneurs to invent, innovate and succeed. Mr. Jones brings 15 years of experience in project management, leadership and budgeting,
while delivering results across global teams. Mr. Jones has served as Cannavolve’s President since 2012. From 2014 to 2017, Mr.
Jones worked as a Technology Manager at Amazon.com, Inc., managing a large global team in designing and deploying new eCommerce for the
AWS Cloud.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Officers are elected annually by the Board of Directors
(subject to the terms of any employment agreement), at its annual meeting, to hold such office until an officer’s successor has
been duly appointed and qualified, unless an officer sooner dies, resigns or is removed by the Board.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 47; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Board Leadership Structure and Role in Risk Oversight</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Our Board of Directors (“Board”) is primarily
responsible for overseeing our risk management processes on behalf of the Company. The Board receives and reviews periodic reports from
management, auditors, legal counsel, and others, as considered appropriate regarding our company’s assessment of risks. In addition,
the Board focuses on the most significant risks facing our company and our company’s general risk management strategy, and also
ensures that risks undertaken by our company are consistent with the board’s appetite for risk. While the Board oversees our company’s
risk management, management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the
most effective approach for addressing the risks facing our company and that our board leadership structure supports this approach.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>Composition of our Board of Directors</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">Our board of directors currently consists of two members.
Our present directors and our former directors are not considered independent. Our directors hold office until their successors have been
elected and qualified or until the earlier of their death, resignation, or removal. There are no family relationships among any of our
directors or executive officers.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><i>Involvement in Certain Legal Proceedings</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">To our knowledge, our directors and executive officers
have not been involved in any of the following events during the past ten years:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; margin-right: 0pt">
<tr style="vertical-align: top">
<td style="width: 0.25in"> </td>
<td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"> </td>
<td style="width: 24px"><span style="font-size: 10pt">2.</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"> </td>
<td style="width: 24px"><span style="font-size: 10pt">3.</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"> </td>
<td style="width: 24px"><span style="font-size: 10pt">4.</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">being found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"> </td>
<td style="width: 24px"><span style="font-size: 10pt">5.</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"> </td>
<td style="width: 24px"><span style="font-size: 10pt">6.</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>Code of Ethics</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">The Company has a code of ethics that applies to all
of the Company’s employees, including its principal executive officer, principal financial officer and principal accounting officer,
and the Board. A copy of this code is available in the Company’s Registration Statement on Form SB-2 filed with the SEC on April
17, 2006. The Company intends to disclose any changes in or waivers from its code of ethics by posting such information on its website
or by filing a Form 8-K.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 48; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Nominating Committee</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not adopted any procedures by which security
holders may recommend nominees to our Board of Directors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Audit Committee</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors acts as the Audit Committee
and the Board has no separate committees. The Company has no qualified financial expert at this time because it has not been able to hire
a qualified candidate. Further, the Company believes that it has inadequate financial resources at this time to hire such an expert.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Indemnification of Directors and Officers</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our directors and executive officers are indemnified
as provided by the California law and our Bylaws. These provisions state that our directors may cause us to indemnify a director or former
director against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, actually and reasonably
incurred by him as a result of him acting as a director. The indemnification of costs can include an amount paid to settle an action or
satisfy a judgment. Such indemnification is at the discretion of our board of directors and is subject to the Securities and Exchange
Commission’s policy regarding indemnification.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions,
or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public
policy as expressed in the Act and is, therefore, unenforceable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Section 16(a) Beneficial Ownership Reporting Compliance</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <br/>
Section 16(a) of the Securities Exchange Act of 1934, requires our directors, executive officers and persons who own more than 10% of
our common stock to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other of our
equity securities. During the year ended December 31, 2021, our officers, directors and 10% stockholders made the required filings pursuant
to Section 16(a).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_019"></span>ITEM 11. EXECUTIVE COMPENSATION</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Executive Officers’ Compensation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summary compensation table sets forth
all compensation awarded to, earned by, or paid to the named executive officers paid by the Company during the fiscal years ended December
31, 2021 and December 31, 2020, in all capacities for the accounts of our executive officers, including the Chief Executive Officer.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 49; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Summary Compensation Table</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1pt solid; text-align: center; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Name
and Principal Position</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Fiscal<br/> Year</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Salary</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Stock<br/> Award</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Option<br/> Awards</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Non-Equity<br/> Incentive Plan<br/> Compensation</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Change in<br/> Pension Value<br/> and Non-<br/> Qualified<br/> Deferred<br/> Compensation<br/> Earnings</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="4" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">All Other<br/> Compensation</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="2" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="4" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="2" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 0%; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 8%; padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">George Furlan,</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">94,000</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">94,000</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-left: 10pt; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Interim CEO, Interim President, Interim CFO, and COO</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">84,000</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">84,000</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">James Mansour, CMO </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">110,000</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> 0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span>0</td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right">0</td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> 0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">110,000</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">60,000</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span>0</td>
<td style="padding-right: 0.8pt"></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right">0<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="padding-right: 0.8pt"></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span>0</td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0</span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">60,000 </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the cash and non-cash
compensation for the fiscal years ended December 31, 2021 and 2020, awarded to or earned by Mr. Jones, Cannavolve’s principal executive
officer.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1pt solid; text-align: center; padding-right: 0.8pt"><span style="font-size: 10pt">Name and Principal Position</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td style="border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">Fiscal<br/>
Year</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">Salary</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">Stock Award</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">Option Awards</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">Non-Equity Incentive Plan Compensation</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">Change in Pension Value and Non- Qualified Deferred Compensation Earnings</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">All Other Compensation</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">Total</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">($)</span></td>
<td style="padding-right: 0.8pt; text-align: center"> </td>
<td colspan="3" style="border-bottom: black 1pt solid; padding-right: 2.8pt; text-align: center"><span style="font-size: 10pt">($)</span></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 19%; padding-right: 0.8pt"><span style="font-size: 10pt">Dante Jones,</span></td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 6%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">2020</span></td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 7%; padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt">41,000</span></td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 6%; padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt">0</span></td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 3%; padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt"> 0</span></td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 3%; padding-right: 0.8pt"> </td>
<td style="width: 6%; padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt"> 0</span></td>
<td style="width: 3%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 3%; padding-right: 0.8pt"> </td>
<td style="width: 6%; padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt"> 0</span></td>
<td style="width: 3%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 3%; padding-right: 0.8pt"> </td>
<td style="width: 6%; padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt"> 0</span></td>
<td style="width: 3%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 1%; padding-right: 0.8pt"> </td>
<td style="width: 7%; padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt">41,000</span></td>
<td style="width: 1%; padding-right: 0.8pt"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 10pt; padding-right: 0.8pt"><span style="font-size: 10pt">President</span></td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">2021</span></td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt">0</span></td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: right"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt">0</span></td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt">0</span></td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt">0</span></td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt">0</span></td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: right"><span style="font-size: 10pt">0</span></td>
<td style="padding-right: 0.8pt"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Outstanding Equity Awards at Fiscal Year-End Table</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company did not issue equity awards during the year ended December
31, 2021.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employment Agreements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">George Furlan</span>  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 26, 2019 (the “Effective Date”),
the Company entered into an Employment Agreement with George Furlan to engage his services as Chief Operating Officer of the Company pursuant
to which the Company agreed to pay Mr. Furlan a base salary of $60,000 per year with such base salary being increased to $120,000 per
year beginning on the one (1) year anniversary of the completion of a financing by the Company of no less than $3,000,000. The Employment
Agreement also contains an annual bonus based on the amount of revenue generated by the Company from the sale of certain products. The
Employment Agreement has a term of three years from the effective date. Pursuant to the agreement, Mr. Furlan may be terminated for “cause”
as defined and Mr. Furlan may resign for “good reason” as defined. In the event Mr. Furlan is terminated without cause or
resigns for good reason, the Company will be required to pay Mr. Furlan a payment equal to the lesser of (i) the aggregate amount of base
salary payable for the remainder of the employment term or (ii) an amount equal to 100% of the base salary for the year in which the termination
occurs, as well as a payment equal to the amount of the annual bonus, if any, that the Mr. Furlan would have earned for the fiscal year
in which the termination occurred. In the event Mr. Furlan is terminated with cause, resigns without good reason, dies or is disabled,
the Company will be required to pay Mr. Furlan all accrued salary and earned bonus and reimbursement for business expenses. Under the
agreement Mr. Furlan is subject to confidentiality, non-compete and non-solicitation restrictions. Pursuant to the Employment Agreement,
on the Effective Date, Mr. Furlan also entered into a Restricted Stock Agreement to purchase 718,403 shares of the Company’s Common
Stock at $0.01186 per share for an aggregate purchase price of $8,520.26, which such shares vest as to 239,467 of shares on the Effective
Date and the remaining 478,936 shares will vest in 12 equal installments of 39,911 shares each on the last day of each fiscal quarter.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 50; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Grants of Plan Based Awards</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We did not make any plan-based equity or non-equity
awards grants to named executives during the years ended December 31, 2021 and 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Option Exercises</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no options exercised by our named officers
during the years ended December 31, 2021 and 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Compensation of Directors</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no non-executive directors. Our directors
did not earn compensation for the years ended December 31, 2021 and 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pension, Retirement or Similar Benefit Plans</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no arrangements or plans in which we provide
pension, retirement or similar benefits for directors or executive officers. We have no material bonus or profit sharing plans pursuant
to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may be granted
at the discretion of the board of directors or a committee thereof.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Executive Compensation Philosophy</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board of Directors determines the compensation
given to our executive officers in their sole determination. Our Board of Directors reserves the right to pay our executives or any future
executives a salary, and/or issue them shares of common stock issued in consideration for services rendered and/or to award incentive
bonuses which are linked to our performance, as well as to the individual executive officer’s performance. This package may also
include long-term stock-based compensation to certain executives, which is intended to align the performance of our executives with our
long-term business strategies. Additionally, while our Board of Directors has not granted any performance base stock options to date,
the Board of Directors reserves the right to grant such options in the future, if the Board in its sole determination believes such grants
would be in the best interests of the Company.<br/>
<br/>
<b>Incentive Bonus</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board of Directors may grant incentive bonuses
to our executive officers and/or future executive officers in its sole discretion, if the Board of Directors believes such bonuses are
in the Company’s best interest, after analyzing our current business objectives and growth, if any, and the amount of revenue we
are able to generate each month, which revenue is a direct result of the actions and ability of such executives.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Long-Term, Stock Based Compensation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to attract, retain and motivate executive
talent necessary to support the Company’s long-term business strategy we may award our executives and any future executives with
long-term, stock-based compensation in the future, at the sole discretion of our Board of Directors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_020"></span>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth certain information,
as of April 14, 2022, with respect to the beneficial ownership of the outstanding common stock by (i) any holder of more than five (5%)
percent; (ii) each of the Company’s executive officers and directors; and (iii) the Company’s directors and executive officers
as a group. Except as otherwise indicated, each of the stockholders listed below has sole voting and investment power over the shares
beneficially owned.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 51; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Name of Beneficial Owner (1)</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Common Stock<br/> Beneficially<br/> Owned   (11)</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Percentage of<br/> Common Stock<br/> (2)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Officers and Directors</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">George Furlan * (3)</td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">5,028,821</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">9.68</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">James Mansour * (4)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">5,028,821</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">9.68</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dante Jones * (5)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">763,798</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1.47</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">All officers and directors as a group (3 persons)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">10,821,440</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">20.84</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">5% Stockholders</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Principal Holdings, LLC, (6)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">8,692,187</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">16.74</td><td style="text-align: left">% </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Bogaard Holdings LLC (7)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,196,327</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">4.23</td><td style="text-align: left">% </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Pure Energy 714 LLC (8)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,593,494</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">3.06</td><td style="text-align: left">% </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Gregg Templeton (9)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">5,028,821</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">9.68</td><td style="text-align: left">% </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Bagel Hole Inc. (10)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,832,410</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">5.45</td><td style="text-align: left">%</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"><span style="font-size: 10pt">*</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Officer and/or director of the Company</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 0.25in; padding-right: 0.8pt"> </td>
<td style="width: 0.35in; padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">Except as otherwise indicated, the address of each beneficial owner is c/o Sentient Brands Holdings Inc., 555 Madison Avenue, 5<sup>th </sup>Floor, New York, NY 10022.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">Applicable percentage ownership is based on 51,920,387 shares of common stock outstanding as of April 14, 2022, together with securities exercisable or convertible into shares of common stock within 60 days of April 14, 2022 for each stockholder. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock that are currently exercisable or exercisable within 60 days of April 14, 2022 are deemed to be beneficially owned by the person holding such securities for the purpose of computing the percentage of ownership of such person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(3)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">On December 26, 2019, the Company and George Furlan entered into a Restricted Stock Purchase Agreement pursuant to which the George Furlan purchased from the Company an aggregate of 5,028,821 restricted shares of common stock (the “Furlan Shares”) at $0.01186 per share in consideration of an aggregate purchase price of $8,520.26. 1,676269 of the Furlan Shares vested on December 26, 2019 and the remaining 3,352,552 Furlan Shares shall vest in 12 quarterly installments of 279,377 Furlan Shares thereafter. (Furlan Shares reflected on a post-forward split basis.)</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(4)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">On January 8, 2020, the Company and James
    Mansour entered into a Restricted Stock Purchase Agreement pursuant to which the James Mansour purchased from the Company an
    aggregate of 5,028,821 restricted shares of common stock (the “Mansour Shares”) at $0.01186 per share in consideration
    of an aggregate purchase price of $8,520.26. 2,514,407 of the Mansour Shares vested on January 8, 2020 and the remaining 2,514,414
    Mansour Shares shall vest in 12 quarterly installments of 209,531 Mansour Shares thereafter. (Mansour Shares reflected on a post-forward split basis.)</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(5)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">Dante Jones received the shares of common stock of the Company in connection with the Agreement and Plan of Reorganization entered into and closed between the Company and Jaguaring Company, d/b/a Cannavolve, on February 14, 2020.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(6)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">Principal Holdings, LLC is owned and controlled by Danielle Doukas.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(7)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">Bogaard Holdings LLC is owned and controlled by Jelena Vadanjel.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(8)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">Pure Energy 714 LLC is owned and controlled by Louis Sorrentino.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(9)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">Gregg Templeton is a former employee of the Company.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(10)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">Bagel Hole Inc. is owned and controlled solely by Philip Romanzi, the Company’s former sole officer and director.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">(11)</span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">On March 2, 2021, the Company effected a 7:1 forward stock split of its issued and outstanding shares of common stock. All shares of common stock reflected in the above table, and in any corresponding footnotes, are accounted for on a post-forward split basis.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No Director, executive officer, affiliate or any owner
of record or beneficial owner of more than 5% of any class of voting securities of the Company is a party adverse to the Company or has
a material interest adverse to the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<!-- Field: Page; Sequence: 52; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_021"></span>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following includes a summary of transactions since
the beginning of the 2021 fiscal year, or any currently proposed transaction, in which the Company was or is to be a participant and the
amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of their total assets at year-end for the last
two completed fiscal years, and in which any related person had or will have a direct or indirect material interest (other than compensation
described under “Executive Compensation”). We believe the terms obtained or consideration that we paid or received, as applicable,
in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received,
as applicable, in arm’s-length transactions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Related party transactions of the Company</b> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Transactions with Related Persons</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At no time during the last two fiscal years has any
executive officer, director or any member of these individuals’ immediate families, any corporation or organization with whom any
of these individuals is an affiliate or any trust or estate in which any of these individuals serves as a trustee or in a similar capacity
or has a substantial beneficial interest been indebted to the Company or was involved in any transaction in which the amount exceeded
$120,000 and such person had a direct or indirect material interest.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Procedures for Approval of Related Party Transactions</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board of Directors is charged with reviewing and
approving all potential related party transactions. All such related party transactions must then be reported under applicable SEC rules.
We have not adopted other procedures for review, or standards for approval, of such transactions, but instead review them on a case-by-case
basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Director Independence</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Board of Directors has undertaken a review of
its composition and the independence of each director. Based on the review of each director’s background, employment and affiliations,
including family relationships, the Board of Directors has determined that there are no “independent directors” under the
rules and regulations of the SEC.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 53; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_022"></span>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Boyle CPA LLC served as our independent auditors for
the years ended December 31, 2021 and 2020. The following is a summary of the fees billed to the Company for professional services rendered
for the fiscal years ended December 31, 2021 and 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">December 31,<br/> 2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 48%; text-align: left; text-indent: -10pt">Audit Fees</td><td style="width: 10%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">26,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">20,500</td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Audit Related Fees</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">9,700</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">9,975</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Tax Fees</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All Other Fees</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Totals</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,700</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>  </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">AUDIT FEES. Consists of fees billed for professional
services rendered for the audit of the Company’s consolidated financial statements and review of the interim consolidated financial
statements included in quarterly reports and services in connection with statutory and regulatory filings or engagements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">AUDIT-RELATED FEES. Consists of fees billed for preparation
of financial statements and related services that are reasonably related to the performance of the audit or review of the Company’s
consolidated financial statements and are not reported under “Audit Fees.”</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TAX FEES. Consists of fees billed for professional
services for tax compliance, tax advice and tax planning.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ALL OTHER FEES. Consists of fees for products and
services other than the services reported above. There were no management consulting services provided in fiscal 2021 or 2020.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">POLICY ON AUDIT COMMITTEE PRE-APPROVAL OF AUDIT AND
PERMISSIBLE NON-AUDIT SERVICES OF INDEPENDENT AUDITORS</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not have a designated Audit
Committee, and accordingly, the Company’s Board of Directors’ policy is to pre-approve all audit and permissible non-audit
services provided by the independent auditors. These services may include audit services, audit-related services, tax services and other
services. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category
of services and is generally subject to a specific budget. The independent auditors and management are required to periodically report
to the Company’s Board of Directors regarding the extent of services provided by the independent auditors in accordance with this
pre-approval, and the fees for the services performed to date. The Board of Directors may also pre-approve particular services on a case-by-case
basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
<!-- Field: Page; Sequence: 54; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_023"></span>ITEM 15. EXHIBITS</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid; width: 0.5in; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit No.</b></span></td>
<td style="width: 0.05in; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit Description</b></span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.1</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335019000226/intb_ex99z1.htm">Reorganization Agreement between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve, and the Cannavolve shareholders listed in the agreement, dated March 13, 2019 (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2019).</a></span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.2</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335019000472/intb_ex99z2.htm">Amended Reorganization Agreement between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve and the Cannavolve shareholders listed in the agreement, dated April 27, 2019 (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the SEC on May 6, 2019).</a></span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.3</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335019000472/intb_ex99z3.htm">Amendment No. 1 to Reorganization Agreement between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve, and the Cannavolve shareholders listed in the agreement, dated April 27, 2019 (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed with the SEC on May, 6 2019).</a></span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.4</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000018/intb_ex99z1.htm">Second Amended Agreement and Plan of Reorganization between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve Holdings, the Cannavolve Shareholders listed in the agreement dated January 2, 2020 (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 8, 2020).</a></span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.5</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex2z5.htm">Termination Agreement of the Reorganization between Intelligent Buying Inc. and Jaguaring Company d/b/a Cannavolve Holdings, the Cannavolve Shareholders listed in the agreement dated February 12, 2020. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a> </span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.6</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex2z6.htm">Agreement and Plan of Reorganization by and among Intelligent Buying Inc., Jaguaring Company d/b/a Cannavolve Holdings and the Cannavolve Shareholders listed in the agreement dated February 14, 2020. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a> </span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.7</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000612/e2634_ex2-7.htm">Form of Agreement and Plan of Merger by and among Sentient Brands Holdings Inc., a California corporation, and Sentient Brands Holdings Inc., a Nevada corporation, dated January 28, 2021.</a></span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000135028406000053/exhibit31aoi.htm">Articles of Incorporation of Intelligent Buying Inc. and Certificate of Amendment of Articles of Incorporation of Intelligent Buying, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form SB-2 filed with the SEC on April 17, 2006).</a></span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.2</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex3z2.htm">Bylaws of Intelligent Buying, Inc. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a></span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.3</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000135028406000053/exhibit42.htm">Certificate of Determination for Series A Convertible Preferred Stock of Intelligent Buying, Inc. (incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form SB-2 filed with the SEC on April 17, 2006</a>).</span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.4</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex3z4.htm">Certificate of Determination for Series B Preferred Stock of Intelligent Buying, Inc. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a> </span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.5</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000320/e2488_ex3-1.htm">Certificate of Amendment of Articles of Incorporation of Intelligent Buying Inc., a California corporation. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on March 3, 2021).</a> </span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.6</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000320/e2488_ex3-2.htm">Articles of Incorporation of Sentient Brands Holdings Inc., a Nevada corporation. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on March 3, 2021).</a></span></td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.7</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000320/e2488_ex3-2.htm">Bylaws of Sentient Brands Holdings Inc., a Nevada corporation. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on March 3, 2021).</a> </span></td></tr>
</table>
<p style="margin: 0"> </p>
<!-- Field: Page; Sequence: 55; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="margin: 0"></p>
<p style="margin-top: 0; margin-bottom: 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">4.1</span></td>
<td style="width: 0.05in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000612/e2634_ex4-1.htm">Form of 10% Promissory Note of Intelligent Buying, Inc. issued to an accredited investor dated December 2, 2020.</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.2</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000612/e2634_ex4-2.htm">Form of Securities Purchase Agreement by and among Intelligent Buying, Inc. and an accredited investor dated December 2, 2020.</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.3</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000612/e2634_ex4-3.htm">Form of Stock Purchase Warrant of Intelligent Buying, Inc. issued to an accredited investor dated December 2, 2020.</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.4</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000612/e2634_ex4-4.htm">Form of Stock Pledge Agreement issued by an affiliate of Intelligent Buying, Inc. to an accredited investor dated December 2, 2020.</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.5</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000612/e2634_ex4-5.htm">Form of 10% Convertible Debenture of Intelligent Buying, Inc. issued to an accredited investor dated December 3, 2020</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.6</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000612/e2634_ex4-6.htm">Form of Securities Purchase Agreement by and among Intelligent Buying, Inc. and an accredited investor dated December 3, 2020.</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.7</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000612/e2634_ex4-7.htm">Form of Stock Purchase Warrant of Intelligent Buying, Inc. issued to an accredited investor dated December 3, 2020.</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.8</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000736/e2700_ex4-1.htm">Form of Securities Purchase Agreement. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on May 3, 2021).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.9</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000736/e2700_ex4-2.htm">Form of Senior Secured Convertible Promissory Note. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on May 3, 2021).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.10</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000736/e2700_ex4-3.htm">Form of Common Share Purchase Warrant. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on May 3, 2021).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.11</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221000736/e2700_ex4-4.htm">Form of Pledge and Security Agreement. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on May 3, 2021).</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.12</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221002041/e3275_ex4-12.htm">Form of 18% Promissory Note of Sentient Brands Holdings Inc. issued to an accredited investor dated September 23, 2021. (Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on November 22, 2021).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.13</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221002041/e3275_ex4-13.htm">Form of Securities Purchase Agreement by and among Sentient Brands Holdings Inc. and an accredited investor dated November 18, 2021. (Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on November 22, 2021).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.14</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221002041/e3275_ex4-14.htm">Form of Senior Secured Convertible Promissory Note issued to an accredited investor dated November 18, 2021. (Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on November 22, 2021).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.15 </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221002041/e3275_ex4-15.htm">Form of Common Share Purchase Warrant issued to an accredited investor dated November 18, 2021. (Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on November 22, 2021).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.16</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112221002041/e3275_ex4-16.htm">Form of Pledge and Security Agreement by and among Sentient Brands Holdings Inc. and an accredited dated November 18, 2021. (Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on November 22, 2021).</a></span></td></tr>
</table>
<p style="margin: 0"> </p>
<p style="margin: 0"></p>
<!-- Field: Page; Sequence: 56; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="margin: 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></td>
<td style="width: 0.05in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335019000226/intb_ex99z2.htm">Convertible Promissory Note of Intelligent Buying Inc. issued to PureEnergy714 LLC2019 (incorporated by reference to Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2019).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">10.2</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335019000226/intb_ex99z3.htm">Convertible Promissory Note issued by Jaguaring, Inc. d/b/a Cannavolve (incorporated by reference to Exhibit 99.3 to the Company’s Current Report on Form 8-K filed with the SEC on March 19, 2019).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">10.3</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z3.htm">Form of Subscription Agreement for Rule 506 Offering. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">10.4#</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z4.htm">Executive Consulting Agreement between Intelligent Buying, Inc. and James Mansour dated January 8, 2020. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">10.5#</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z5.htm">Employment Agreement between Intelligent Buying, Inc. and George V. Furlan dated December 2019. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">10.6</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z6.htm">Independent Contractor Agreement between Jaguaring Inc. d/b/a Cannavolve and Dante Jones dated May 1, 2019. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">10.7</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z10.htm">Office Agreement for Jaguaring Inc. d/b/a Cannavolve dated May 23, 2018. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">10.8</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z12.htm">Promissory Note issued by Jaguaring Inc. d/b/a Cannavolve dated June 6, 2019. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">10.9</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z13.htm">Employment Agreement between Intelligent Buying, Inc. and Gregg Templeton dated February 28, 2019. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">10.10</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z10.htm">Office Agreement for Jaguaring Inc. d/b/a Cannavolve dated May 23, 2018. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">10.11</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z11.htm">Promissory Note issued by Jaguaring Inc. d/b/a Cannavolve dated June 11, 2019. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">10.12</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z12.htm">Promissory Note issued by Jaguaring Inc. d/b/a Cannavolve dated June 6, 2019. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="width: 0.5in; padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">10.13#</span></td>
<td style="width: 0.05in"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z14.htm">Restricted Stock Purchase Agreement between Intelligent Buying, Inc. and James Mansour.</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">10.14#</span></td>
<td> </td>
<td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000155335020000166/intb_ex10z15.htm">Restricted Stock Purchase Agreement between Intelligent Buying, Inc. and George Furlan. (Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 14, 2020).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"> </p>
<p style="margin-top: 0; margin-bottom: 0"> </p></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">10.15</span></td>
<td> </td>
<td style="text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000173112220000612/e1965_10-16.htm">Share Exchange Agreement dated as of May 28, 2020 by and among Intelligent Buying Inc., and the shareholders of Jaguaring Company d/b/a Cannavolve Holdings. (Incorporated by reference to the Form 10-K Annual Report filed with the Securities and Exchange Commission on May 29, 2020).</a> </span></td></tr>
</table>
<p style="margin: 0"> </p>
<p style="margin: 0"></p>
<!-- Field: Page; Sequence: 57; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="margin: 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify; width: 0.5in"><span style="font-size: 10pt">14.1</span></td>
<td style="width: 0.05in"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1358633/000135028406000053/exhibit141codeethics.htm">Code of Ethics of Intelligent Buying, Inc. (incorporated by reference to Exhibit 14.1 to the Company’s Registration Statement on Form SB-2 filed with the SEC on April 17, 2006).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">31.1*</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001358633/000173112222000776/e3701_ex31-1.htm"><span style="font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">31.2*</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001358633/000173112222000776/e3701_ex31-2.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">32.1*</span></td>
<td> </td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001358633/000173112222000776/e3701_ex32-1.htm"><span style="font-size: 10pt">Certification of Chief Executive Officer &amp; Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="padding-right: 0.8pt; text-align: justify"> </td>
<td> </td>
<td style="padding-right: 0.8pt"> </td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="padding-right: 0.8pt; text-align: justify"><span style="font-size: 10pt">32.2*</span></td>
<td style="padding-right: 0.8pt"> </td>
<td style="padding-right: 0.8pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001358633/000173112222000776/e3701_ex32-2.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"><span style="font-size: 10pt">*</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Filed herewith</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"><span style="font-size: 10pt">#</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Indicates management contract or compensatory plan.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">  </p>
<!-- Field: Page; Sequence: 58; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_024"></span>SIGNATURES</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of Section 13 or 15(d)
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">Sentient Brands Holdings Inc.</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 43%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 7%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="width: 50%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">Dated: April 29, 2022</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
<td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ George Furlan</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">George Furlan</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Interim Chief Executive Officer, Interim President, Interim Chief Financial Officer, and Director</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>
<!-- Field: Page; Sequence: 59; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>POWER OF ATTORNEY</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Know all persons by these presents that each individual
whose signature appears below constitutes and appoints George Furlan, our Interim Chief Executive Officer and Interim Chief Financial
Officer as a true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name,
place and stead, in any and all capacities, to (i) act on, sign and file with the Securities and Exchange Commission any and all amendments
to this Report together with all schedules and exhibits thereto, (ii) act on, sign and file with the Securities and Exchange Commission
any and all exhibits to this Report and any and all exhibits and schedules thereto, (iii) act on, sign and file any and all such certificates,
notices, communications, reports, instruments, agreements and other documents as may be necessary or appropriate in connection therewith
and (iv) take any and all such actions which may be necessary or appropriate in connection therewith, granting unto such agent, proxy
and attorney-in-fact, full power and authority to do and perform each and every act and thing necessary or appropriate to be done, as
fully for all intents and purposes as he might or could do in person, and hereby approving, ratifying and confirming all that such agent,
proxy and attorney-in-fact, or any of his or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange
Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates
indicated.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">SIGNATURE</span></td>
<td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; width: 53%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">TITLE</span></td>
<td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="border-bottom: black 1pt solid; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">DATE</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ George Furlan</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Interim Chief Executive Officer, Interim President, Interim Chief Financial Officer, and Director</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">April 29, 2022</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">George Furlan</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ James Mansour</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Chief Marketing Officer</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">April 29, 2022</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">James Mansour</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Dante Jones</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">April 29, 2022</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">Dante Jones</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
<td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<!-- Field: Page; Sequence: 60; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SENTIENT BRANDS HOLDINGS INC. AND SUBSIDIARIES<br/>
CONSOLIDATED FINANCIAL STATEMENTS<br/>
December 31, 2021 and 2020</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>
<!-- Field: Page; Sequence: 61; Options: NewSection; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"> </p>
<p style="font: 20pt Cooper Black,serif; margin: 0; color: #009900">Boyle CPA, LLC</p>
<p style="font: 14pt Calibri, Helvetica, Sans-Serif; margin: 0; color: #0070C0">Certified Public Accountants &amp; Consultants</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Shareholders and</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Board of Directors of Sentient Brands Holdings, Inc.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Opinion on
the Financial Statements</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying balance sheets of
Sentient Brands Holdings, Inc. (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of operations,
changes in stockholders’ deficiency, and cash flows for each of the two years in the period ended December 31, 2021, and the related
notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in
all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its
cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted
in the United States of America.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline; background-color: white">Substantial
Doubt About the Company’s Ability to Continue as a Going Concern</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in Note 3 to the financial statements,
the Company has incurred losses since inception and had an accumulated deficit at December 31, 2021. These factors raise substantial doubt
about its ability to continue as a going concern for one year from the issuance of these financial statements. Management’s plans
are also described in Note 3. The financial statements do not include adjustments that might result from the outcome of this uncertainty.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Basis of
Opinion</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with standards
of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal
control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Critical
Audit Matters</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Critical audit
matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ <span id="xdx_901_edei--AuditorName_c20210101__20211231_zF0Ya3XiZrB2"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorName">Boyle CPA, LLC</ix:nonnumeric></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company’s auditor since
2019</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Red Bank, NJ</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">April 28, 2022</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="padding: 0pt; width: 49%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">331 Newman Springs Road</span></td>
<td style="padding: 0pt; text-align: right; width: 51%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">P (732) 784-1582</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building 1, 4<sup>th</sup> Floor, Suite 143 </span></td>
<td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F (732) 510-0665</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--AuditorLocation_c20210101__20211231_zLzSc47KYI16"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorLocation">Red Bank, NJ</ix:nonnumeric></span> 07701 <span id="xdx_909_edei--AuditorFirmId_c20210101__20211231_zyKGaqoRRRuc" style="display: none"><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorFirmId">6285</ix:nonnumeric></span></span></td>
<td style="padding: 0pt; text-align: right; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<!-- Field: Page; Sequence: 62; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 6pt; text-align: center"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; width: 100%"><b>SENTIENT BRANDS HOLDINGS INC.</b> <b><br/>
AND SUBSIDIARIES</b></td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"><span style="font-size: 10pt"><b>CONSOLIDATED BALANCE SHEETS</b> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>
<table cellpadding="0" cellspacing="0" id="xdx_303_121_z35i0PutrrG6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS">
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"> </td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" id="xdx_49E_20211231_znS6wsxZ3QNk" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" id="xdx_494_20201231" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2020</td></tr>
<tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zMVn86ChYYkh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">ASSETS</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_znTSjQiiVgUk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">CURRENT ASSETS</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzPA5_zKGYlqUPGh6d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt">Cash</td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">96,198</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">68,047</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td></tr>
<tr id="xdx_403_eus-gaap--Supplies_i02I_maCzPA5_zCTYgPYAfmV9" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Advances to Supplier</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0052">—</span></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Supplies" unitref="USD">154,893</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_407_eus-gaap--InventoryNet_i02I_d0_maCzPA5_zWoK1xw6gyq3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Inventory</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" unitref="USD">258,781</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; color: rgb(204,238,255); text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:zerodash" name="us-gaap:InventoryNet" unitref="USD">—</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_409_eus-gaap--AssetsCurrent_i02TI_mtCzPA5_maCzoqo_zhwnwxjQsbyg" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL CURRENT ASSETS</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" unitref="USD">354,979</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" unitref="USD">222,940</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzoqo_zc8PdIHmXZ0i" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">FIXED ASSETS (net of Depreciation)</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" unitref="USD">31,783</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" unitref="USD">36,803</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_40B_eus-gaap--Assets_i01TI_mtCzoqo_zv8cz0RjULzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL ASSETS</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" unitref="USD">386,762</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" unitref="USD">259,743</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">LIABILITIES AND STOCKHOLDERS’ DEFICIENCY</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_400_eus-gaap--LiabilitiesCurrentAbstract_i01B_zY8Gh36afxL4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">CURRENT LIABILITIES</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maCztdF_zug4X1LW2t29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts payable and accrued expenses</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitref="USD">186,528</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitref="USD">251,187</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_407_eus-gaap--NotesPayableCurrent_i02I_maCztdF_zmadQfK4cGk4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Notes payable</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" unitref="USD">258,292</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" unitref="USD">175,047</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_40A_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maCztdF_zojnCMXP2C1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Convertible Notes Payable</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayableCurrent" unitref="USD">876,363</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayableCurrent" unitref="USD">170,758</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_40A_eus-gaap--ShortTermBorrowings_i02I_maCztdF_z6kGc476ZVfg" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">PPP Loan</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0082">—</span></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" unitref="USD">231,500</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maCztdF_zCvwr2eCHW54" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Derivative liabilities</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0085">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_409_eus-gaap--LiabilitiesCurrent_i02TI_mtCztdF_maCzzHr_zs2WIlmAyba4" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" unitref="USD">1,321,183</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" unitref="USD">828,492</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_40A_eus-gaap--Liabilities_i02I_mtCzzHr_maCz0XN_maLASEzfBH_zDyMOkAiVlN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL LIABILITIES</td><td style="font-weight: bold"> </td>
<td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" unitref="USD">1,321,183</ix:nonfraction></td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td>
<td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" unitref="USD">828,492</ix:nonfraction></td><td style="font-weight: bold; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">STOCKHOLDERS’ DEFICIENCY</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40A_eus-gaap--PreferredStockValue_i01I_maSEzAk7_zbevScUR3JCf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Preferred Stock – Par Value of $0<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zNBj3qVheR99"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_znsfIpbsq4xb"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitref="USDPShares"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitref="USDPShares">.001</ix:nonfraction></ix:nonfraction></span></span>; <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_c20211231_pdd" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_c20201231_pdd" title="Preferred stock, shares authorized"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" unitref="Shares"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" unitref="Shares">25,000,000</ix:nonfraction></ix:nonfraction></span></span> shares authorized; <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_c20211231_pdd" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_c20211231_pdd" title="Preferred stock, shares outstanding"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" unitref="Shares"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" unitref="Shares">1,000,000</ix:nonfraction></ix:nonfraction></span></span> and <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_c20201231_pdd" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_c20201231_pdd" title="Preferred stock, shares outstanding"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" unitref="Shares"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" unitref="Shares">0</ix:nonfraction></ix:nonfraction></span></span> shares issued and outstanding as of September 30, 2020 and December 31, 2019</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" unitref="USD">1,000</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" unitref="USD">1,000</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_403_eus-gaap--CommonStockValue_i01I_maCzOvZ_maSEzAk7_zbrRyeAOHUql" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Common Stock - Par Value of $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common stock, par value"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" unitref="USDPShares"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" unitref="USDPShares">0.001</ix:nonfraction></ix:nonfraction></span></span>; <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common stock, shares authorized"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares">50,000,000</ix:nonfraction></ix:nonfraction></span></span> shares authorized; <span id="xdx_907_ecustom--CommonStockShareIssued_c20211231_pdd" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockOtherSharesOutstanding_c20211231_pdd" title="Common stock, shares outstanding"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="snbh:CommonStockShareIssued" unitref="Shares"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" unitref="Shares">51,920,387</ix:nonfraction></ix:nonfraction></span></span> and <span id="xdx_906_ecustom--CommonStockShareIssued_c20201231_pdd" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockOtherSharesOutstanding_c20201231_pdd" title="Common stock, shares outstanding"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" format="ixt:numdotdecimal" name="snbh:CommonStockShareIssued" unitref="Shares"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" unitref="Shares">50,782,116</ix:nonfraction></ix:nonfraction></span></span> shares issued and outstanding as of December 31, 2021 and 2020, respectively</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" unitref="USD">51,921</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" unitref="USD">50,782</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i01I_maCzOvZ_maSEzAk7_zNwqkbY9FX3i" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" unitref="USD">1,333,567</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" unitref="USD">1,333,356</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzOvZ_maSEzAk7_zr42KvMRmRqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" unitref="USD">2,320,909</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" unitref="USD">1,953,887</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_408_eus-gaap--StockholdersEquity_iTI_pp0p0_mtSEzAk7_maLASEzfBH_zA3N64YgCC23" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL STOCKHOLDERS’ DEFICIENCY</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitref="USD">934,421</ix:nonfraction></td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitref="USD">568,749</ix:nonfraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0p0_mtLASEzfBH_zjyeww97LOPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">TOTAL LIABILITIES &amp; STOCKHOLDERS’ DEFICIENCY</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitref="USD">386,762</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitref="USD">259,743</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>  </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
consolidated financial statements</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<!-- Field: Page; Sequence: 63; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">  </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; width: 100%"><b>SENTIENT BRANDS HOLDINGS INC.</b> <b><br/>
AND SUBSIDIARIES</b></td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"><span style="font-size: 10pt"><b>STATEMENTS OF OPERATIONS</b> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b></b></p>
<table cellpadding="0" cellspacing="0" id="xdx_303_113_zvpvvfP6Lvlc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - STATEMENTS OF OPERATIONS">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td id="xdx_493_20210101__20211231_zF1sx75VllFc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td id="xdx_49E_20200101__20201231_zVRyJ47SSQ1b" style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr id="xdx_408_eus-gaap--CostOfRevenueAbstract_iB_zEJOgLndZPal" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">REVENUES:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_403_eus-gaap--Revenues_i01_maCzosw_zwZNbPoWEzBc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">TOTAL REVENUES</td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" unitref="USD">681</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" unitref="USD">7,017</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td></tr>
<tr id="xdx_407_eus-gaap--CostOfGoodsAndServicesSold_msCzosw_zHXoMF6E6Hj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cost of sales</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" unitref="USD">23</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" unitref="USD">4,724</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_407_eus-gaap--GrossProfit_iT_mtCzosw_maCzJ36_zaRULw24ZgB4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Gross Profit</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" unitref="USD">658</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" unitref="USD">2,293</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_403_eus-gaap--OperatingExpensesAbstract_iB_zC7udB1E7Bjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating Expenses</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzL2P_z148BolAbMC3" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">General and Administrative</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" unitref="USD">70,039</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" unitref="USD">135,654</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_402_eus-gaap--LegalFees_i01_maCzL2P_zdzREJ0jFoyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Legal and Professional</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LegalFees" unitref="USD">293,070</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LegalFees" unitref="USD">342,016</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_40B_eus-gaap--ManagementFeeExpense_i01_maCzL2P_zAOmI4iZPmWf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Management Fees</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ManagementFeeExpense" unitref="USD">159,000</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ManagementFeeExpense" unitref="USD">210,636</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_404_eus-gaap--OperatingExpenses_iT_mtCzL2P_msCzJ36_zM1hkUyQZM6i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">TOTAL OPERATING EXPENSES</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" unitref="USD">522,109</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" unitref="USD">787,589</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_mtCzJ36_maCzw3M_zflGCJoQBJld" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" unitref="USD">521,451</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" unitref="USD">785,296</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_408_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_z6XnqmRtBdPd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other Income (Expenses)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40B_eus-gaap--InterestExpense_i01N_di_msCzw3M_zYJfUdh2LKXe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest expense</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" unitref="USD">66,545</ix:nonfraction></td><td style="text-align: left">) </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> (<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" unitref="USD">30,965</ix:nonfraction></td><td style="text-align: left">) </td></tr>
<tr id="xdx_400_eus-gaap--AmortizationOfDebtDiscountPremium_i01N_di_msCzw3M_zmwGkiWhWmk1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Discount amortization</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" unitref="USD">10,526</ix:nonfraction></td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> <span style="-sec-ix-hidden: xdx2ixbrl0182">—</span></td><td style="text-align: left"> </td></tr>
<tr id="xdx_40C_eus-gaap--OtherNonoperatingIncomeExpense_maCzw3M_zkVdwbutNjK3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other income</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" unitref="USD">231,500</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0185">—</span></td><td style="padding-bottom: 1pt; text-align: left"></td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtCzw3M_zbBtf1ZoBeUf" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET LOSS</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" unitref="USD">367,022</ix:nonfraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" unitref="USD">816,261</ix:nonfraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_404_ecustom--NetLossPerCommonShareBasicAndDiluted_i_pdd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET LOSS PER COMMON SHARE – BASIC AND DILUTED</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="snbh:NetLossPerCommonShareBasicAndDiluted" sign="-" unitref="USDPShares">0.007</ix:nonfraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="INF" format="ixt:numdotdecimal" name="snbh:NetLossPerCommonShareBasicAndDiluted" sign="-" unitref="USDPShares">0.015</ix:nonfraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40D_ecustom--WeightedAverageNumberOfSharesOutstanding_zsK1XqXVUVy7" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="snbh:WeightedAverageNumberOfSharesOutstanding" unitref="Shares">51,580,786</ix:nonfraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="INF" format="ixt:numdotdecimal" name="snbh:WeightedAverageNumberOfSharesOutstanding" unitref="Shares">52,711,029</ix:nonfraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
consolidated financial statements</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>
<!-- Field: Page; Sequence: 64; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; width: 100%"><b>SENTIENT BRANDS HOLDINGS INC.</b> <b><br/>
AND SUBSIDIARIES</b></td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"><span style="font-size: 10pt"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<table cellpadding="0" cellspacing="0" id="xdx_304_112_zro1tBJBBp63" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td id="xdx_49A_20210101__20211231_zPX5LHhQI3Ik" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td id="xdx_49B_20200101__20201231_zmmDk1pSzBF1" style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td>
<td colspan="7" style="font-weight: bold; text-align: center">For the year ended</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zLTEqMA56Yi2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">OPERATING ACTIVITIES:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_409_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01N_di_msCzUFz_zdrOCgMZqRqc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitref="USD">367,022</ix:nonfraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitref="USD">816,261</ix:nonfraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40D_eus-gaap--Depreciation_i02_maCzUFz_zUFmyig73C85" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Depreciation expense</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" unitref="USD">5,020</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" unitref="USD">5,020</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_40A_ecustom--WriteOffReceivablesAndInventory_i02N_di_msCzUFz_zRcAZWDksY1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Write off receivables and inventory</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="snbh:WriteOffReceivablesAndInventory" sign="-" unitref="USD">12,042</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_407_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maCzUFz_zfEi5uStu0zk" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Amortization of discount</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitref="USD">10,526</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40D_ecustom--ForgivenessOfSbaLoan_i02N_di_msCzUFz_z86AycVKwpTi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Forgiveness of PPP Loan</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="snbh:ForgivenessOfSbaLoan" unitref="USD">231,500</ix:nonfraction></td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40E_ecustom--NonCashFinancingFees_i02_maCzUFz_zpQFRI4aW6Ra" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non cash financing fees</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="snbh:NonCashFinancingFees" unitref="USD">250</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_ziKuLUZsMeXk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in operating assets and liabilities:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msCzUFz_z1g4eBTsCLn2" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Inventory</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" unitref="USD">258,781</ix:nonfraction></td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" unitref="USD">27,560</ix:nonfraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--IncreaseDecreaseInFinanceReceivables_i02N_di_msCzUFz_zIFJeDamRyPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Loans receivables</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">—</span></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInFinanceReceivables" sign="-" unitref="USD">17,611</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_407_eus-gaap--IncreaseDecreaseInCustomerAdvances_i02_maCzUFz_zMGh8EGloQd8" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Advances to supplier</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInCustomerAdvances" unitref="USD">154,893</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInCustomerAdvances" sign="-" unitref="USD">11,874</ix:nonfraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maCzUFz_zbxKhyTJnRuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" unitref="USD">64,658</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">) </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitref="USD">111,261</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzUFz_maCzUdN_z3IirCeHD4gj" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CASH USED IN OPERATING ACTIVITIES</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" unitref="USD">751,272</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" unitref="USD">709,761</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zY4fr5dHVy89" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">INVESTMENT ACTIVITIES:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_408_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCz3N2_zZTI92GpMzz6" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Purchase of office equipment</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0241">—</span></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitref="USD">39,277</ix:nonfraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCz3N2_maCzUdN_z2DjYlGSesyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CASH USED IN INVESTMENT ACTIVITIES</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" unitref="USD">39,277</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zX9wwMtknXA1" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">FINANCING ACTIVITIES:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_406_eus-gaap--ProceedsFromRepaymentsOfDebt_i01_maCzz9X_zj25KI28JjXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Proceeds (Payment) of loan payable</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" unitref="USD">695,078</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" unitref="USD">80,001</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_404_eus-gaap--ProceedsFromShortTermDebt_i01_maCzz9X_zmWFIr8hkc0a" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Proceeds from short term loan</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" unitref="USD">83,245</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" unitref="USD">256,500</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzz9X_zvzMdc85z1Ei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Net proceeds from issuance of common stock</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitref="USD">1,100</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitref="USD">471,560</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzz9X_maCzUdN_zJ0XCrwXHXDc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET CASH PROVIDED BY FINANCING ACTIVITIES</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitref="USD">779,423</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitref="USD">808,061</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzUdN_zkFvigudECSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">INCREASE (DECREASE) IN CASH</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitref="USD">28,151</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitref="USD">59,023</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zvFkvv5Wl2ii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">CASH-BEGINNING OF PERIOD</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">68,047</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="AsOf2019-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">9,024</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zk0uDpmaAKlc" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">CASH-END OF PERIOD</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">96,198</ix:nonfraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">68,047</ix:nonfraction></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
<tr id="xdx_40B_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zrF5A27oqkn9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Supplemental disclosures of cash flow information:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_406_ecustom--CashPaidDuringYearFor_i01_zNF3iRxrgDGd" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash paid during the year for:</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_407_eus-gaap--InterestPaidNet_i01_zojeLljBcVLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Interest</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" unitref="USD">21,052</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
<tr id="xdx_409_eus-gaap--IncomeTaxesPaidNet_i01_z1nVERttZTda" style="vertical-align: bottom; background-color: White">
<td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Taxes</td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
consolidated financial statements</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<!-- Field: Page; Sequence: 65; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="text-align: center; width: 100%"><p style="margin-top: 0; margin-bottom: 0"><b>    SENTIENT BRANDS HOLDINGS
INC.</b>   <br/>
<b>AND SUBSIDIARIES</b></p></td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"><span style="font-size: 10pt"><b>UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIENCY</b></span></td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"><span style="font-size: 10pt"><b>For the Year Ended </b> </span></td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"><span style="font-size: 10pt"><b>December 31, 2021 and 2020</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>
<table cellpadding="0" cellspacing="0" id="xdx_304_114_zaNw4fVBMmPj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)">
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; text-indent: -10pt; padding-left: 10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z4F3e5qsK04k" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zbhui3xbBpX5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zW7PN8idagBa" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_ztp0LtGcpKDb" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td id="xdx_4BC_z3nILhQu4x14" style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">December 31, 2021</td><td style="padding-bottom: 1pt"> </td>
<td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt"> </td>
<td colspan="7" style="border-bottom: Black 1pt solid; text-align: center">Preferred Stock</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="text-align: center">Paid in</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="text-align: center">Accumulated</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="text-align: center"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
<tr id="xdx_439_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zdR378LRQcp9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 37%; text-indent: -10pt; padding-left: 10pt">Balance - December 31, 2020</td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPNLUhAUQAT3" style="width: 5%; text-align: right" title="Beginning balance, shares"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" unitref="Shares">50,782,116</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 5%; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">50,782</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zU7Sp9NsWlfg" style="width: 5%; text-align: right" title="Beginning balance, shares"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_PreferredStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" unitref="Shares">1,000,000</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 5%; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">1,000</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 5%; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">1,333,356</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 5%; text-align: right">(<ix:nonfraction contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">1,953,887</ix:nonfraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 5%; text-align: right">(<ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">568,749</ix:nonfraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40F_ecustom--CommonStockIssued_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Common stock issued</td><td> </td>
<td style="text-align: left"> </td><td id="xdx_984_ecustom--CommonStockIssuedShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" style="text-align: right" title="Common stock issued, shares"><ix:nonfraction contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:CommonStockIssuedShares" unitref="Shares">1,350,000</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="snbh:CommonStockIssued" unitref="USD">1,350</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="snbh:CommonStockIssued" unitref="USD">1,350</ix:nonfraction></td><td style="text-align: left"> </td></tr>
<tr id="xdx_40C_ecustom--CommonStockCancellationValue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Common stock cancellation</td><td> </td>
<td style="text-align: left"> </td><td id="xdx_980_ecustom--CommonStockCancellationShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" style="text-align: right" title="Common stock cancellation, shares">(<ix:nonfraction contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:CommonStockCancellationShares" sign="-" unitref="Shares">211,729</ix:nonfraction></td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(<ix:nonfraction contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="snbh:CommonStockCancellationValue" sign="-" unitref="USD">211</ix:nonfraction></td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><ix:nonfraction contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" name="snbh:CommonStockCancellationValue" unitref="USD">211</ix:nonfraction></td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305"></span></td><td style="text-align: left"> </td></tr>
<tr id="xdx_404_eus-gaap--ProfitLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-family: Calibri, Helvetica, Sans-Serif; color: white; padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; font-family: Calibri, Helvetica, Sans-Serif; color: white; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-family: Calibri, Helvetica, Sans-Serif; color: white; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310"></span></td><td style="padding-bottom: 1pt; font-family: Calibri, Helvetica, Sans-Serif; color: white; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" unitref="USD">367,022</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" unitref="USD">367,022</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_430_c20210101__20211231_eus-gaap--StockholdersEquity_iE_ze8ZrZvhsTa1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balances December 31, 2021</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXYC9lh17gV9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Ending balance, shares"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" unitref="Shares">51,920,387</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">51,921</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6WZxXEKdPE1" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Ending balance, shares"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_PreferredStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" unitref="Shares">1,000,000</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">1,000</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">1,333,567</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonfraction contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">2,393,030</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">934,421</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">) </td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">December 31, 2020</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Common Stock</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Preferred Stock</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="3" style="font-size: 10pt; text-align: center">Paid in</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="3" style="font-size: 10pt; text-align: center">Accumulated</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="text-align: center"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Shares</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Amount</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Shares</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Amount</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Capital</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Deficit</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Total</td></tr>
<tr id="xdx_430_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zYbD9QVCuIRh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 37%; font-size: 10pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2019</td><td style="width: 2%; font-size: 10pt"> </td>
<td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgLaqoUckr04" style="width: 5%; font-size: 10pt; text-align: right" title="Beginning balance, shares"><ix:nonfraction contextref="AsOf2019-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" unitref="Shares">55,825,021</ix:nonfraction></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 5%; font-size: 10pt; text-align: right"><ix:nonfraction contextref="AsOf2019-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">55,825</ix:nonfraction></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; color: #CCEEFF"> </td>
<td style="width: 1%; color: #CCEEFF; text-align: left"> </td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVY3iEPOj9o2" style="color: rgb(204,238,255); width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%; color: #CCEEFF"> </td>
<td style="width: 1%; color: #CCEEFF; text-align: left">$</td><td style="width: 5%; color: #CCEEFF; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326"></span></td><td style="width: 1%; color: #CCEEFF; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 5%; font-size: 10pt; text-align: right"><ix:nonfraction contextref="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">857,754</ix:nonfraction></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 5%; font-size: 10pt; text-align: right">(<ix:nonfraction contextref="AsOf2019-12-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">1,137,626</ix:nonfraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt"> </td>
<td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 5%; font-size: 10pt; text-align: right">(<ix:nonfraction contextref="AsOf2019-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">224,047</ix:nonfraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Common stock issued</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr id="xdx_409_ecustom--ShareExchangevalue_iP3us-gaap--SharesOutstanding_z44zAaL01HQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-indent: -10pt; padding-left: 20pt">Share exchange</td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_ecustom--ShareExchangeShares_iP3custom--ShareExchangevalue_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8H74cr5LQth" style="font-size: 10pt; text-align: right" title="Share exchange, shares"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:ShareExchangeShares" unitref="Shares">4,914,777</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="snbh:ShareExchangevalue" unitref="USD">4,915</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98D_ecustom--ShareExchangeShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_pdd" style="font-size: 10pt; text-align: right" title="Share exchange, shares"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:ShareExchangeShares" unitref="Shares">1,000,000</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:numdotdecimal" name="snbh:ShareExchangevalue" unitref="USD">1,000</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" name="snbh:ShareExchangevalue" unitref="USD">121,480</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="snbh:ShareExchangevalue" unitref="USD">127,395</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueNewIssues_iP3custom--ShareExchangeShares_zO0xP14im6og" style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Issuance of common stock</td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_iP3us-gaap--StockIssuedDuringPeriodValueNewIssues_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXgzTT0w8iya" style="font-size: 10pt; text-align: right" title="Issuance of common stock, shares"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitref="Shares">17,725,400</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="USD">17,725</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="USD">382,275</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="USD">400,000</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr id="xdx_404_ecustom--CommonStockCancelledValue_iP3us-gaap--StockIssuedDuringPeriodSharesNewIssues_z8M5ed8m2Jlg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Common stock cancelled</td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_ecustom--CommonStockCancelledShares_iP3custom--CommonStockCancelledValue_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmRjQKCEcwvj" style="font-size: 10pt; text-align: right" title="Common stock cancelled, shares">(<ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:CommonStockCancelledShares" sign="-" unitref="Shares">28,800,471</ix:nonfraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="snbh:CommonStockCancelledValue" sign="-" unitref="USD">28,800</ix:nonfraction></td><td style="font-size: 10pt; text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" name="snbh:CommonStockCancelledValue" unitref="USD">28,800</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356"></span></td><td style="font-size: 10pt; text-align: left"> </td></tr>
<tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_iP3custom--CommonStockCancelledShares_zrjyiBiKWpkb" style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Adjustment to paid in capital</td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td id="xdx_98F_ecustom--AdjustmentToPaidInCapitalShares_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjp6LZDrdvj2" style="font-size: 10pt; text-align: right" title="Adjustment to paid in capital, shares"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:AdjustmentToPaidInCapitalShares" unitref="Shares">1,117,389</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" unitref="USD">1,117</ix:nonfraction></td><td style="font-size: 10pt; text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" sign="-" unitref="USD">56,953</ix:nonfraction></td><td style="font-size: 10pt; text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-size: 10pt"> </td>
<td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" sign="-" unitref="USD">55,836</ix:nonfraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--ProfitLoss_zJWfkpSDKz0e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" unitref="USD">816,261</ix:nonfraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonfraction contextref="From2020-01-012020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" unitref="USD">816,261</ix:nonfraction></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
<tr id="xdx_43A_c20200101__20201231_eus-gaap--StockholdersEquity_iE_z9xvhhXb7xPd" style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balances December 31, 2020</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBjaSnePgcxb" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance, shares"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" unitref="Shares">50,782,116</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">50,782</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8lc86wjz2wk" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance, shares"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_PreferredStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" unitref="Shares">1,000,000</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">1,000</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" unitref="USD">1,333,356</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonfraction contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">1,953,887</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td>
<td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">568,749</ix:nonfraction></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">  <b> </b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part of these
consolidated financial statements</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>
<!-- Field: Page; Sequence: 66; Value: 1 -->
<div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> </p></div>
<div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="width: 100%; text-align: center"><span style="font-size: 10pt"><b>SENTIENT BRANDS HOLDINGS INC.</b></span></td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"><span style="font-size: 10pt"><b>DECEMBER 31, 2021 AND 2020</b> </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
<ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_800_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z0EHyFACbbPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_822_znqFszTq0Ljk">ORGANIZATION AND NATURE OF OPERATIONS</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
description</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements presented are those of Sentient Brands Holdings Inc. (the “Company”). The Company was incorporated under
the laws of the State of California on March 22, 2004, and, until October 2016, the Company was in the business of media advertising
and acquiring high-end computer and networking equipment from resellers and end-users and then reselling this equipment at discounted
prices. The Company is currently in the business of product development and brand management with a focus on building innovative brands
in the Luxury and Premium Market space. The Company has a Direct-to Consumer business model focusing on the integration of CBD, wellness
and beauty for conscious consumers. The Company incorporates an omnichannel approach in its marketing strategies to ensure that its products
are accessible across both digital and retail channels. The Company develops Lifestyle Brands with carefully thought-out ingredients,
packaging, fragrance and design. The Company’s leadership team has extensive experience in building world-class brands such as
Hugo Boss, Victoria’s Secret, Versace, and Bath &amp; Body Works. The Company is focused on two key market segments targeting:
wellness and responsible luxury, which the Company believes represent unique opportunities for its Oeuvre product line. The Company intends
to leverage its in-house innovation capabilities to launch new products that “disrupt” adjacent product categories. The Company
plans to grow by leveraging its deep connections within its existing network and attract consumers through increased brand awareness
and investing in unique social media marketing. The Company’s goal is to create customer experiences that have sustainable resonance
with consumers and consistently implement strategies that result in long-term profit growth.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2020, the Company filed a Certificate of Amendment of Articles of Incorporation (the “Certificate”) with the
State of California to (i) effect a forward stock split of its outstanding shares of common stock at a ratio of <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20201201__20201209" title="Forward Stock Split"><ix:nonnumeric contextref="From2020-12-012020-12-09" name="us-gaap:StockholdersEquityReverseStockSplit">7 for 1</ix:nonnumeric></span> (7:1) (the “Forward
Stock Split”), (ii) increase the number of authorized shares of common stock from <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zinRydPM7kUa" title="Common stock, shares authorized"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares">50,000,000</ix:nonfraction></span> shares to <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20201209_pdd" title="Common stock, shares authorized"><ix:nonfraction contextref="AsOf2020-12-09" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares">500,000,000</ix:nonfraction></span> shares, and
(iii) effectuate a name change (the “Name Change”). Fractional shares that resulted from the Forward Stock Split will be
rounded up to the next highest number. As a result of the Name Change, the Company’s name changed from “Intelligent Buying,
Inc.” to “Sentient Brands Holdings Inc.”. The Certificate was approved by the majority of the Company’s shareholders
and by the Board of Directors of the Company. The effective date of the Forward Stock Split and the Name Change was March 2, 2021.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the above, the Company filed an Issuer Company-Related Action Notification Form with the Financial Industry Regulatory
Authority. The Forward Stock Split and the Name Change was implemented by FINRA on March 2, 2021. Our symbol on OTC Markets was INTBD
for 20 business days from March 2, 2021 (the “Notification Period”). Our new CUSIP number is 81728V 102. As a result of the
name change, our symbol was changed to “SNBH” following the Notification Period. All share and per share information has
been retroactively adjusted to reflect this forward stock split.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, on January 29, 2021, the Company, merged with and into its wholly owned subsidiary, Sentient Brands Holdings Inc., a Nevada
corporation, pursuant to an Agreement and Plan of Merger between Sentient Brands Holdings Inc., a California corporation, and Sentient
Brands Holdings Inc., a Nevada corporation. Sentient Brands Holdings Inc., a Nevada corporation, continued as the surviving entity of
the migratory merger. Pursuant to the migratory merger, the Company changed its state of incorporation from California to Nevada and
each share of its common stock converted into one share of common stock of the surviving entity in the migratory merger. No dissenters’
rights were exercised by any of the Company’s stockholders in connection with the migratory merger.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the consummation of the migratory merger, the articles of incorporation and bylaws of the Nevada corporation that was newly-created as
a wholly owned subsidiary of the Company became the articles of incorporation and bylaws for the surviving entity in the migratory merger.</span></p>
<ix:exclude><p id="xdx_238_zWkzxWaOeVrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></ix:exclude>
<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
<div id="xdx_237_zz26bBWKqpff" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_236_zysrrgWtWj8c" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> </p></div>
<div id="xdx_23C_zylMsKIXOCRk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23C_zPr34QQRbS8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Basis
of Presentation</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements are presented in conformity with accounting principles generally accepted in the United States of America, as reported
on our fiscal years ending on December 31, 2021 and 2020. We have summarized our most significant accounting policies.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zaZjXdUJUCk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_824_zMDM1T7e6w64">SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zZq8CvrJBIF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zMGg34UcWERf">Uses
of estimates in the preparation of financial statements</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with generally accepted accounting principles accepted in the United States of America
(“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenue and
expenses during each reporting period. Actual results could differ from those estimates.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zc6VzDnLd3ac" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zfgQAG6Z18K1">Reclassifications</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
reclassifications have been made to the 2020 presentation to make them consistent with 2021<i>.</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziFpUWqWUXFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z7URWviDH558">Cash</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all short-term highly liquid investments with an original maturity date of purchase of three months or less to be cash
equivalents.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zdlxuNgB7gQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zWhFS8GuAR3h">Revenue
Recognition</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021 and 2020, our revenue recognition policy was in accordance with ASC 606, “Revenue from Contracts
with Customers”, which requires the recognition of sales following five steps: (i) identify the contract(s) with a customer, (ii)
identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the
performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zlqouMvxicEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zqSw73cQIGRk">Net
loss per common share – basic and diluted</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authoritative
guidance on Earnings per Share requires dual presentation of basic and diluted earnings or loss per share (“EPS”) for all
entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation
to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution; diluted EPS reflects the potential dilution
that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in
the issuance of common stock that then shared in the earnings of the entity.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding
during the period. Diluted loss per share reflects the potential dilution that could occur if dilutive securities and other contracts
to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the
earnings of the Company, unless the effect is to reduce a loss or increase earnings per share.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock"><p id="xdx_845_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_z1NnVwZhd0gc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zZZXJJ8Q6OUc">Stock-based
compensation</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC No. 718, Compensation – Stock Compensation (“ASC 718”), the Company measures the compensation costs
of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over
the period during which employees are required to provide services.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2021, and 2020, there were no stock based awards issued or outstanding.</span></p>
<ix:exclude><p id="xdx_23C_zJCRVhUhdDDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></ix:exclude>
<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
<div id="xdx_23D_zp2UprvEsMv" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_234_zNT0uKu2s28g" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> </p></div>
<div id="xdx_23A_zGbllpvRf7Db" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_zj9IizbJSpwk" style="margin: 0pt"> </p></div>
<!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23A_zKygurR7r2bj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z2U7uCjtz7Bd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zPDt5EDQKIMc">Fair
value of financial instruments</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
value our financial assets and liabilities on a recurring basis using the fair value hierarchy established in Accounting Standards Codification
(“ASC”) 820, Fair Value Measurements and Disclosures.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820 describes three levels of inputs that may be used to measure fair value, as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 input, which include quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 inputs, which include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted
prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated
by observable market data for substantially the full term of the asset or liability; and</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 inputs, which include unobservable inputs that are supported by little or no market activity and that are significant to the fair value
of the underlying asset or liability. Level 3 assets and liabilities include those whose fair value measurements are determined using
pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zX3hvEgJlNJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zeFC7cKoRGHe">Income
Taxes</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company’s income tax benefit differs from the expected income tax benefit by applying the U.S. Federal statutory rate of <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_c20210101__20211231_zAWYhioI11je" title="Effective federal income tax rate"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitref="Pure">21</ix:nonfraction></span>% to
net income (loss) as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax effects of temporary differences that give rise to the Company’s net deferred tax liability as of December 31, 2021 and 2020
are as follows:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
<ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zjypzzgkxi9i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -10pt; padding-left: 10pt"><span id="xdx_8BE_zFXwzmo8u6X2" style="display: none">Summary of deferred tax assets and liabilities</span></td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td>
<td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt"> </td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr id="xdx_40F_eus-gaap--ComponentsOfDeferredTaxAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred Tax Assets</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -10pt; padding-left: 10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 56%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net Operating Losses</td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--OperatingLossCarryforwards_c20211231_pp0p0" style="width: 12%; text-align: right" title="Net operating loss carry forward"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitref="USD">392,287</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td>
<td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLossCarryforwards_c20201231_pp0p0" style="width: 12%; text-align: right" title="Net operating loss carry forward"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitref="USD">358,200</ix:nonfraction></td><td style="width: 1%; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -10pt; padding-left: 10pt"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Less: Valuation Allowance</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20211231_ztCjCHnZCu5d" style="border-bottom: Black 1pt solid; text-align: right" title="Change in valuation allowance">(<ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitref="USD">392,287</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20201231_z8I6zoEn565c" style="border-bottom: Black 1pt solid; text-align: right" title="Change in valuation allowance">(<ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitref="USD">358,200</ix:nonfraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Deferred Tax Assets   Net</td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_c20211231_pdp0" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred tax assets"><span style="-sec-ix-hidden: xdx2ixbrl0427">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td>
<td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--DeferredTaxAssetsLiabilitiesNet_c20201231_pdp0" style="border-bottom: Black 1pt solid; text-align: right" title="Deferred tax assets"><span style="-sec-ix-hidden: xdx2ixbrl0429">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr>
</table></ix:nonnumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span> </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Deferred
taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating
loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences
are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a
valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets
will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of
enactment. The U.S. federal income tax rate is 21%.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zDUIZCkJx0Pb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zI4ovWwAuB65">Impairment
of Long-Lived Assets</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets and certain identifiable intangible assets to be held and used are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted
future cash flows resulting from the use of the asset and its eventual disposition. Measurement of an impairment loss for long-lived
assets and certain identifiable intangible assets that management expects to hold, and use is based on the fair value of the asset. Long-lived
assets and certain identifiable intangible assets to be disposed of are reported at the lower of carrying amount or fair value less costs
to sell.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<ix:exclude><!-- Field: Page; Sequence: 69; Value: 1 -->
<div id="xdx_23D_zLARWcUK8Y3j" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_233_zbpTdqMFNsIl" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> </p></div>
<div id="xdx_233_z8FhFq4mlSHa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_235_zOTW0tyQ2QK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zz9Ncuw1LjJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zydqsh1tNs4g">Recently
Issued and Adopted Accounting Standards</span></i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that
may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements
and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting
or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
</ix:nonnumeric></ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zTjerlh30wCe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_82E_z4xiK4UOyfl">GOING CONCERN</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred
losses since inception and has an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20211231_zy3ZlMtsqoSc" title="Accumulated deficit"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitref="USD">2,320,909</ix:nonfraction></span> and $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20201231_zxoHdLg35IHb" title="Accumulated deficit"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitref="USD">1,953,887</ix:nonfraction></span> as of December 31, 2021 and 2020 respectively. The
Company currently has limited liquidity and has not completed its efforts to establish a stabilized source of revenues sufficient to
cover operating costs over an extended period of time. These factors among others, raises substantial doubt about its ability to continue
as a going concern. The financial statements do not include any adjustments that may result from the outcome of these uncertainties.
The Company will require additional financing moving forward and is pursuing various strategies to accomplish this, including seeking
equity funding and/or debt funding from private placement sources. Although management believes that it will be able to obtain the necessary
funding to allow the Company to remain a going concern through the methods discussed above, there can be no assurances that such methods
will prove successful.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. There
are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a
going concern.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_ztxpIAzRGREi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_820_zVKwX5khXgz">INVENTORIES</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost and net realizable value. Cost is determined using the moving average method and net realizable value
is the estimated selling price less costs of disposal in the ordinary course of business. The cost of inventories includes direct costs
plus shipping and packaging materials.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, the Company product inventories valued at approximately $<span id="xdx_90C_eus-gaap--InventoryNet_c20211231_pp0p0" title="Inventories"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" unitref="USD">258,781</ix:nonfraction></span> and <span id="xdx_900_eus-gaap--InventoryNet_iI_pp0p0_c20201231_z0odzaL7slye" title="Inventories"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" unitref="USD">0</ix:nonfraction></span> respectively, are contained in our storage and fulfilment center located at CN Logistics
in Lincoln Park, NJ.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zzNPvRpNCYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_820_z2Kv3pSQDEAc">CONVERTIBLE NOTES PAYABLE</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 27, 2021 (the “Issuance Date”), the Company entered into a Securities Purchase Agreement with an accredited
investor (the “April 2021 Investor”) providing for the sale by the Company to the April 2021 Investor of a <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zV4CZEaanv5d" title="Interest rate"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitref="Pure">10</ix:nonfraction></span>%
Senior Secured Convertible Promissory Note in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Principal amount"><ix:nonfraction contextref="AsOf2021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitref="USD">315,789</ix:nonfraction></span> (the
“April 2021 Note”, and, the “Financing”). The principal amount of the April 2021 Note includes an Original
Issue Discount of $<span id="xdx_90B_ecustom--OriginalIssueDiscount_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Original Issue Discount"><ix:nonfraction contextref="AsOf2021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="snbh:OriginalIssueDiscount" scale="0" unitref="USD">15,789</ix:nonfraction></span>,
resulting in $<span id="xdx_905_ecustom--ProceedsFromFinancing_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Proceeds from financing"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="snbh:ProceedsFromFinancing" scale="0" unitref="USD">300,000</ix:nonfraction></span> in
total proceeds received by the Company in the Financing. The April 2021 Note is convertible at the option of the April 2021 Investor
into shares of common stock of the Company at $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pdd" title="Conversion price"><ix:nonfraction contextref="AsOf2021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitref="USDPShares">0.40</ix:nonfraction></span> per
share. In addition to the April 2021 Note, the April 2021 Investor also received <span id="xdx_900_ecustom--NumberOfCommonStockReceived_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_z281HvGlMwy1" title="Number of common stock received"><span id="xdx_90F_ecustom--NumberOfCommonStockReceived_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_z5CaL5Miatjj" title="Number of common stock received"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:NumberOfCommonStockReceived" unitref="Shares"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:NumberOfCommonStockReceived" unitref="Shares">250,000</ix:nonfraction></ix:nonfraction></span></span> shares
of common stock of the Company (the “Commitment Shares”), and a common share purchase warrant (the “April 2021
Warrant”, and together with the April 2021 Note and the Commitment Shares, the “Securities”) to acquire <span id="xdx_908_ecustom--CommonStockPurchaseWarrant_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zZZqK1PNPvWk" title="Common stock purchase warrant"><span id="xdx_900_ecustom--CommonStockPurchaseWarrant_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zFeQrAX56aHh" title="Common stock purchase warrant"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:CommonStockPurchaseWarrant" unitref="Shares"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:CommonStockPurchaseWarrant" unitref="Shares">500,000</ix:nonfraction></ix:nonfraction></span></span> shares
of common stock of the Company. The April 2021 Warrant is exercisable for five <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zUPNGlx5P497" style="display: none" title="Warrant term"><ix:nonnumeric contextref="AsOf2021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonnumeric></span> years at an exercise price of $<span id="xdx_905_ecustom--WarrantExercisePrice_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pdd" title="Warrant exercise price"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:WarrantExercisePrice" unitref="USDPShares">0.60</ix:nonfraction></span>. During
the year the company paid monthly interest totaling $<span id="xdx_900_eus-gaap--InterestPaid_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Monthly interest paid"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaid" scale="0" unitref="USD">21,052</ix:nonfraction></span>.64. Principal balance as of December 31, 2021 remains at
$<span id="xdx_906_eus-gaap--ConvertibleNotesPayable_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Convertible Notes Payable"><ix:nonfraction contextref="AsOf2021-12-31_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitref="USD">315,789</ix:nonfraction></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 23, 2021 (the “Issuance Date”)</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
the Company issued an <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210901__20210923__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zRDUh6Cti6jj" title="Interest rate"><ix:nonfraction contextref="From2021-09-012021-09-23_custom_PromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitref="Pure">18</ix:nonfraction></span>% Promissory Note in the principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210923__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zt4qDsnZPBRd" title="Principal amount"><ix:nonfraction contextref="AsOf2021-09-23_custom_PromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitref="USD">125,000</ix:nonfraction></span> (the “September 2021 Note”) to an accredited
investor (the “September 2021 Investor”). The September 2021 Note matures six (6) months from the Issuance Date (the “Maturity
Date”), and the September 2021 Investor, at its sole election on the Maturity Date, may convert the interest accrued on the September
2021 Note into shares of common stock of the Company at $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210923__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zZHXAchHjJ4h" title="Conversion price"><ix:nonfraction contextref="AsOf2021-09-23_custom_PromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitref="USDPShares">0.05</ix:nonfraction></span> per share. During the last quarter of 2021 the Company paid $<span id="xdx_907_eus-gaap--RepaymentsOfConvertibleDebt_c20211001__20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Repayment of convertible notes payable"><ix:nonfraction contextref="From2021-10-012021-12-31_custom_PromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitref="USD">67,500</ix:nonfraction></span> with
remaining balance of $<span id="xdx_903_eus-gaap--ConvertibleNotesPayable_c20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Convertible Notes Payable"><ix:nonfraction contextref="AsOf2021-12-31_custom_PromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitref="USD">57,500</ix:nonfraction></span> as of December 31,2021. Accrued interest for this notes as of December 31, 2021 was $<span id="xdx_900_eus-gaap--InterestPayableCurrent_c20211231__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Accrued interest"><ix:nonfraction contextref="AsOf2021-12-31_custom_PromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="0" unitref="USD">5,397</ix:nonfraction></span>. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 -->
<div id="xdx_238_zoT417xrSDlc" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23B_z3kzSKlBNva6" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> </p></div>
<div id="xdx_232_zu5rnpDZkqPi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_23B_z1l98gH56Sd7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2021 (the “Issuance Date”), the Company entered into a Securities Purchase Agreement with an accredited
investor (the “November 2021 Investor”) providing for the sale by the Company to the November 2021 Investor of a <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20211101__20211118__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zBH5VYI2rrrj" title="Interest rate"><ix:nonfraction contextref="From2021-11-012021-11-18_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitref="Pure">10</ix:nonfraction></span>%
Senior Secured Convertible Promissory Note in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20211118__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Principal amount"><ix:nonfraction contextref="AsOf2021-11-18_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitref="USD">400,000</ix:nonfraction></span>
(the “November 2021 Note”, and, the “Financing”), to be paid by the November 2021 Investor to the Company in
two tranches (each, a “Tranche”). The first Tranche consists of a payment by the November 2021 Investor to the Company
on the Issue Date of $200,000, from which the November 2021 Investor retained $<span id="xdx_903_eus-gaap--LegalFees_c20211101__20211118__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Legal fees"><ix:nonfraction contextref="From2021-11-012021-11-18_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LegalFees" scale="0" unitref="USD">5,000</ix:nonfraction></span> to cover its legal fees. A second Tranche
consisting of $200,000 will be paid by the November 2021 Investor to the Company not later than 30 days after the Issuance Date,
resulting in $<span id="xdx_909_ecustom--ProceedsFromFinancing_c20211101__20211118__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Proceeds from financing"><ix:nonfraction contextref="From2021-11-012021-11-18_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="snbh:ProceedsFromFinancing" scale="0" unitref="USD">395,000</ix:nonfraction></span>
in total proceeds to be received by the Company in the Financing. In addition to the November 2021 Note, the November 2021 Investor
also received a common share purchase warrant (the “November 2021 Warrant”, and together with the November 2021 Note,
the “Securities”) to acquire <span id="xdx_907_ecustom--CommonStockPurchaseWarrant_c20211101__20211118__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pdd" title="Common stock purchase warrant"><ix:nonfraction contextref="From2021-11-012021-11-18_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:CommonStockPurchaseWarrant" unitref="Shares">666,667</ix:nonfraction></span>
shares of common stock of the Company. The November 2021 Warrant is exercisable for five years <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYp_c20211118__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_z1WKpHItIUej" style="display: none" title="Warrant term"><ix:nonnumeric contextref="AsOf2021-11-18_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonnumeric></span> at an exercise price of $<span id="xdx_901_ecustom--WarrantExercisePrice_c20211101__20211118__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pdd" title="Warrant exercise price"><ix:nonfraction contextref="From2021-11-012021-11-18_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:WarrantExercisePrice" unitref="USDPShares">0.45</ix:nonfraction></span>. The
closing of the Financing in the amount of $<span id="xdx_90A_ecustom--ClosingFinancingAmount_c20211216__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Closing financing amount"><ix:nonfraction contextref="AsOf2021-12-16_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="snbh:ClosingFinancingAmount" scale="0" unitref="USD">400,000</ix:nonfraction></span> occurred on December 16, 2021. The maturity date (“Maturity Date”)
for each Tranche is at the end of the period that begins from the date each Tranche is paid and ends 12 months thereafter, and
interest associated with the November 2021 Note is 10% per annum.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ShortTermDebtTextBlock"><p id="xdx_80D_eus-gaap--ShortTermDebtTextBlock_zDYPTuuFqXPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_828_zxSR4p0RV6a">NOTES PAYABLE</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 3, 2020, specific terms were reached between the Company and Pure Energy 714 LLC on the remaining $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20210103__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredDemandNoteMember_pp0p0" title="Debt Instrument, Face Amount"><ix:nonfraction contextref="AsOf2021-01-03_custom_UnsecuredDemandNoteMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitref="USD">150,046</ix:nonfraction></span> of prior advances
made to the Company pursuant to an unsecured demand note entered into between the Company and Pure Energy 714 LLC. The terms call for
repayment of the advances including interest on any unconverted principal amount at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20210103__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredDemandNoteMember_zHDxwK7Mp9ea" title="Interest rate"><ix:nonfraction contextref="From2021-01-012021-01-03_custom_UnsecuredDemandNoteMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitref="Pure">12</ix:nonfraction></span>% per annum and a repayment date
on or before June 3, 2021, at the rate of 12% per annum. If the demand note is unpaid by June 3, 2021, default interest of 3% monthly
will apply. An additional $<span id="xdx_902_eus-gaap--ProceedsFromLoans_c20210301__20210316__us-gaap--LongtermDebtTypeAxis__custom--UnsecuredDemandNoteMember_pp0p0" title="Proceeds from loans"><ix:nonfraction contextref="From2021-03-012021-03-16_custom_UnsecuredDemandNoteMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLoans" scale="0" unitref="USD">10,000</ix:nonfraction></span> was received on March 16, 2021, but subsequently returned in April 20,2021. As of December 31,
2021, outstanding balances including accrued interest was $<span id="xdx_90D_eus-gaap--NotesPayable_c20211231_pp0p0" title="Outstanding balances"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" unitref="USD">194,957</ix:nonfraction></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="snbh:PPPLoanTextBlock"><p id="xdx_80D_ecustom--PPPLoanTextBlock_z77NGjeOJpqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_82C_zFubym6lXRwg">PPP Loan</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 18, 2020, the Company, through its wholly owned subsidiary, Jaguaring Company, entered into Paycheck Protection Program Promissory
Note and Agreement with KeyBank National Association, pursuant to which the Company received loan proceeds of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_c20200418__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramPromissoryNoteMember_pp0p0" title="Debt amount"><ix:nonfraction contextref="AsOf2020-04-18_custom_PaycheckProtectionProgramPromissoryNoteMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitref="USD">231,500</ix:nonfraction></span> (the “PPP
Loan”). The PPP Loan was made under, and is subject to the terms and conditions of, the PPP which was established under the CARES
Act and is administered by the U.S. Small Business Administration. The term of the PPP Loan is two years with a maturity date of <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20200401__20200418__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramPromissoryNoteMember_zEA7tWRxv0td" title="Maturity date"><ix:nonnumeric contextref="From2020-04-012020-04-18_custom_PaycheckProtectionProgramPromissoryNoteMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">April
18, 2022</ix:nonnumeric></span> and contains a favorable fixed annual interest rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200418__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramPromissoryNoteMember_zOZZj1D7LX17" title="Interest rate"><ix:nonfraction contextref="AsOf2020-04-18_custom_PaycheckProtectionProgramPromissoryNoteMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitref="Pure">1.00</ix:nonfraction></span>%. Payments of principal and interest on the PPP Loan will be deferred
for the first six months of the term of the PPP Loan until November 18, 2020. Principal and interest are payable monthly and may be prepaid
by the Company at any time prior to maturity with no prepayment penalties. Under the terms of the CARES Act, recipients can apply for
and receive forgiveness for all or a portion of loans granted under the PPP. Such forgiveness will be determined, subject to limitations,
based on the use of loan proceeds for certain permissible purposes as set forth in the PPP, including, but not limited to, payroll costs
(as defined under the PPP) and mortgage interest, rent or utility costs (collectively, “Qualifying Expenses”), and on the
maintenance of employee and compensation levels during the eight-week period following the funding of the PPP Loan. The Company has been
using the proceeds of the PPP Loan, for Qualifying Expenses. As of December 31, 2021 the balance of this loan was forgiven and recognized
in other income.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zZ1tPTgB6gJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <b>NOTE
8. <span id="xdx_82F_zaAukpEnKKV6">STOCKHOLDERS’ (DEFICIENCY)</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
stock</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zXUYzxHyWUKj" title="Preferred stock, share authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231_zb2V24AfnYAc" title="Preferred stock, share authorized"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" unitref="Shares"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" unitref="Shares">25,000,000</ix:nonfraction></ix:nonfraction></span></span> shares of Preferred Stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_z2Fo6DTC2Hyl" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_zsqtSEfEI1F4" title="Preferred stock, par value"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitref="USDPShares"><ix:nonfraction contextref="AsOf2020-12-31" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitref="USDPShares">.001</ix:nonfraction></ix:nonfraction></span></span> per share. As of September 30, 2021 and December
30, 2020, <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zES5sJucnopf" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zclJCz7aecv5" title="Preferred stock, shares outstanding"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" unitref="Shares"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" unitref="Shares">1,000,000</ix:nonfraction></ix:nonfraction></span></span> shares of Series B Preferred Stock were issued and outstanding.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
five years from the date of issuance, the Series B Preferred Stock shall have the number of votes equal to fifty-one percent (51%) of
the cumulative total vote of all classes of stock of the Corporation, common or preferred, whether such other class of stock is voting
as a single class or the other classes of stock are voting together as a single group, and with respect to such vote, such holder shall
have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, or any other class of preferred
stock, and shall be entitled to notice of any stockholders’ meeting in accordance with the bylaws of the Corporation, and shall
be entitled to vote, together with holders of Common Stock and any class of preferred stock entitled to vote, with respect to any question
upon which holders of Common Stock or any class of preferred stock have the right to vote. After five years, the Series B Preferred Stock
shall automatically, and without further action by the Corporation, be cancelled and void, and may not be reissued.</span></p>
<ix:exclude><p id="xdx_23C_zmMZ31Qhrgy7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></ix:exclude>
<ix:exclude><!-- Field: Page; Sequence: 71; Value: 1 -->
<div id="xdx_230_z7TlRpWk1gl7" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23F_z9uLEtlXEvzd" style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> </p></div>
<div id="xdx_23E_zdgoRB3RTUEh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"> </p></div>
<!-- Field: /Page --></ix:exclude>
<ix:exclude><p id="xdx_234_zCcAL5N6Kwd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Common
stock</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 29, 2021, the Company, merged with and into its wholly owned subsidiary, Sentient Brands Holdings Inc., a Nevada corporation,
pursuant to an Agreement and Plan of Merger between Sentient Brands Holdings Inc., a California corporation, and Sentient Brands Holdings
Inc., a Nevada corporation. Sentient Brands Holdings Inc., a Nevada corporation, continued as the surviving entity of the migratory merger.
Pursuant to the migratory merger, the Company changed its state of incorporation from California to Nevada and each share of its common
stock converted into one share of common stock of the surviving entity in the migratory merger. No dissenters’ rights were exercised
by any of the Company’s stockholders in connection with the migratory merger.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 3, 2021, the Company implemented a forward stock split its outstanding shares of common stock at a ratio of <span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20210301__20210303" title="Forward Stock Split"><ix:nonnumeric contextref="From2021-03-012021-03-03" name="us-gaap:StockholdersEquityReverseStockSplit">7 for 1</ix:nonnumeric></span>, resulting
in the number of authorized shares of common stock of the Company going from <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zWV0E9eswLDg" title="Common stock, shares authorized"><ix:nonfraction contextref="AsOf2021-12-31" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares">50,000,000</ix:nonfraction></span> shares to 500,000,000 shares. All share and per
share information has been retroactively adjusted to reflect this forward stock split.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 27, 2021 (the “Issuance Date”), the Company entered into a Securities Purchase Agreement with an accredited investor
(the “April 2021 Investor”) providing for the sale by the Company to the April 2021 Investor of a <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zfDU0RANWAma" title="Interest rate"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitref="Pure">10</ix:nonfraction></span>% Senior Secured
Convertible Promissory Note in the principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_zXTXwoNYFHp8" title="Principal amount"><ix:nonfraction contextref="AsOf2021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitref="USD">315,789</ix:nonfraction></span>. In addition to the April 2021 Note, the April 2021 Investor also received <span id="xdx_905_ecustom--NumberOfCommonStockReceived_c20210401__20210427__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pdd" title="Number of common stock received"><ix:nonfraction contextref="From2021-04-012021-04-27_custom_SecuritiesPurchaseAgreementMember_custom_SeniorSecuredConvertiblePromissoryNoteMember_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="snbh:NumberOfCommonStockReceived" unitref="Shares">250,000</ix:nonfraction></span> shares
of common stock of the Company.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2021, the Company sold <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210601__20210629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pdd" title="Number of common stock sold"><ix:nonfraction contextref="From2021-06-012021-06-29_custom_AccreditedInvestorMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitref="Shares">1,100,000</ix:nonfraction></span> shares of common stock to an accredited investor in consideration for an aggregate
purchase price of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210601__20210629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AccreditedInvestorMember_pp0p0" title="Proceeds from sale of common stock"><ix:nonfraction contextref="From2021-06-012021-06-29_custom_AccreditedInvestorMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitref="USD">1,100</ix:nonfraction></span>.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_803_eus-gaap--CommitmentsDisclosureTextBlock_zHvfrBNGRI52" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82F_zzVNZXhb9Nag">COMMITMENTS AND CONTINGENCIES</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2019, the Company entered into an Employment Agreement (the “Furlan Agreement”) with George Furlan pursuant
to which Mr. Furlan was appointed as the Company’s Chief Executive Officer. The Furlan Agreement provides for a base salary of
$<span id="xdx_900_eus-gaap--SalariesAndWages_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--FurlanAgreementMember_zt4sZn8bDKcb" title="Base salary"><ix:nonfraction contextref="From2021-01-012021-12-31_custom_FurlanAgreementMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalariesAndWages" scale="0" unitref="USD">60,000</ix:nonfraction></span> per year with such base salary being increased to $<span id="xdx_90C_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--FurlanAgreementMember_za1nc1tFxKke" title="Base salary"><ix:nonfraction contextref="From2021-01-012021-12-31_custom_FurlanAgreementMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="0" unitref="USD">120,000</ix:nonfraction></span> per year beginning on the one (1) year anniversary of the completion
of a financing by the Company of no less than $3,000,000. The Furlan Agreement also contains an annual bonus based on the amount
of revenue generated by the Company from the sale of certain products. The Furlan Agreement has a term of three years from the effective
date. Pursuant to the Furlan Agreement, the Company and Mr. Furlan also entered into a into a Restricted Stock Agreement to purchase
<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--FurlanAgreementMember_zkiPRMl2aQLh" title="Number of restricted stock issued"><ix:nonfraction contextref="From2021-01-012021-12-31_custom_FurlanAgreementMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitref="Shares">718,403</ix:nonfraction></span> shares of the Company’s Common Stock.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On January 8, 2020,
the Company entered into an Executive Consulting Agreement (the “Mansour Agreement”) with James Mansour pursuant to which
Mr. Mansour was appointed as an Executive Consultant. The Mansour Agreement provides for a base salary of $<span id="xdx_909_eus-gaap--SalariesAndWages_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--MansourAgreementMember_zfLaYobBwJni"><ix:nonfraction contextref="From2021-01-012021-12-31_custom_MansourAgreementMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SalariesAndWages" scale="0" unitref="USD">60,000</ix:nonfraction></span> per year. The Mansour
Agreement has a term of three years from the effective date. Pursuant to the Mansour Agreement, the Company and Mr. Mansour also entered
into a into a Restricted Stock Agreement to purchase 718,403 shares of the Company’s Common Stock.</span><span style="font-size: 8pt"> </span></p>
<p style="margin: 0; text-align: justify; font-family: Times New Roman, Times, Serif"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</ix:nonnumeric><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_zlcWeKdPlm24" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_829_zs2IX9NNhqCc">SUBSEQUENT EVENTS</span></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the first quarter of 2022, the Company received
short term loans (collectively, the “Loans”) from an accredited investor in the aggregate amount of $<span id="xdx_908_eus-gaap--ProceedsFromLoans_c20220101__20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdriaticAdvisorsMember_pp0p0" title="Proceeds from short term loan"><ix:nonfraction contextref="From2022-01-012022-03-31_us-gaap_SubsequentEventMember_custom_AdriaticAdvisorsMember" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLoans" scale="0" unitref="USD">96,075</ix:nonfraction></span>. The maturity
date of each Loan is at the end of the period that begins on the date each Loan was made and ends six months thereafter, and interest
on each of the Loans is <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220101__20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdriaticAdvisorsMember_zhi76YQI4Ss6" title="Interest rate"><ix:nonfraction contextref="From2022-01-012022-03-31_us-gaap_SubsequentEventMember_custom_AdriaticAdvisorsMember" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitref="Pure">18</ix:nonfraction></span>% per annum.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events for recognition and disclosure through April 28, 2022, which is the date the financial statements
were available to be issued. No other matters were identified affecting the accompanying financial statements and related disclosures.</span></p>
</ix:nonnumeric><p id="xdx_81B_zqxEhWQ9NM2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">F-12 </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt"> </div></div><!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
